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Figure 7 
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Figures 12A-B 
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Figures 12C-F 
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Figure 13A 
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Figure 13B 
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USE OF THE SALMONELLA SPP TYPE III 
SECRETION PROTEINS AS A PROTECTIVE 
VACCINATION 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
2 
lance is not feasible. Vaccines against these pathogens could 
provide a major weapon in controlling this disease. How-
ever, although some progress has been made in recent years, 
vaccines against Salmonella spp. have not proven to be 
5 broadly protective, and almost all are entirely directed only 
to the typhoid causing serovars. A Salmonella serotype-
independent subunit vaccine that could target both typhoid 
and NTS serovars would be of tremendous public health In accordance with 37 C.F.R. § 1.76, a claim of priority is 
included in an Application Data Sheet filed concurrently 
herewith. The present application is a continuation in part 10 
application of U.S. patent application Ser. No. 14/437,535 
filed Apr. 22, 2015 which is a 35 U.S.C. § 371 U.S. National 
stage application of PCT/US2013/66105 filed Oct. 22, 2013 
which claims priority to U.S. Provisional application No. 
61/716,911 filed Oct. 22, 2012, the complete disclosures of 15 
which are herein incorporated by reference. 
value. 
SUMMARY 
Proteins associated with the tip of the T3SA in both SPI-1 
and SPI-2 are extracellular, and thus are excellent candidates 
for the development of broadly protective serotype-indepen-
dent subunit vaccines against Salmonella. Herein, the suc-
cessful use of extracellular SPI-1 and SPI-2 proteins to 
immunize mammals against the effects of Salmonella infec-
tion is shown. Accordingly, compositions ( e.g. immuno-
FIELD OF THE INVENTION 
The invention generally relates to protecting against Sal-
monella-type pathogens and, more particularly, to compo-
sitions and methods for immunizing against infection by 
typhoidal and non-typhoidal Salmonella serovars. 
BACKGROUND 
Salmonella is a genus of over 2000 serovars and includes 
organisms that cause a wide range of human and animal 
diseases. For example, Salmonella enterica serovars Typhi 
and Paratyphi A and B cause enteric ("typhoid") fever. 
Salmonella enterica serovars Typhimurium and Enteritidis 
are known as the non-typhoidal Salmonella (NTS) and cause 
salmonellosis-a gastroenteritis which is usually a self-
limiting illness in healthy individuals. 
As is the case with many gram-negative pathogens, Sal-
monella spp. use type III secretion systems (T3SSs) as 
virulence factors to deliver proteins into host cells and to 
subsequently cause/induce infection. The T3SS is a molecu-
20 genie compositions) comprising one or more of the SPI-1 
and SPI-2 proteins, or immunogenic fragments thereof, are 
provided, as are methods of using the compositions to elicit 
an immune response in and/or to vaccinate a mammal. 
Advantageously, in some aspects the methods and compo-
25 sitions provide broad serovar-independent protection against 
infection by both typhoid and NTS Salmonella serovars. 
In one aspect, the invention provides methods of eliciting 
an immune response against at least one Salmonella serovar 
in a subject in need thereof. The methods comprise the steps 
30 of administering to the subject a composition comprising i) 
at least one Salmonella pathogenicity island 1 (SPI-1) and/or 
Salmonella pathogenicity island 2 (SPI-2) extracellular pro-
tein; and ii) a physiologically acceptable carrier; wherein 
said composition is administered in an amount so as to elicit 
35 an immune response to the at least one Salmonella serovar 
in said subject. In some aspects, the composition further 
comprises an adjuvant. In other aspects, the composition 
comprises an extracellular protein selected from the group 
consisting of: SipD, SipB, SseB and SseC. For example, the lar "syringe and needle" apparatus, also known as a "type III 
secretion apparatus" (T3SA) which promotes uptake of the 
bacterium by the host cell, and then adaptation of the 
intracellular environment of the host cell to allow a produc-
tive infection. Salmonella has two functionally distinct 
T3SS's which are encoded by Salmonella "pathogenicity 
islands" 1 and 2 (SPI-1 and -2). The SPI-1 T3SS is central 45 
to the ability of Salmonella to invade nonphagocytic cells 
via the injection, from the bacteria and into the cell by way 
40 composition may comprise SipD and SipB; and the com-
position may further comprise SseB. In some aspects, the 
Salmonella serovar is Salmonella enterica serovar. In further 
aspects, the at least one Salmonella enterica serovar may be: 
typhoid serovar Typhi, typhoid serovar Paratyphi A, typhoid 
serovar Paratyphi B, non-typhoidal serovar Typhimurium 
and non-typhoidal serovar Enteritidis. In additional aspects, 
the subject is selected from a human and an agricultural 
animal, with exemplary agricultural animals including 
cattle, poultry, swine, horses, sheep and goats. 
In other aspects, the invention provides immunogenic 
compositions comprising i) at least one Salmonella patho-
genicity island 1 (SPI-1) and/or Salmonella pathogenicity 
island 2 (SPI-2) extracellular protein; and ii) a physiologi-
cally acceptable carrier. In some aspects, the immunogenic 
composition further comprises an adjuvant. In further 
aspects, the at least one SPI-1 and/or SPI-2 extracellular 
protein is SipD, SipB, SseB or SseC. In some aspects, the at 
least one SPI-1 and/or SPI-2 extracellular proteins in the 
immunogenic compositions include SipD and SipB. In other 
of the T3 SA conduit, effector proteins which trigger exten-
sive actin rearrangements on the surface of host cells. While 
this allows ingress of the pathogen into the host cell, a 50 
second T3SS island, SPI-2, is essential for bacterial repli-
cation/proliferation inside host cells. Upon intracellular acti-
vation of SPI-2, the bacteria proliferate within membrane-
bound vacuoles of phagocytic eukaryotic cells (Salmonella-
containing vacuoles, SCVs), with macrophages being the 55 
main cell type supporting bacterial growth in vivo. Bacterial 
effector proteins are translocated across the vacuolar mem-
brane via the SPI-2 T3SS apparatus and into the host 
endomembrane system and cytoplasm, causing systemic 
disease. 60 aspects, the immunogenic compositions further comprise 
SseB. The Salmonella NTS serotypes are a primary cause of 
foodborne illnesses worldwide. In the U.S. NTS are a 
leading cause of hospitalization and death due to foodborne 
illnesses, with Salmonella enterica serovar Typhimurium 
being the most frequent cause. 95% of the total cases ofNTS 
are caused by contaminated food. Unfortunately, absolute 
protection from infection by enhanced agricultural surveil-
In other aspects of the invention, what is provided are 
methods of treating or preventing Salmonella infection by 
one or both of a typhoid Salmonella serovar and a non-
65 typhoid Salmonella serovar in a subject in need thereof. The 
methods comprise administering to the subject an amount of 
a composition comprising i) at least one Salmonella patho-
US 9,950,053 B2 
3 
genicity island 1 (SPI-1) and/or Salmonella pathogenicity 
island 2 (SPI-2) extracellular protein; and ii) a physiologi-
cally acceptable carrier. In some aspects, the immunogenic 
composition further comprises an adjuvant. In further 
aspects, the at least one SPI-1 and/ or SPI-2 extracellular 5 
protein is SipD, SipB, SseB or SseC. In some aspects, the at 
least one SPI-1 and/or SPI-2 extracellular proteins in the 
immunogenic compositions include SipD and SipB. In other 
aspects, the immunogenic compositions further comprise 
SseB. The amounts that are administered are sufficient to 
10 
treat or prevent said Salmonella infection in said subject. 
In yet other aspects, the invention provides methods of 
lessening the severity of symptoms of Salmonella infection 
in a subject in need thereof, comprising administering to the 
subject an amount of a composition comprising i) at least 
one Salmonella pathogenicity island 1 (SPI-1) and/or Sal- 15 
monella pathogenicity island 2 (SPI-2) extracellular protein; 
and ii) a physiologically acceptable carrier. In some aspects, 
the immunogenic composition further comprises an adju-
vant. In further aspects, the at least one SPI-1 and/or SPI-2 
extracellular protein is SipD, SipB, SseB or SseC. In some 20 
aspects, the at least one SPI-1 and/ or SPI-2 extracellular 
proteins in the immunogenic compositions include SipD and 
SipB. In other aspects, the immunogenic compositions fur-
ther comprise SseB. The amounts that are administered are 
sufficient to lessen the severity of said symptoms in said 25 
subject. 
In additional aspects, the invention provides methods of 
decreasing fecal shedding of Salmonella from a subject who 
is or is likely to be infected with Salmonella, comprising 
administering to the subject an amount of a composition 30 
comprising i) at least one Salmonella pathogenicity island 1 
(SPI-1) and/or Salmonella pathogenicity island 2 (SPI-2) 
extracellular protein; and ii) a physiologically acceptable 
carrier. In some aspects, the immunogenic composition 
further comprises an adjuvant. In further aspects, the at least 35 
one SPI-1 and/or SPI-2 extracellular protein is SipD, SipB, 
SseB or SseC. In some aspects, the at least one SPI-1 and/or 
SPI-2 extracellular proteins in the immunogenic composi-
tions include SipD and SipB. In other aspects, the immu-
nogenic compositions further comprise SseB. The amount 40 
that is administered is sufficient to lessen the severity of said 
symptoms in said subject. 
The foregoing has outlined in broad terms the more 
important features of the invention disclosed herein so that 
the detailed description that follows may be more clearly 45 
understood, and so that the contribution of the instant 
inventors to the art may be better appreciated. The instant 
invention is not limited in its application to the details of the 
construction and to the arrangements of the components set 
forth in the following description or illustrated in the draw- 50 
ings. Rather the invention is capable of other embodiments 
and of being practiced and carried out in various other ways 
not specifically enumerated herein. Additionally, the disclo-
sure that follows is intended to apply to all alternatives, 
modifications and equivalents as may be included within the 55 
spirit and the scope of the invention as defined by the 
appended claims. Further, it should be understood that the 
phraseology and terminology employed herein are for the 
purpose of description and should not be regarded as lim-
iting, unless the specification specifically so limits the inven- 60 
tion. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Other objects and advantages of the invention will 65 
become apparent upon reading the following detailed 
description and upon reference to the drawings in which: 
4 
FIG. 1. Schematic illustration of the mouse testing pro-
tocol for Example 1. 
FIG. 2. IgG antibody titers from mice immunized with 
T3SS proteins at day 28. Each bar represents data from 
pooled samples (N=l0). 
FIG. 3. Survival after challenge. Balb-c mice (N=5 per 
group) were vaccinated twice with attenuated Salmonella 
vaccine strain Aro, or 3 times with of a composition com-
prising SipB, SipD and SseB protein (10 µg of each) with or 
without adjuvant dmLT. Mice were challenged vias orogas-
tric challenge with lxl06 CFU of Salmonella strain SL1344. 
Survival was monitored for 14 days after challenge. 
FIG. 4 contains a schematic illustration of the mouse 
testing protocol for Example 2. 
FIGS. SA-SF. FIGS. SA and B: number of SipB specific 
ASCs in spleens of immunized mice at days 42 and 56, 
respectively; FIGS. SC and SD: number of SipD specific 
ASCs at days 42 and 56, respectively; FIGS. SE and SF: 
number of SseB specific ASCs at days 42 and 56, respec-
tively. 
FIGS. 6A-6C. IgG titers in immunized mice at day 56. 
FIG. 6A: SipB specific IgG; FIG. 6B: SipD specific IgG; 
FIG. 6C: SseB specific IgG. 
FIG. 7. Stool IgA titers in immunized mice at day 56. 
FIGS. SA and SB. Protection efficacy in immunized mice 
after challenge (at day 56) with (FIG. SA) S. enterica Typhi 
or (FIG. SB) S. enterica Typhimurium. 
FIG. 9. Schematic illustration of the calf testing protocol 
for Example 3. 
FIGS. lOA and lOB. Antibody titers of calves immunized 
as described in Example 3, on day 56 post-immunization. 
FIG. lOA: serum IgG; FIG. lOB: saliva IgA. 
FIGS. llA and llB. Bacterial shedding in response to 
challenge with S. enterica Newport (FIG. 11 A) or S. 
enterica Typhimurium (FIG. llB) in calves on day 56 
post-immunization. 
FIGS. 12A-12F. Sequences of proteins of interest and 
nucleic acid sequence encoding them. FIG. 12A: amino acid 
sequence of SipB (SEQ ID NO: 1); FIG. 12B: nucleic acid 
sequence encoding SipB (SEQ ID NO: 2); FIG. 12C: amino 
acid sequence of SipD (SEQ ID NO: 3); FIG. 12D: nucleic 
acid sequence encoding SipD (SEQ ID NO: 4); FIG. 12E: 
amino acid sequence of SseB (SEQ ID NO: 5); FIG. 12F: 
nucleic acid sequence encoding SseB (SEQ ID NO: 6). 
FIGS. 13A and 13B. FIG. 13A: Amino acid; and FIG. 
13B: encoding nucleic acid sequences of SipB-SipD chi-
mera (SEQ ID NOS: 7 and 8, respectively). 
FIG. 14 is a schematic representation of an experimental 
plan for mouse experiments. 
FIGS. lSA-lSD are graphs showing the kinetics of serum 
IgG response against SipD, SipB, SseB, and SseC. Serum 
samples from blood collected at days 0, 14, 28, 42, and 56 
were analyzed for their titers against the four proteins that 
are part of the SlF (SipD and B) and S2F (SseB and C). All 
the titers are from pooled serum from the group of mice 
tested (N=l0). 
FIGS. 16A and 16B are graphs showing the results from 
an orogastric/systemic challenge with S. Typhimurium 
SL1344 and S. Enteritidis P125109. Immunized mice 
(n=l0) were challenged with (FIG. 16A) 2xl08cfu S. Typh-
imurium SL1344 and (FIG. 16B) 8xl07cfu S. Enteritidis 
orogastrically. Survival was monitored for 21 days. p<0.05 
for llSPI-1/2 and S1F+S2F compared to PBS group. 
FIG. 17 is a series of graphs showing rRectal temperatures 
and shedding of S. Newport following bacterial challenge of 
calves. Top: Temperatures of the calves over the course of 
eight days after challenge. Black boxes indicate temperature 
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from calves vaccinated with SseB+dmLT and white boxes 
are sham-vaccinated calves. Middle: fecal shedding (CPUs/ 
gram of feces) for individual calves over the ten day study. 
Black boxes indicate shedding from each calf vaccinated 
with SseB+dmLT and white circles are sham-vaccinated 5 
calves. Bottom: Total shedding of bacteria (CPUs) over the 
entire ten day period. *P<0.05 comparing groups that 
received SseB+dmLT and PBS using T test. 
specified elements----or, as appropriate, equivalents 
thereof-and that other elements can be included and still 
fall within the scope/definition of the defined item, compo-
sition, apparatus, method, process, system, etc. 
The term "about" or "approximately" means within an 
acceptable error range for the particular value as determined 
by one of ordinary skill in the art, which will depend in part 
on how the value is measured or determined, i.e., the 
limitations of the measurement system. For example, 
"about" can mean within 1 or more than 1 standard devia-
tion, per the practice in the art. Alternatively, "about" can 
FIG. 18 is a schematic representation of the Sl Fusion (Sl 
or SlF). SlF is a genetic fusion of SipD and SipB. Upon 10 
protein purification, the linear model is depicted in the 
diagram where SipD is expressed first (light grey) with 
translation continuing into SipB (dark grey). 
mean a range of up to 20%, up to 10%, up to 5%, or up to 
1 % of a given value or range. Alternatively, particularly with 
respect to biological systems or processes, the term can 
mean within an order of magnitude within 5-fold, and also 
within 2-fold, of a value. Where particular values are 
FIG. 19 is a schematic representation of the S2 Fusion (S2 
or S2F). S2F is a genetic fusion of SseB and SseC. Upon 15 
protein purification, the linear model is depicted in the 
drawing where SseB is expressed first (light grey) with 
translation continuing into SipB (dark grey). 
described in the application and claims, unless otherwise 
stated the term "about" meaning within an acceptable error 
range for the particular value should be assumed. The 
DETAILED DESCRIPTION 
While this invention is susceptible of embodiment in 
many different forms, there is shown in the drawings, and 
will herein be described hereinafter in detail, some specific 
embodiments of the instant invention. It should be under-
stood, however, that the present disclosure is to be consid-
ered an exemplification of the principles of the invention and 
is not intended to limit the invention to the specific embodi-
ments or algorithms so described. 
20 recitation of numerical ranges by endpoints includes all 
numbers within that range (e.g., 1 to 5 includes 1, 1.5, 2, 
2.75, 3, 3.80, 4, and 5). 
The term "at least" followed by a number is used herein 
to denote the start of a range beginning with that number 
25 (which may be a ranger having an upper limit or no upper 
limit, depending on the variable being defined). For 
example, "at least 1" means 1 or more than 1. The term "at 
most" followed by a number is used herein to denote the end 
of a range ending with that number (which may be a range 
30 having 1 or O as its lower limit, or a range having no lower 
limit, depending upon the variable being defined). For 
example, "at most 4" means 4 or less than 4, and "at most 
40%" means 40% or less than 40%. 
Unless otherwise defined, all terms (including technical 
and scientific terms) used herein have the same meaning as 
commonly understood by one of ordinary skill in the art to 
which this invention belongs. It will be further understood 
that terms, such as those defined in commonly used diction-
aries, should be interpreted as having a meaning that is 35 
consistent with their meaning in the context of the relevant 
When, in this specification, a range is given as "(a first 
number) to (a second number)" or "(a first number)-(a 
second number)", this means a range whose lower limit is 
the first number and whose upper limit is the second number. 
For example, 25 to 100 should be interpreted to mean a 
range whose lower limit is 25 and whose upper limit is 100. 
art and will not be interpreted in an idealized or overly 
formal sense unless expressly so defined herein. 
It should be noted that where reference is made herein to 
a method comprising two or more defined steps, the defined 
steps can be carried out in any order or simultaneously 
(except where context excludes that possibility), and the 
method can also include one or more other steps which are 
carried out before any of the defined steps, between two of 
the defined steps, or after all of the defined steps ( except 
where context excludes that possibility). 
Definitions 
The terminology used herein is for the purpose of describ-
ing particular embodiments only and is not intended to be 
limiting of the invention. As used herein, the singular forms 
"a", "an" and "the" are intended to include the plural forms 
as well, unless the context clearly indicates otherwise. Thus, 
for example, reference to a "serovar" includes reference to 
one or more of such serovars, unless otherwise specified. 
The use of plural terms is also not intended to be limiting, 
unless otherwise specified. Furthermore, to the extent that 
the terms "including", "includes", "having", "has", "with", 
or variants thereof are used in either the detailed description 
and/or the claims, such terms are intended to be inclusive in 
a manner similar to the term "comprising." 
As used herein, the terms "comprising," "comprise" or 
"comprised," and variations thereof, in reference to defined 
or described elements of an item, composition, apparatus, 
method, process, system, etc. are meant to be inclusive or 
open ended, permitting additional elements, thereby indi-
cating that the defined or described item, composition, 
apparatus, method, process, system, etc. includes those 
40 Additionally, it should be noted that where a range is given, 
every possible subrange or interval within that range is also 
specifically intended unless the context indicates to the 
contrary. For example, if the specification indicates a range 
of 25 to 100 such range also is intended to include subranges 
45 such as 26 to 100, 27 to 100, etc., 25 to 99, 25 to 98, etc., 
as well as any other possible combination oflower and upper 
values within the stated range, e.g., 33-47, 60-97, 41-45, 
28-96, etc. Note that integer range values have been used in 
this paragraph for purposes of illustration only and decimal 
50 ranges (e.g., 46.7-91.3) should also be understood to be 
intended as a possibility unless specifically excluded. 
As used herein, a "chimeric" molecule is one which 
comprises one or more unrelated types of components, 
moieties or two or more chemically distinct regions which 
55 can be conjugated to each other, fused, linked, transcribed, 
translated, attached via a linker, chemically synthesized, 
expressed from a nucleic acid sequence, etc. For example, a 
fusion gene, a peptide and a nucleic acid sequence, a peptide 
and a detectable label, two or more peptide sequences, two 
60 or more nucleic acid sequences ( e.g. from different regions 
of a genome, nucleic acid sequences not found contiguous in 
nature, fusion genes) and the like. As used herein, a "fusion 
gene" is a gene created by removing the stop protein from 
the sequence of a gene and attaching the DNA sequence of 
65 a second gene to the first. By fusing one nucleotide sequence 
to another, the host cell will express the sequences together, 
as a single fused protein. Fusion genes may contain two or 
US 9,950,053 B2 
7 
more fused genes. Accordingly, "fusion protein" as used 
herein is a protein produced by expression of a fusion gene 
8 
thereof, peptide nucleic acids (PNA), locked nucleic acids 
(LNA), phosphorothioate, methylphosphonate, and the like. 
The nucleic acid sequences may be composed of different 
regions. The term also applies to nucleic acids which have 
or two or more proteins fused or connected by any method. 
The term encompasses peptides, mutants, derivatives and 
any variants. 
As used herein, the terms "conjugated," "linked," 
"attached," "fused" and "tethered," when used with respect 
5 been substantially purified from other components which 
naturally accompany the nucleic acid, e.g., RNA or DNA or 
proteins, which naturally accompany it in the cell. The term 
therefore includes, for example, a recombinant DNA which to two or more moieties, means that the moieties or domains 
are physically associated or connected with one another, 
either directly or via one or more additional moieties that 10 
serve as a linking agent, to form a structure that is suffi-
ciently stable so that the moieties remain physically asso-
ciated under the conditions in which the structure is used, 
e.g., physiological conditions. The linkage can be based on 
genetic fusion according to the methods known in the art and 15 
described herein or can be performed by, e.g., chemical 
cross-linking. The additional domain present in the construct 
may be linked by a flexible linker, such as a polypeptide 
linker to one of the binding site domains; the polypeptide 
linker can comprise plural, hydrophilic or peptide-bonded 20 
amino acids of a length sufficient to span the distance 
between the C-terminal end of one of the domains and the 
N-terminal end of the other of the domains when the 
polypeptide assumes a conformation suitable for binding 
when disposed in aqueous solution. The term "connected" 
will be used for the sake of brevity and is meant to include 
all possible methods of physically associating each domain 
of the chimeric molecule to each other. 
is incorporated into a vector, into an autonomously repli-
cating plasmid or virus, or into the genomic DNA of a 
prokaryote or eukaryote, or which exists as a separate 
molecule ( e.g., as a cDNA or a genomic or cDNA fragment 
produced by PCR or restriction enzyme digestion) indepen-
dent of other sequences. It also includes a recombinant 
DNA, for instance, DNA which is part of a hybrid gene 
encoding additional polypeptide sequences. 
A "polynucleotide" means a single strand or parallel and 
anti-parallel strands of a nucleic acid. Thus, a polynucleotide 
may be either a single-stranded or a double-stranded nucleic 
acid. 
The term "expression vector" as used herein refers to a 
vector containing a nucleic acid sequence coding for at least 
part of a gene product capable of being transcribed. In some 
cases, RNA molecules are then translated into a protein, 
25 polypeptide, or peptide. In other cases, these sequences are 
not translated, for example, in the production of antisense 
molecules, siRNA, ribozymes, and the like. Expression 
vectors can contain a variety of control sequences, which 
refer to nucleic acid sequences necessary for the transcrip-As used herein, unless otherwise indicated, the terms 
"peptide", "polypeptide" or "protein" are used interchange-
ably herein, and refer to a polymer of amino acids of varying 
sizes. These terms do not connote a specific length of a 
polymer of amino acids. Thus, for example, the terms 
oligopeptide, protein, and enzyme are included within the 
definition of polypeptide or peptide, whether produced using 35 
recombinant techniques, chemical or enzymatic synthesis, 
30 tion and possibly translation of an operatively linked coding 
sequence in a particular host organism. In addition to control 
sequences that govern transcription and translation, vectors 
and expression vectors may contain nucleic acid sequences 
that serve other functions as well. 
By "encoding" or "encoded", "encodes", with respect to 
a specified nucleic acid, is meant comprising the information 
for translation into the specified protein. A nucleic acid 
encoding a protein may comprise non-translated sequences 
( e.g., intrans) within translated regions of the nucleic acid, 
or be naturally occurring. This term also includes polypep-
tides that have been modified or derivatized ("derivatives"), 
such as by glycosylation, acetylation, phosphorylation, and 
the like. 40 or may lack such intervening non-translated sequences ( e.g., 
as in cDNA). The information by which a protein is encoded 
is specified by the use of codons. Typically, the amino acid 
sequence is encoded by the nucleic acid using the "univer-
As used herein, "variants" of polypeptides refers to an 
amino acid sequence that is altered by one or more amino 
acid residues. The variant may have "conservative" changes, 
wherein a substituted amino acid has similar structural or 
chemical properties (e.g., replacement of leucine with iso- 45 
leucine ). More rarely, a variant may have "nonconservative" 
changes (e.g., replacement of glycine with tryptophan). 
Analogous minor variations may also include amino acid 
deletions or insertions, or both. Guidance in determining 
which amino acid residues may be substituted, inserted, or 
deleted without abolishing biological activity may be found 
using computer programs well known in the art, for 
example, LASERGENE software (DNASTAR). 
sal" genetic code. 
As used herein, "heterologous" in reference to a nucleic 
acid is a nucleic acid that originates from a foreign species, 
or, if from the same species, is substantially modified from 
its native form in composition and/or genomic locus by 
deliberate human intervention. For example, a promoter 
50 operably linked to a heterologous structural gene is from a 
species different from that from which the structural gene 
was derived, or, if from the same species, one or both are 
substantially modified from their original form. A heterolo-
gous protein may originate from a foreign species or, if from As used herein, a "nucleic acid" or "nucleic acid 
sequence" or "cDNA" refers to a nucleic acid segment or 
fragment which has been separated from sequences which 
flank it in a naturally occurring state, e.g., a DNA fragment 
which has been removed from the sequences which are 
normally adjacent to the fragment, e.g., the sequences adja-
cent to the fragment in a genome in which it naturally 
occurs, and refers to nucleic acid sequences in which one or 
more intrans have been removed. The terms "nucleic acid 
sequence", "polynucleotide," and "gene" are used inter-
changeably throughout the specification and includes linear 
or circular oligomers or polymers of natural and/or modified 
monomers or linkages, including deoxyribonucleosides, 
ribonucleosides, substituted and alpha-anomeric forms 
55 the same species, is substantially modified from its original 
form by deliberate human intervention. 
The term "variant," when used in the context of a poly-
nucleotide sequence, may encompass a polynucleotide 
sequence related to a wild type gene. This definition may 
60 also include, for example, "allelic," "splice," "species," or 
"polymorphic" variants. A splice variant may have signifi-
cant identity to a reference molecule, but will generally have 
a greater or lesser number of polynucleotides due to alter-
nate splicing of exons during mRNA processing. The cor-
65 responding polypeptide may possess additional functional 
domains or an absence of domains. Species variants are 
polynucleotide sequences that vary from one species to 
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another. Of particular utility in the invention are variants of 
wild type target gene products. Variants may result from at 
least one mutation in a nucleic acid sequence and may result 
10 
more of the proteins and/or antigenic portions thereof results 
in an immune response that is protective against later 
challenge by the disease causing organism itself, either 
in altered mRNAs or in polypeptides whose structure or 
function may or may not be altered. Any given natural or 5 
recombinant gene may have none, one, or many allelic 
forms. Common mutational changes that give rise to vari-
ants are generally ascribed to natural deletions, additions, or 
substitutions of nucleotides. Each of these types of changes 
may occur alone, or in combination with the others, one or 10 
preventing infection altogether, or lessening the impact of 
infection by decreasing disease symptoms that would oth-
erwise occur, had the subject not been vaccinated as 
described herein. The compositions embodied herein, 
induce immune responses to all Salmonella serovars and 
include typhoidal and non-typhoidal serovars as well as 
Salmonella subspecies. 
more times in a given sequence. 
The resulting polypeptides generally will have significant 
amino acid identity relative to each other. A polymorphic 
variant is a variation in the polynucleotide sequence of a 
particular gene between individuals of a given species. 
Polymorphic variants also may encompass "single nucleo-
tide polymorphisms" (SNPs,) or single base mutations in 
which the polynucleotide sequence varies by one base. The 
presence of SNPs may be indicative of, for example, a 
certain population with a propensity for a disease state, that 
is susceptibility versus resistance. 
The term "Salmonella" is meant to include all Salmonella 
species and subspecies, including both typhoidal and non-
typhoidal species, and all S. enterica subspecies. 
The terms "Salmonella pathogenicity island 1 (SPI-1)" 
and "Salmonella pathogenicity island 2 (SPI-2)" is meant to 
include all of the genes encoded by SPI-1 and SPI-2 respec-
tively. Reference to each of the molecules embodied herein, 
is meant to include, without limitation, nucleic acids, poly-
nucleotides, oligonucleotides, peptides, polypeptides, pro-
teins, homologous and/or orthologous molecules, mutants, 
variants, alleles, different species, and active fragments 
thereof. Accordingly, the terms "SPI-1", "SPI-2", "SipD", 
"SipB", "SicA", "SseB", "SseC", "SscA" etc., includes, for 
each of these molecules: nucleic acids, polynucleotides, 
oligonucleotides, peptides, polypeptides, proteins, homolo-
gous and/or orthologous molecules, mutants, variants, 
alleles, different species, and active fragments thereof. 
"Vaccine" as used herein is a preparation that stimulates 
an immune response that produces immunity against par-
ticular antigens, e.g. Salmonella serotypes or serovars. Vac-
cines may be used to prevent infection, to create resistance 
to an infection or to ameliorate the effects of infection. 
Vaccines may contain, but are not limited to, live, attenuated 
infectious material such as viruses or bacteria, and dead or 
inactivated organisms or purified products derived there-
from. A vaccine can be administered by injection, orally or 
by inhalation. Injection may be, but are not limited to, 
subcutaneous (sc ), intramuscular (im), intraperitoneal (ip ), 
intradermal (id) or intravenous (iv). 
As used herein, the terms "elicit an immune response", 
"induces or enhances an immune response", or "stimulates 
an immune response" are used interchangeably herein, and 
refer to a statistically measurable induction or increase in an 
immune response over a control sample to which the pep-
tide, polypeptide or protein has not been administered. 
Preferably the induction or enhancement of the immune 
response results in a prophylactic or therapeutic response in 
a subject. The subject mounts one or both of an innate and/or 
As used herein, an "adjuvant" is a substance that is able 
to favor or amplify the cascade of immunological events, 
ultimately leading to a better immunological response, i.e., 
the integrated bodily response to an antigen. An adjuvant is 
15 in general not required for the immunological response to 
occur, but favors or amplifies this response. 
The term "immunoregulatory" is meant a vaccine, com-
position or substance that is immunogenic (i.e. stimulates or 
increases an immune response) or immunosuppressive (i.e. 
20 reduces or suppresses an immune response). 
"Immunogen" or "antigen" as used herein is a substance 
that is foreign to the body that stimulates an immune 
response, such as the production of antibodies when intro-
duced into the body. Immunogens or antigens are also 
25 capable of reacting with the products of an immune 
response. Immunogens or antigens may include, but are not 
limited to proteins or polypeptides, enzymes, toxins, bacte-
ria, viruses, foreign tissues, foreign blood cells, and the cells 
of transplanted organs. Correspondingly, "immunogenicity" 
30 is the ability of an immunogen or antigen to stimulate an 
immune response. In the context of this invention, an 
"antigen" or "antigenic" composition or "immunogen" 
include without limitation any SPI-1 and/or SPI-2 molecules 
comprising proteins, polypeptides, peptides, polynucle-
35 otides, oligonucleotides, fragments, derivatives or variants 
thereof. Accordingly, an antigen includes the chimeric mol-
ecules comprising SipD, SipB, SseB or SseC proteins, 
polypeptides, peptides, polynucleotides, oligonucleotides, 
fragments, derivatives or variants thereof, as embodied 
40 herein. 
"Cells of the immune system" or "immune cells", is 
meant to include any cells of the immune system that may 
be assayed, including, but not limited to, B lymphocytes, 
also called B cells, T lymphocytes, also called T cells, 
45 natural killer (NK) cells, natural killer T (NK) cells, lym-
phokine-activated killer (LAK) cells, monocytes, macro-
phages, neutrophils, granulocytes, mast cells, platelets, 
Langerhans cells, stem cells, dendritic cells, peripheral 
blood mononuclear cells, tumor-infiltrating (TIL) cells, gene 
50 modified immune cells including hybridomas, drug modified 
immune cells, and derivatives, precursors or progenitors of 
the above cell types. 
"Immune effector cells" refers to cells capable of binding 
an antigen and which mediate an immune response selective 
55 for the antigen. These cells include, but are not limited to, T 
cells (T lymphocytes), B cells (B lymphocytes), monocytes, 
macrophages, natural killer (NK) cells and cytotoxic T 
lymphocytes (CTLs), for example CTL lines, CTL clones, 
and CTLs from tumor, inflammatory, or other infiltrates. 
an adaptive immune reaction against antigenic determinants 60 
of the proteins or antigenic portions thereof that are admin-
istered. In particular, the adaptive immune reaction entails 
production of e.g. B and T cell lymphocytes and antibodies 
specific for binding and forming complexes with the anti-
genic determinants. In some embodiments, the proteins 65 
and/or antigenic fragments thereof elicit a protective 
immune response in the subject, i.e. administration of one or 
"Immune related molecules" refers to any molecule iden-
tified in any immune cell, whether in a resting ("non-
stimulated") or activated state, and includes any receptor, 
ligand, cell surface molecules, nucleic acid molecules, poly-
peptides, variants and fragments thereof. 
"T cells" or "T lymphocytes" are a subset of lymphocytes 
originating in the thymus and having heterodimeric recep-
tors associated with proteins of the CD3 complex (e.g., a 
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rearranged T cell receptor, the heterodimeric protein on the 
T cell surfaces responsible for antigen/MHC specificity of 
the cells). T cell responses may be detected by assays for 
their effects on other cells ( e.g., target cell killing, activation 
of other immune cells, such as B-cells) or for the cytokines 5 
they produce. 
instance, a cow, a horse, a dog, a cat, a goat, a sheep or a pig, 
or fowl such as chickens, duck, turkey or any other organism 
which can benefit from the treatments embodied herein. In 
some cases, the methods of the invention find use in experi-
mental animals, in veterinary application, and in the devel-
opment of animal models for disease, including but not 
A "secondary immune response" or "adaptive immune 
response" may be active or passive, and may be humoral 
( antibody based) or cellular that is established during the life 
limited to, rodents including mice, rats, and hamsters; and 
primates. 
As defined herein, a "therapeutically effective" amount of 
a compound or agent (i.e., an effective dosage) means an 
amount sufficient to produce a therapeutically (e.g., clini-
cally) desirable result. The compositions can be adminis-
tered from one or more times per day to one or more times 
per week; including once every other day. The skilled artisan 
of an animal, is specific for an inducing antigen, and is 10 
marked by an enhanced immune response on repeated 
encounters with said antigen. A key feature of the T lym-
phocytes of the adaptive immune system is their ability to 
detect minute concentrations of pathogen-derived peptides 
presented by MHC molecules on the cell surface. 15 will appreciate that certain factors can influence the dosage 
and timing required to effectively treat a subject, including 
but not limited to the severity of the disease or disorder, 
previous treatments, the general health and/or age of the 
"Antibody" or "immunoglobulin," as used herein is a 
protein produced by the immune system that helps destroy 
disease-causing organisms. Antibodies are made and 
secreted by B lymphocytes in response to stimulation by 
antigens, which may include vaccines. Antibodies are gen- 20 
erally specific, binding only to the specific antigen that 
stimulated its production. A given antigen can have many 
epitopes, each one reacting with the immune system to 
create antibodies specific for each of the epitopes. Antibod-
subject, and other diseases present. Moreover, treatment of 
a subject with a therapeutically effective amount of the 
compounds of the invention can include a single treatment 
or a series of treatments. 
As defined herein, an "effective" amount of a compound 
or agent (i.e., an effective dosage) means an amount suffi-
cient to produce a (e.g., clinically) desirable result. Accord-
ingly, an "efficacious" vaccine comprises a therapeutically 
ies can be effective defenders against both bacteria and 25 
viruses, in addition to toxins. Antibodies can be polyclonal 
or monoclonal. 
As used herein, the terms "protect", "protecting", "pro-
vide protection to", "providing protection to", and "aids in 
the protection" do not require complete protection from any 
indication of infection. For example, "aids in the protection" 
can mean that the protection is sufficient such that, after 
challenge, symptoms of the underlying infection are at least 
reduced, and/or that one or more of the underlying cellular, 
physiological, or biochemical causes or mechanisms causing 
the symptoms are reduced and/or eliminated. It is under-
stood that "reduced," as used in this context, means relative 
to the state of the infection, including the molecular state of 
the infection, not just the physiological state of the infection. 
"Treatment" is an intervention performed with the inten-
tion of preventing the development or altering the pathology 
or symptoms of a disorder. Accordingly, "treatment" refers 
to both therapeutic treatment and prophylactic or preventa-
tive measures. "Treatment" may also be specified as pallia-
tive care. Those in need of treatment include those already 
with the disorder as well as those in which the disorder is to 
be prevented. Accordingly, "treating" or "treatment" of a 
state, disorder or condition includes: ( 1) preventing or 
delaying the appearance of clinical symptoms of the state, 
disorder or condition developing in a human or other mam-
mal that may be afflicted with or predisposed to the state, 
disorder or condition but does not yet experience or display 
clinical or subclinical symptoms of the state, disorder or 
condition; (2) inhibiting the state, disorder or condition, i.e., 
arresting, reducing or delaying the development of the 
disease or a relapse thereof (in case of maintenance treat-
ment) or at least one clinical or subclinical symptom thereof; 
or (3) relieving the disease, i.e., causing regression of the 
state, disorder or condition or at least one of its clinical or 
subclinical symptoms. The benefit to an individual to be 
treated is either statistically significant or at least perceptible 
to the patient or to the physician. 
The terms "patient" or "individual" or "subject" are used 
interchangeably herein, and refers to an animal, such as a 
mammalian subject to be treated, with human patients being 
preferred, or a companion or domesticated or food-or feed-
producing or livestock or game or racing or sport animal, for 
effective amount of a given antigen. 
As used herein, a "pharmaceutically acceptable" compo-
nent/carrier etc. is one that is suitable for use with humans 
30 and/or animals without undue adverse side effects (such as 
toxicity, irritation, and allergic response) commensurate 
with a reasonable benefit/risk ratio. When it is used, for 
example, to describe an excipient in a pharmaceutical vac-
cine, it characterizes the excipient as being compatible with 
35 the other ingredients of the composition and not disadvan-
tageously deleterious to the intended recipient. 
The term "carrier" refers to a diluent, adjuvant, excipient, 
or vehicle with which the compound is administered. Phar-
maceutical acceptable carriers can be sterile liquids, such as 
40 water and/or oils, including those of petroleum, animal, 
vegetable or synthetic origin, such as peanut oil, soybean oil, 
mineral oil, sesame oil and the like. Water or aqueous 
solution saline solutions and aqueous dextrose and glycerol 
solutions can be employed as carriers, particularly for inject-
45 able solutions. 
General Techniques 
For further elaboration of general techniques useful in the 
practice of this invention, the practitioner can refer to 
standard textbooks and reviews in cell biology, microbiol-
50 ogy, bacteriology, molecular biology, tissue culture, and 
physiology. 
General methods in molecular and cellular biochemistry 
can be found in such standard textbooks as Molecular 
Cloning: A Laboratory Manual, 3rd Ed. (Sambrook et al., 
55 Harbor Laboratory Press 2001); Short Protocols in Molecu-
lar Biology, 4th Ed. (Ausubel et al. eds., John Wiley & Sons 
1999); Protein Methods (Bollag et al., John Wiley & Sons 
1996); Nonviral Vectors for Gene Therapy (Wagner et al. 
eds., Academic Press 1999); Viral Vectors (Kaplift & Loewy 
60 eds., Academic Press 1995); Immunology Methods Manual 
(I. Lefkovits ed., Academic Press 1997); and Cell and Tissue 
Culture: Laboratory Procedures in Biotechnology (Doyle & 
Griffiths, John Wiley & Sons 1998). Some reagents, cloning 
vectors, and kits for genetic manipulation referred to in this 
65 disclosure are available from commercial vendors. For 
example, such as BioRad, Stratagene, Invitrogen, Sigma-
Aldrich, and ClonTech. 
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Compositions 
A vaccine that prevents colonization of Salmonella in 
deeper tissues (i.e. lymph nodes) reduces the risk of intro-
ducing this broad host-range pathogen from contaminating 
food products going into the market. The result is a safe 5 
source of protein that is important for consumer nutrition. 
Animal protein is an important component of a balanced diet 
for children in the United States. Children tend to be some 
14 
Accordingly, proteins which make up SPI-1 and/or the 
SPI-2 of Salmonella, or antigenic portions thereof, are used 
to elicit an immune response in subjects to whom they are 
administered. 
Exemplary proteins which may be used in the practice of 
the invention include but are not limited to: SipD, SipB, 
SseB and SseC, which may be administered alone or in 
various forms and combinations as described herein. Exem-
plary full length sequences of SipD, SipB, and SseB and of the hardest hit when Salmonella outbreaks occur. Their 
immune system is still developing and they have not been 
exposed to the variety of immunogens that boost that 
system. Foods in the meat category, such as, hamburgers, 
chicken and deli meats are the foods most likely to be 
contaminated with Salmonella. Salmonella has also been 
associated with dairy, plants, fruits and vegetables, such as, 
spinach, lettuce, tomatoes, cantaloupe and the like; and, 
processed foods such as peanut butter, ice cream, and the 
like. 
10 nucleic acids that encode them are provided in FIGS. 
12A-12F (SEQ ID NOS: 1-6). The phrase(s) "SipD, SipB, 
SseB and SseC protein(s)" as used herein refer to both the 
full length proteins as depicted in the figures, to antigenic 
regions (portions, fragments, etc.), derivatives, or variants 
15 thereof. 
The proteins, polypeptides/peptides, polynucleotides, oli-
gonucleotides, derivatives or variants thereof, which may be 
used in the practice of the invention include sequences 
which have at least about 50, 55, 60, 65, 70, 75, 80, 85, or 
20 90% identity to the sequences comprising SEQ ID NOS: 
1-8, 13-24, or 25, or to sections of those sequences which 
correspond to antigenic regions. Typically, the level of 
identity is at least about 92, 93, 94, 95, 96, 97, 98 or 99%. 
Those of skill in the art are familiar with methods and 
The surface-exposed proteins at the tip of the two type III 
secretion (TTS) apparatus needles of Salmonella (both SPI-1 
and SPI-2), as described herein for the development of 
vaccines, are protective against all S. enterica subspecies, as 
disclosed in detail in the examples section which follows. 
These include, but are not limited to: the initial tip protein 25 
SipD and the first 'translocator' protein SipB from Salmo-
nella pathogenicity island-I (SPI-1). Without being bound 
by theory, it is believed that disruption of the function of 
SPI-1 (e.g. by antibody binding to one or more of these 
proteins) prevents Salmonella protein delivery to host cells 30 
and thus blocks bacterial effects on the host cell. In addition, 
after entry into the cell, the proteins from SPI-2 are 
expressed and are surface exposed, and these proteins, 
which include but are not limited to: SseB and SseC, also 
35 
provide vaccine targets. Without being bound by theory, it is 
believed that disruption of the SPI-2 apparatus (e.g. by 
antibody binding to one or more of these proteins) prevents 
successful replication of the bacteria within the host, and 
also blocks spread of the bacteria within the host, preventing 40 
systemic infection. 
The present invention provides compositions for use in 
eliciting an immune response and/or vaccinating an indi-
vidual against Salmonella infection, and/or against disease 
symptoms caused by Salmonella infection. The composi- 45 
tions include one or more substantially purified proteins, 
polypeptides or antigenic regions thereof as described 
herein, or substantially purified nucleic acid sequences ( e.g. 
DNA cDNA, RNA, etc.) encoding such proteins, polypep-
tides or antigenic regions thereof, and a pharmacologically 50 
suitable/compatible carrier. By "substantially purified" it is 
meant that the molecule is largely free of other organic 
molecules, cellular debris, solvents, etc. when tested using 
standard techniques known to those of skill in the art ( e.g. 
gel electrophoresis, column chromatography, sequencing, 55 
mass spectroscopy, etc.). For example, the molecule is 
generally at least about 50, 55, 60, 65, 70, or 75% pure by 
wt/%, and preferably is at least about 80, 85, 90, 95% or 
more pure (e.g. 96, 97, 98, 99 or even 100% pure). The 
preparation of proteins, polypeptides, and peptides as 60 
described herein is well-known to those in the art, and 
includes, for example, recombinant preparation; isolation 
from a natural source; chemical synthesis; etc. The purifi-
cation of proteinaceous materials is also known. However, 
specific exemplary methods for preparing the vaccinating 65 
agents utilized in the practice of the invention are described 
in detail in the Examples section below. 
software programs for sequence comparison to determine 
identity. 
The proteins, polypeptides/peptides, polynucleotides, oli-
gonucleotides, derivatives or variants thereof, which may be 
used in the practice of the invention, include SipD, SipB, 
SseB and SseC, which have at least about 50, 55, 60, 65, 70, 
75, 80, 85, or 90% identity to the sequences presented 
herein, or to sections of those sequences which correspond 
to antigenic regions. Typically, the level of identity is at least 
about 92, 93, 94, 95, 96, 97, 98 or 99%. Those of skill in the 
art are familiar with methods and software programs for 
sequence comparison to determine identity. 
The invention also encompasses the use of nucleic acids 
encoding the proteins/polypeptides/peptides, chimeric mol-
ecules described herein, i.e. nucleic acid vaccines are also 
contemplated, as are vectors for producing the proteins. 
Exemplary nucleic acid sequences encoding e.g. SipD, 
SipB, and SseB are presented in FIGS. 12B, 12D and 12F 
(SEQ ID NOS: 2, 4 and 6, respectively). An exemplary 
nucleic acid sequence encoding e.g. SipD-SipB and SseB-
SseC chimeric molecules comprise SEQ ID NOS: 13 and 15 
respectively, However, those of skill in the art will appre-
ciate that the genetic code is redundant and that many 
sequences may encode a given amino acid sequence. All 
nucleic acid sequences ( e.g. DNA, RNA, cDNA, DNA/RNA 
hybrids, etc.) which successfully encode and express the 
proteins/polypeptides/peptides described herein may be 
used in the practice of the invention, so long as administra-
tion results in elicitation of an immune response (e.g. a 
protective immune response) as described herein. 
In some embodiments of the invention, the proteins, 
polypeptides or peptides that are used in the vaccine are 
chimeric or fusion proteins. The chimeric protein is trans-
lated from a single, contiguous nucleic acid molecule, and 
which comprises sequences from at least two different 
proteins or antigenic regions thereof. For example, a chi-
mera of the invention may include two or more of SipD, 
SipB, SseB and SseC, or antigenic regions of two or more 
of these. Typically, the individual sequences are joined via a 
linker or spacer sequence of e.g. from about 2 to about 20 
amino acids, usually from about 2 to about 10 amino acids. 
The amino acids in linking sequences are typically 
uncharged and the linker sequence usually does not exhibit 
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secondary or tertiary structure, but does allow the fused 
protein/peptide segments to adopt functional secondary, 
tertiary, etc. conformations. One such exemplary chimera 
includes SipB and SipD. The amino acid sequence of this 
chimera is shown in FIG. 13A (SEQ ID NO: 7). The chimera 5 
may be encoded by any suitable nucleic acid sequence, e.g. 
the exemplary nucleic acid sequence depicted in FIG. 13B 
(SEQ ID NO: 8). In one embodiment the chimeric peptide 
is SEQ ID NOS: 14 or 16. 
16 
In yet another embodiment, the vaccine comprises a 
therapeutically effective amount of one or more of: a SipB, 
a SipD, an SseB, an SseC, proteins, peptides, derivatives or 
variants thereof. The different molecules can be combined in 
doses over a period of time, administered separately or in 
any combination as determined by a health professional 
based on the severity of disease, age, sex or health of the 
subject. 
In yet another embodiment, the vaccine comprises a 
therapeutically effective amount of SipB proteins, peptides, 
derivatives or variants thereof. 
In some embodiments, the compositions of the invention 10 
comprise one or more molecules having at least about 60% 
sequence identity to SEQ ID NOS: 1-8, 13-24, or 25. In 
some embodiments, the compositions of the invention com-
prise one or more molecules of SEQ ID NOS: 1-8, 13-24, or 
In yet another embodiment, the vaccine comprises a 
therapeutically effective amount of SipD proteins, peptides, 
15 
derivatives or variants thereof. 25 . In some embodiments, the compositions of the inven-
tion comprise one or more molecules of SEQ ID NOS: 1-8, 
13-24, or 25 proteins, polypeptides, peptides, polynucle-
otides, oligonucleotides, fragments, derivatives or variants 
thereof. 
In yet another embodiment, the vaccine comprises a 
therapeutically effective amount of SseB proteins, peptides, 
derivatives or variants thereof. 
In yet another embodiment, the vaccine comprises a 
20 therapeutically effective amount of SseC proteins, peptides, 
derivatives or variants thereof. 
In an embodiment, a vaccine comprises a therapeutically 
effective amount of a chimeric molecule, the chimeric 
molecule comprising at least one Salmonella pathogenicity 
island 1 (SPI-1) and/or Salmonella pathogenicity island 2 
(SPI-2) molecule or variants thereof. In embodiments, the 
SPI-1 and/or SPI-2 molecules comprise proteins, polypep- 25 
tides, peptides, polynucleotides, oligonucleotides, frag-
ments, derivatives or variants thereof. In other embodi-
ments, the chimeric molecule comprises SipD, SipB, SseB 
or SseC proteins, polypeptides, peptides, polynucleotides, 
oligonucleotides, fragments, derivatives or variants thereof. 30 
In one embodiment, the chimeric molecule comprises a 
SipD protein, peptide, derivative or variants thereof con-
nected to a SipB protein, peptide, derivative or variants 
thereof. In another embodiment, the chimeric molecule 
comprises an SseB protein, peptide, derivative or variants 35 
thereof, connected to an SseC protein, peptide or variants 
thereof. The vaccine can be formulated in a pharmaceuti-
cally acceptable carrier and/or an adjuvant. Alternatively, the 
adjuvant may be administered separately. 
In another embodiment, the vaccine comprises an expres-
sion vector encoding one or more molecules comprising at 
least one Salmonella pathogenicity island 1 (SPI-1) and/or 
Salmonella pathogenicity island 2 (SPI-2) molecules, 
derivatives or variants thereof. In embodiments, the expres-
sion vector encodes for at least one of SipD, SipB, SseB or 
SseC proteins, fragments, derivatives, variants or any com-
binations thereof. In one embodiment, the expression vector 
encodes for a SipD protein, peptide, derivative or variants 
thereof connected to a SipB protein, peptide, derivative or 
variants thereof. In another embodiment, the expression 
vector encodes for an SseB protein, peptide, derivative or 
variants thereof, connected to an SseC protein, peptide or 
variants thereof. 
In another embodiment, the vaccine comprises an expres-
sion vector encoding a chimeric molecule comprising a SipB 
protein, peptide, derivative or variants thereof connected to 
at least one of: a SipD, and/or an SseB, and/or an SseC 
protein, peptide, derivative or variants thereof. 
In another embodiment, the vaccine comprises an expres-
sion vector encoding a chimeric molecule comprising an 
SseB protein, peptide, derivative or variants thereof con-
nected to at least one of: a SipB, and/or SipD, and/or an SseC 
protein, peptide, derivative or variants thereof. 
In another embodiment, the vaccine comprises an expres-
sion vector encoding a chimeric molecule comprising an 
SseC protein, peptide, derivative or variants thereof con-
nected to at least one of: a SipB, and/or a SipD, and/or an 
SseB protein, peptide, derivative or variants thereof. 
In another embodiment, the vaccine comprises a thera- 40 
peutically effective amount of a chimeric molecule compris-
ing a SipD protein, peptide, derivative or variants thereof 
connected to a SipB protein, peptide, derivative or variants 
thereof; and, a therapeutically effective amount of a chimeric 
molecule comprising an SseB protein, peptide or variants 45 
thereof, connected to an SseC protein, peptide, derivative or 
variants thereof. In another embodiment, the vaccine com-
prises a therapeutically effective amount of a chimeric 
molecule comprising a SipD protein, peptide, derivative or 
variants thereof connected to at least one of: a SipB, and/or 50 
an SseB, and/or an SseC, protein, peptide, derivative or 
variants thereof. In yet another embodiment, the vaccine comprises an 
expression vector encoding one or more of: a SipB, a SipD, 
an SseB, an SseC protein, peptide, derivative or variants 
55 thereof. 
In another embodiment, the vaccine comprises a thera-
peutically effective amount of a chimeric molecule compris-
ing a SipB protein, peptide, derivative or variants thereof 
connected to at least one of: a SipD, and/or an SseB, and/or 
an SseC, protein, peptide, derivative or variants thereof. 
In yet another embodiment, the vaccine comprises an 
expression vector encoding SipB proteins, peptides, deriva-
tives or variants thereof. In another embodiment, the vaccine comprises a thera-
peutically effective amount of a chimeric molecule compris-
ing an SseB protein, peptide, derivative or variants thereof 
connected to at least one of: a SipB, and/or SipD, and/or an 
SseC, protein, peptide, derivative or variants thereof. 
In yet another embodiment, the vaccine comprises an 
60 expression vector encoding SipD proteins, peptides, deriva-
tives or variants thereof. 
In another embodiment, the vaccine comprises a thera-
peutically effective amount of a chimeric molecule compris-
ing an SseC protein, peptide, derivative or variants thereof 65 
connected to at least one of a SipB, and/or a SipD, and/or an 
SseB, protein, peptide, derivative or variants thereof. 
In yet another embodiment, the vaccine comprises an 
expression vector encoding SseB proteins, peptides, deriva-
tives or variants thereof. 
In yet another embodiment, the vaccine comprises an 
expression vector encoding SseC proteins, peptides, deriva-
tives or variants thereof. 
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In yet another embodiment, the vaccine comprises an 
expression vector comprising at least one of SEQ ID NOS: 
1-8, 13-24, or 25. 
18 
and esters thereof, and other forms resulting from post-
translational modification. Also included is any parent 
sequence, up to and including 10, 9, 8, 7, 6, 5 and 4 amino 
acids in length ( cyclized, or linear, or branched from the core In another embodiment, a chimeric molecule comprises at 
least one Salmonella pathogenicity island 1 (SPI-1) and/or 
Salmonella pathogenicity island 2 (SPI-2) protein, peptides, 
variants, derivatives or combinations thereof. In some 
embodiments, the SPI-1 proteins, peptides, derivatives or 
variants thereof, are SipD and SipB. In other embodiments, 
the SPI-2 protein, peptides, derivatives or variants thereof 
are SseB and SseC. In an embodiment, a chimeric molecule 
comprises a SipD protein, peptide, derivatives or variants 
thereof, connected to a SipB protein, peptide or variants 
thereof. In another embodiment, the chimeric molecule 
comprises an SseB protein, peptide, derivatives or variants 
thereof, connected to an SseC protein, peptide, derivatives 
or variants thereof. 
5 parent sequence), for which the specified sequence is a 
subsequence. A person skilled in the art would appreciate 
that where the peptide can be a monomer, dimer, a trimer, 
etc. The uses of the peptides of the present invention include 
use of peptides wherein the active fragment or fragments are 
10 complexed to one or more binding partners. Modified pep-
tides which retain the activity of the peptides of the inven-
tion are encompassed within the scope of the present inven-
tion. 
In another embodiment, SPI-1 and SPI-2 peptides, or 
In one embodiment, the chimeric molecule comprises a 
molecule having at about 50% sequence identity to SEQ ID 
NOS: 7, 8, 13-16. In other embodiments the chimeric 
molecule comprises any one of SEQ ID NOS: 7, 8, 13-16. 
15 antigenic domains thereof, comprise at least one non-native 
amino acid residue or a non-amino acid molecule. A "non-
native" amino acid residue comprises any change to an 
amino acid which is encoded by the SPI-1 and SPI-2 nucleic 
acid sequences. Thus, a non-native amino acid residue or 
20 non-amino acid molecule comprises, without limitation: a 
chemical equivalent, analog, synthetic molecule, derivative, 
variant, substitution, peptide nucleic acid, a linker molecule, 
inorganic molecule etc. 
In yet another embodiment, a chimeric molecule com-
prises a nucleic acid sequence encoding at least one Salmo-
nella pathogenicity island 1 (SPI-1) and/or Salmonella 
pathogenicity island 2 (SPI-2) protein, peptides, variants, 25 
derivatives or combinations thereof. In an embodiment, the 
SPI-1 nucleic acid sequence encodes for SipD and/or SipB 
proteins, peptides, derivatives or variants thereof. In another 
embodiment, the SPI-2 nucleic acid sequence encodes for 
SseB and/or SseC protein, peptides, derivatives or variants 30 
thereof. 
The mutations can be introduced at the nucleic acid level 
or at the amino acid level. With respect to particular nucleic 
acid sequences, because of the degeneracy of the genetic 
code, a large number of functionally identical nucleic acids 
encode any given protein. For instance, the codons GCA, 
GCC, GCG and GCU all encode the amino acid alanine. 
Thus, at every position where an alanine is specified by a 
codon, the codon can be altered to any of the corresponding 
codons described without altering the encoded polypeptide. 
Such nucleic acid variations are "silent variations," which 
are one species of conservatively modified variations. If 
In another embodiment, a chimeric molecule comprises a 
nucleic acid sequence encoding at least one Salmonella 
pathogenicity island 1 (SPI-1) and at least one Salmonella 
pathogenicity island 2 (SPI-2) protein, peptides, derivatives, 
variants or combinations thereof. Preferably, the SPI-1 and 
SPI-2 protein, peptides, derivatives or variants comprise 
SipD, SipB, SseB, or SseC. 
35 mutations at the nucleic acid level are introduced to encode 
In another embodiment, a vaccine formulation comprises 
a therapeutically effective amount of a first chimeric mo!- 40 
ecule and a second chimeric molecule in a pharmaceutically 
acceptable carrier, the first chimeric molecule comprising at 
least one Salmonella pathogenicity island 1 (SPI-1) mol-
ecule linked or connected to at least one SPI-1 molecule; the 
second chimeric molecule comprising at least one Salmo- 45 
nella pathogenicity island 2 (SPI-2) linked or connected to 
at least one SPI-2 molecule. In one embodiment, the at least 
one SPI-1 molecule is connected to an SPI-2 molecule. 
In certain embodiments, the SPI-1 and/or SPI-2 molecules 
of the invention can be administered to cells as a single 50 
protein containing SipD, SipB, SseB, or SseC ( or active 
domains thereof), separated by a cleavable linker. Examples 
of cleavable linkers are known in the art (see, e.g., U.S. Pat. 
Nos. 5,258,498 and 6,083,486.) 
Modified polypeptides: The invention is not limited to 55 
wild type SPI-1 and SPI-2 molecules but includes without 
limitation, allelic variants, species variants, splicing vari-
ants, mutants, fragments, and the like. 
In an embodiment, SPI-1 and SPI-2 includes the peptide 
itself, chemical equivalents thereto, isomers thereof ( e.g., 60 
isomers, stereoisomers, retro isomers, retro-inverso isomers, 
all-[D] isomers, all-[L] isomers, or mixed [L] and [DJ 
isomers thereof), conservative substitutions therein, precur-
sor forms thereof; endoproteolytically-processed forms 
thereof, such as cleavage of single amino acids from N or C 65 
terminals or immunologically active metabolites of the 
peptides of the invention, pharmaceutically-acceptable salts 
a particular amino acid, then one or more nucleic acids are 
altered. For example praline is encoded by CCC, CCA, 
CCG, CCU; thus, one base change, e.g. CCC (praline) to 
GCC gives rise to alanine. Thus by way of example every 
natural or non-natural nucleic acid sequence herein which 
encodes a natural or non-natural polypeptide also describes 
every possible silent variation of the natural or non-natural 
nucleic acid. One of skill will recognize that each codon in 
a natural or non-natural nucleic acid ( except AUG, which is 
ordinarily the only codon for methionine, and TGG, which 
is ordinarily the only codon for tryptophan) can be modified 
to yield a functionally identical molecule or a different 
molecule. Accordingly, each silent variation of a natural and 
non-natural nucleic acid which encodes a natural and non-
natural polypeptide is implicit in each described sequence. 
As to amino acid sequences, individual substitutions, 
deletions or additions to a nucleic acid, peptide, polypeptide, 
or protein sequence which alters, adds or deletes a single 
natural and non-natural amino acid or a small percentage of 
natural and non-natural amino acids in the encoded 
sequence, the alteration results in the deletion of an amino 
acid, addition of an amino acid, or substitution of a natural 
and non-natural amino acid with a chemically similar amino 
acid. Conservative substitution tables providing functionally 
similar natural amino acids are well known in the art. Such 
conservatively modified variants are in addition to and do 
not exclude polymorphic variants, interspecies homologs, 
and alleles of the methods and compositions described 
herein. 
A "non-natural amino acid" refers to an amino acid that is 
not one of the 20 common amino acids or pyrolysine or 
selenocysteine. Other terms that may be used synonymously 
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porate a non-natural amino acid, and selection may be based 
on rational design or by random selection for any or no 
particular desired purpose. Selection of desired sites may be 
based on producing a non-natural amino acid polypeptide 
with the term "non-natural amino acid" is "non-naturally 
encoded amino acid," "unnatural amino acid," "non-natu-
rally-occurring amino acid," and variously hyphenated and 
non-hyphenated versions thereof. The term "non-natural 
amino acid" includes, but is not limited to, amino acids 
which occur naturally by modification of a naturally 
encoded amino acid (including but not limited to, the 20 
common amino acids or pyrrolysine and selenocysteine) but 
are not themselves incorporated, without user manipulation, 
into a growing polypeptide chain by the translation complex. 
Examples of naturally-occurring amino acids that are not 
naturally-encoded include, but are not limited to, N-acetyl-
glucosaminyl-L-serine, N-acety lglucosaminy 1-L-threonine, 
and O-phosphotyrosine. Additionally, the term "non-natural 
amino acid" includes, but is not limited to, amino acids 
which do not occur naturally and may be obtained syntheti-
cally or may be obtained by modification of non-natural 
amino acids. 
5 (which may be further modified or remain unmodified) 
having any desired property or activity, binding partner 
conformation modulators, dimer or multimer formation, no 
change to activity or property compared to the native 
molecule, or manipulating any physical or chemical prop-
IO erty of the polypeptide such as solubility, aggregation, or 
stability. For example, locations in the polypeptide required 
for antigenicity of a polypeptide can be identified using 
methods including, but not limited to, point mutation analy-
In some cases, the non-natural amino acid substitution(s) 
or incorporation(s) will be combined with other additions, 
substitutions, or deletions within the polypeptide to affect 
other chemical, physical, pharmacologic and/or biological 
traits. In some cases, the other additions, substitutions or 
deletions may increase the stability (including but not lim-
ited to, resistance to proteolytic degradation) of the poly-
peptide or increase affinity of the polypeptide for its appro-
priate receptor, ligand and/or binding proteins. In some 
cases, the other additions, substitutions or deletions may 
increase the solubility of the polypeptide. In some embodi-
ments sites are selected for substitution with a naturally 
encoded or non-natural amino acid in addition to another site 
for incorporation of a non-natural amino acid for the purpose 
15 sis, alanine scanning or homolog scanning methods. Resi-
dues other than those identified as critical to biological 
activity by methods including, but not limited to, alanine or 
homolog scanning mutagenesis may be good candidates for 
substitution with a non-natural amino acid depending on the 
20 desired activity sought for the polypeptide. Alternatively, the 
sites identified as critical to biological activity may also be 
good candidates for substitution with a non-natural amino 
acid, again depending on the desired activity sought for the 
polypeptide. Another alternative would be to make serial 
25 substitutions in each position on the polypeptide chain with 
a non-natural amino acid and observe the effect on the 
activities of the polypeptide. Any means, technique, or 
method for selecting a position for substitution with a 
non-natural amino acid into any polypeptide is suitable for 
30 use in the methods, techniques and compositions described 
herein. 
The structure and activity of naturally-occurring mutants 
of a polypeptide that contain deletions can also be examined 
to determine regions of the protein that are likely to be 
35 tolerant of substitution with a non-natural amino acid. Once 
of increasing the polypeptide solubility following expres-
sion in recombinant host cells. In some embodiments, the 
polypeptides comprise another addition, substitution, or 
deletion that modulates affinity for the associated ligand, 
binding proteins, and/or receptor, modulates (including but 
not limited to, increases or decreases) receptor dimerization, 
stabilizes receptor dimers, modulates circulating half-life, 
modulates release or bio-availability, facilitates purification, 40 
or improves or alters a particular route of administration. 
Similarly, the non-natural amino acid polypeptide can com-
prise chemical or enzyme cleavage sequences, protease 
cleavage sequences, reactive groups, antibody-binding 
domains (including but not limited to, FLAG or poly-His) or 45 
other affinity based sequences (including but not limited to, 
FLAG, poly-His, GST, etc.) or linked molecules (including 
but not limited to, biotin) that improve detection (including 
but not limited to, GFP), purification, transport thru tissues 
or cell membranes, prodrug release or activation, size reduc- 50 
tion, or other traits of the polypeptide. 
The methods and compositions described herein include 
incorporation of one or more non-natural amino acids into a 
polypeptide. One or more non-natural amino acids may be 
incorporated at one or more particular positions which do 55 
not disrupt activity of the polypeptide. This can be achieved 
by making "conservative" substitutions, including but not 
limited to, substituting hydrophobic amino acids with non-
natural or natural hydrophobic amino acids, bulky amino 
acids with non-natural or natural bulky amino acids, hydro- 60 
philic amino acids with non-natural or natural hydrophilic 
amino acids) and/or inserting the non-natural amino acid in 
a location that is not required for activity. 
A variety of biochemical and structural approaches can be 
employed to select the desired sites for substitution with a 65 
non-natural amino acid within the polypeptide. Any position 
of the polypeptide chain is suitable for selection to incor-
residues that are likely to be intolerant to substitution with 
non-natural amino acids have been eliminated, the impact of 
proposed substitutions at each of the remaining positions can 
be examined using methods including, but not limited to, the 
three-dimensional structure of the relevant polypeptide, and 
any associated ligands or binding proteins. X-ray crystallo-
graphic and NMR structures of many polypeptides are 
available in the Protein Data Bank (PDB, www.rcsb.org), a 
centralized database containing three-dimensional structural 
data of large molecules of proteins and nucleic acids, one 
can be used to identify amino acid positions that can be 
substituted with non-natural amino acids. In addition, mod-
els may be made investigating the secondary and tertiary 
structure of polypeptides, if three-dimensional structural 
data is not available. Thus, the identity of amino acid 
positions that can be substituted with non-natural amino 
acids can be readily obtained. Exemplary sites of incorpo-
ration of a non-natural amino acid include, but are not 
limited to, those that are excluded from potential receptor 
binding regions, or regions for binding to binding proteins or 
ligands may be fully or partially solvent exposed, have 
minimal or no hydrogen-bonding interactions with nearby 
residues, may be minimally exposed to nearby reactive 
residues, and/or may be in regions that are highly flexible as 
predicted by the three-dimensional crystal structure of a 
particular polypeptide with its associated receptor, ligand or 
binding proteins. 
A wide variety of non-natural amino acids can be substi-
tuted for, or incorporated into, a given position in a poly-
peptide. By way of example, a particular non-natural amino 
acid may be selected for incorporation based on an exami-
nation of the three dimensional crystal structure of a poly-
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peptide with its associated ligand, receptor and/or binding 
proteins e.g. innnunoglobulins, a preference for conserva-
tive substitutions 
As further used herein, a "chemical equivalent" of a 
peptide of the invention is a molecule which possesses the 5 
same desired activity, e.g. innnunological activity, as pep-
tides described herein, and exhibits a trivial chemical dif-
ferent, or a molecule which is converted, under mild con-
ditions, into a peptide of the invention ( e.g., esters, ethers, 
reduction products, and complexes of the peptides of the 10 
invention). 
22 
In another embodiment, the naturally occurring side 
chains of the 20 genetically encoded amino acids ( or D 
amino acids) are replaced with other side chains with similar 
properties, for instance with groups such as alkyl, lower 
alkyl, cyclic 4-, 5-, 6-, to 7-membered alkyl amide, amide 
lower alkyl amide di(lower alkyl), lower alkoxy, hydroxy, 
carboxy and the lower ester derivatives thereof, and with 4-, 
5-, 6-, to 7-membered heterocyclic. 
Such substitutions can include but are not necessarily 
limited to: (1) non-standard positively charged amino acids, 
like: ornithine, Nlys; N-(4-aminobutyl)-glycine which has 
the lysine side chain attached to the "N-terminus" and 
compounds with aminopropyl or aminoethyl groups 
attached to the amino group of glycine. (2), Non-naturally 
occurring amino acids with no net charge and side-chains 
similar to arginine, such as, Cit; citrulline and Hci; citrulline 
with one more methylene group; (3) non-standard non-
naturally occurring amino acids with OH (e.g., like serine), 
such as, hSer; homoserine (one more methylen group, Hyp; 
hydroxyproline, Val((~OH); hydroxyvaline, Pen; penicil-
lamin, (Val(~SH); ( 4) praline derivatives, such as, D-Pro, 
such as, 3,4-dehydroproline, Pyr; pyroglutamine (praline 
with C=O in ring), Pro line with fluorine substitutions on the 
ring, 1,3-thiazolidine-+carboxylic acid (praline with S in 
The term "analogue", as used herein, includes any peptide 
having an amino acid sequence substantially identical to a 
sequence described herein, in which at least one residue has 
15 
been conservatively substituted with a functionally-similar 
residue. An "analogue" includes functional variants and 
obvious chemical equivalents of an amino acid sequence of 
SPI-1 and SPI-2 peptides, or functional domains thereof. As 
further used herein, the term "functional variant" refers to 20 
the activity of a peptide that demonstrates an ability to 
signal; interacting with one or more molecules; activating a 
transcription pathway, etc. An "analogue" further includes 
any pharmaceutically-acceptable salt of an analogue as 
described herein. 25 ring); (5) Histidine derivative, such as, Thi; beta-(2-thienyl)-
alanine; or (6) alkyl derivatives, such as, Abu; 2-aminobu-
tyric acid ( ethyl group on Ca), Nva; norvaline (propyl group 
on Ca), Nie; norleucine (butyl group on Ca), Ho!; homo-
leucine (propyl group on Ca), Aib, alpha-aminoisobutyric 
A "derivative", as used herein, refers to a peptide of the 
invention having one or more amino acids chemically 
derivatized by reaction of a functional side group. Exem-
plary derivatized molecules include, without limitation, pep-
tide molecules in which free amino groups have been 
derivatized to form salts or amides, by adding acetyl groups, 
amine hydrochlorides, carbobenzoxy groups, chloroacetyl 
groups, formyl groups, p-toluene sulfonyl groups, or t-bu-
tyloxycarbonyl groups. Free hydroxyl groups may be 
derivatized to form O-acyl or O-alkyl derivatives. Further-
more, free carboxyl groups may be derivatized to form salts, 
esters (e.g., methyl and ethyl esters), or hydrazides. Thus, a 
"derivative" further includes any pharmaceutically-accept-
able salt of a derivative as described herein. 
30 acid (valine without methylene group). A person skilled in 
the art would appreciate that those substitutions that retain 
the activity of the parent peptide/sequence. 
In another alternative embodiment, the C-terminal car-
boxyl group or a C-terminal ester can be induced to cyclize 
35 by internal displacement of the -OH or the ester (-OR) of 
the carboxyl group or ester respectively with the N-terminal 
amino group to form a cyclic peptide. For example, after 
synthesis and cleavage to give the peptide acid, the free acid 
is converted to an activated ester by an appropriate carboxyl 
40 group activator such as dicyclohexylcarbodiimide (DCC) in 
solution, for example, in methylene chloride (CH2Cl2), 
dimethyl formamide (DMF) mixtures. The cyclic peptide is 
then formed by internal displacement of the activated ester 
with the N-terminal amine. Internal cyclization as opposed 
The peptides embodied herein, can a modified C-terminus 
and/or a modified N-terminus. For example, an amidated 
C-terminus, the amino terminus can be acetylated (Ac) or 
the carboxy terminus can be amidated (NH2 ). However, the 
peptides of the invention are preferably not acetylated if 
such a modification would result in loss of desired innnu-
nological activity. Amino terminus modifications include 
methylating (i.e., -NHCH3 or -NH(CH3 ) 2 , acetylating, 
adding a carbobenzoyl group, or blocking the amino termi-
nus with any blocking group containing a carboxylate func-
tionality defined by RCOO-, where R is selected from the 50 
group consisting of naphthyl, acridinyl, steroidyl, and simi-
45 to polymerization can be enhanced by use of very dilute 
solutions. Such methods are well known in the art. 
The peptides of the invention can be cyclized, or a 
desamino or descarboxy residue at the termini of the peptide 
can be incorporated, so that there is no terminal amino or 
carboxyl group, to decrease susceptibility to proteases or to 
restrict the conformation of the peptide. C-terminal func-
tional groups of the compounds of the present invention 
include amide, amide lower alkyl, amide di(lower alkyl), 
lower alkoxy, hydroxy, and carboxy, and the lower ester 
lar groups. Carboxy terminus modifications include replac-
ing the free acid with a carboxamide group or forming a 
cyclic lactam at the carboxy terminus to introduce structural 
constraints. 55 derivatives thereof, and the pharmaceutically acceptable 
salts thereof. In one embodiment backbone substitutions can be made, 
such as NH to NCH3 • The SPI-1 and SPI-2 peptides may 
also be a modification ( e.g., a point mutation, such as an 
insertion or a deletion, or a truncation). By way of example, 
the peptide may comprise an amino acid sequence compris- 60 
ing a modified residue by at least one point insertion of a D 
amino acid as long as desired innnunogenicity is retained. In 
particular, praline analogs in which the ring size of the 
praline residue is changed from 5 members to 4, 6, or 7 
members can be employed. Cyclic groups can be saturated 65 
or unsaturated, and if unsaturated, can be aromatic or 
non-aromatic. 
The peptides of the invention can be cyclized by adding 
an N and/or C terminal cysteine and cyclizing the peptide 
through disulfide linkages or other side chain interactions. 
A desamino or descarboxy residue at the termini of the 
peptide can be incorporated, so that there is no terminal 
amino or carboxyl group, to decrease susceptibility to pro-
teases or to restrict the conformation of the peptide. 
Mutant polypeptides, e.g. SPI-1 and SPI-2, molecules 
comprising SipD, SipB, SseB or SseC or antigenic domains 
thereof, can be assessed in one or more of the assays 
described herein. The polypeptides can include amino acid 
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residues (naturally occurring, synthetic, analogs, deriva-
tives, or modified (e.g., glycosylated or phosphorylated 
residues) that are linked by a peptide bond. 
24 
can be a molecule of genomic DNA, cDNA, synthetic DNA, 
or RNA. The nucleic acid molecule encoding, for example, 
a SipD, SipB, SseB or SseC polypeptide will be at least 65%, 
at least 75%, at least 85%, or at least 95% (e.g., 99%) 
5 identical to the nucleic acid encoding wild-type molecules. 
In addition to containing one or more mutations, a poly-
peptide of the invention can be substantially pure (i.e., 
separated from one or more of the components that naturally 
accompany the polypeptide). Typically, a polypeptide is 
substantially pure when it is at least 60%, by weight, free 
from naturally occurring organic molecules. Alternatively, 
the preparation can be at least 75%, at least 90%, or at least 10 
99%, by weight, of mutant polypeptide. A substantially pure 
mutant polypeptide can be obtained, for example, by expres-
sion of a recombinant nucleic acid encoding a mutant 
polypeptide, e.g. SipD, SipB, SseB or SseC, or by chemi-
cally synthesizing the polypeptide. Purity can be measured 
For nucleic acids, the length of comparison sequences will 
generally be at least 50 nucleotides, preferably at least 60 
nucleotides, more preferably at least 75 nucleotides, and 
most preferably 10 nucleotides. 
The polynucleotides e.g. SPI-1 and SPI-2 molecules com-
prising SipD, SipB, SseB or SseC can also comprise modi-
fications. Examples of some modified polynucleotides envi-
sioned for this invention include those comprising modified 
backbones, for example, phosphorothioates, phosphotri-
15 esters, methyl phosphonates, short chain alkyl or cycloalkyl 
intersugar linkages or short chain heteroatomic or hetero-
cyclic intersugar linkages. In some embodiments, modified 
SPI-1 and SPI-2 polynucleotides comprise those with phos-
phorothioate backbones and those with heteroatom back-
by any appropriate method, including colurmi chromatog-
raphy, polyacrylamide gel electrophoresis, or HPLC analy-
sis. Polypeptides that are derived from eukaryotic organisms 
but synthesized in E. coli, or other prokaryotes, and poly-
peptides that are chemically synthesized will be substan-
tially free from their naturally associated components. 
A wild type SipD, SipB, SseB or SseC can be a polypep-
tide that is identical to the naturally-occurring SipD, SipB, 
SseB or SseC polypeptide. A mutant polypeptide can be a 
polypeptide or portion thereof having at least one mutation 
relative to the wild-type molecule. 
Mutations in polypeptides can be effected in many fol-
lowing ways, for example: deletion of one or more of the 
amino acids, addition of one or more amino acids, or 
substitution of one or more of the amino acids. In the event 
the mutation is a substitution, the substitution can be a 
conservative or non-conservative substitution. Non-conser-
vative substitutions occur when one amino acid residue in a 
polypeptide sequence is replaced by another amino acid that 
has a different physical property (e.g., a different size, 
charge, or polarity) as the amino acid being replaced. For 
example, substitution of a non-aromatic amino acid in the 
place of an aromatic amino acid ( e.g., substitution of an 
alanine in the place of tryptophan) is an example of a 
non-conservative substitution. Alternately, the substitution 
can be a conservative amino acid substitution. A conserva-
tive substitution can be the replacement of one amino acid 
in a polypeptide sequence by another amino acid, wherein 
the replacement amino acid has similar physical properties 
(e.g., size, charge, and polarity) as the amino acid being 
replaced. For example, replacing one aromatic amino acid 
with another aromatic amino acid can be a conservative 
substitution. Some typical examples of conservative amino 
acid substitutions include substitutions with the following 
groups: glycine and alanine; valine, isoleucine, and leucine; 
aspartic acid and glutamic acid; asparagine and glutamine; 
serine and threonine; lysine and arginine; and phenylalanine 
and tyrosine. The substitution can be, for example, a non-
aromatic amino acid substitution. The substitution can also 
be at the corresponding position of a polypeptide from 
another species (for example, a domesticated animal such as 
a cow, pig, sheep, rabbit, goat, dog or cat). The term 
"conservative substitutions", as defined herein, includes 
substitutions having an inconsequential effect on the ability 
of the peptide of the invention to enhance innate immunity. 
The polypeptides described herein can include a heter-
ologous (i.e., non-SipD, -SipB, -SseB or -SseC) sequence. 
Polynucleotides: A mutant polypeptide, whether alone or 
as a part of a chimeric polypeptide, can be encoded by a 
nucleic acid molecule, and substantially pure nucleic acid 
molecules that encode the mutant polypeptides described 
herein are within the scope of the invention. The nucleic acid 
20 bones, CH2-NH-O----CH2 , CH, -N(CH3)---0----CH2 
[known as a methylene(methylimino) or MMI backbone], 
CH2-O-N (CH3)----CH2 , CH2-N(CH3 )-N(CH3 )-CH2 
and O-N(CH3)----CH2----CH2 backbones, wherein the 
native phosphodiester backbone is represented as O-P-
25 O----CH). The amide backbones disclosed by De Mesmaeker 
et al. Acc. Chem. Res. 1995, 28:366-374) are also embodied 
herein. In some embodiments, the oligonucleotides having 
morpholino backbone structures (Summerton and Weller, 
U.S. Pat. No. 5,034,506), peptide nucleic acid (PNA) back-
30 bone wherein the phosphodiester backbone of the oligo-
nucleotide is replaced with a polyamide backbone, the 
nucleobases being bound directly or indirectly to the aza 
nitrogen atoms of the polyamide backbone (Nielsen et al. 
Science 1991, 254, 1497). Oligonucleotides may also com-
35 prise one or more substituted sugar moieties. Oligonucle-
otides may also have sugar mimetics such as cyclobutyls in 
place of the pentofuranosyl group. 
Polynucleotides may also include, additionally or alter-
natively, nucleobase (often referred to in the art simply as 
40 "base") modifications or substitutions. As used herein, 
"urnnodified" or "natural" nucleobases include adenine (A), 
guanine (G), thymine (T), cytosine (C) and uracil (U). 
Modified nucleobases include nucleobases found only infre-
quently or transiently in natural nucleic acids, e.g., hypox-
45 anthine, 6-methyladenine, 5-Me pyrimidines, particularly 
5-methylcytosine (also referred to as 5-methyl-2' deoxycy-
tosine and often referred to in the art as 5-Me-C), 5-hy-
droxymethylcytosine (HMC), glycosyl HMC and gentobio-
syl HMC, as well as synthetic nucleobases, e.g., 
so 2-aminoadenine, 2-(methylamino )adenine, 2-(imidazolylal-
kyl)adenine, 2-(aminoalklyamino)adenine or other hetero-
substituted alkyladenines, 2-thiouracil, 2-thiothymine, 
5-bromouracil, 5-hydroxymethyluracil, 8-azaguanine, 
7-deazaguanine, N 6 (6-aminohexyl)adenine and 2,6-diamin-
55 opurine. Kornberg, A., DNA Replication, W. H. Freeman & 
Co., San Francisco, 1980, pp 75-T7; Gebeyehu, G., et al. 
Nucl. Acids Res. 1987, 15:4513). A "universal" base known 
in the art, e.g., inosine, may be included. 5-Me-C substitu-
tions have been shown to increase nucleic acid duplex 
60 stability by 0.6-1.2° C. (Sanghvi, Y. S., in Crooke, S. T. and 
Lebleu, B., eds., Anti sense Research and Applications, CRC 
Press, Boca Raton, 1993, pp. 276-278) and are presently 
preferred base substitutions. 
Another modification of the polynucleotides of the inven-
65 tion involves chemically linking to the polynucleotide, one 
or more moieties or conjugates which enhance the activity or 
cellular uptake of the polynucleotide. Such moieties include 
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but are not limited to lipid moieties such as a cholesterol 
moiety, a cholesteryl moiety (Letsinger et al., Proc. Natl. 
Acad. Sci. USA 1989, 86, 6553), cholic acid (Manoharan et 
al. Bioorg. Med. Chem. Let. 1994, 4, 1053), a thioether, e.g., 
hexyl-S-tritylthiol (Manoharan et al. Ann. N.Y. Acad. Sci. 
1992, 660, 306; Manoharan et al. Bioorg. Med. Chem. Let. 
1993, 3, 2765), a thiocholesterol (Oberhauser et al., Nucl. 
Acids Res. 1992, 20, 533), an aliphatic chain, e.g., dodecan-
diol or undecyl residues (Saison-Behmoaras et al. EMBO J. 
1991, 10, 111; Kabanov et al. FEES Lett. 1990, 259, 327; 
Svinarchuk et al. Biochimie 1993, 75, 49), a phospholipid, 
e.g., di-hexadecyl-rac-glycerol or triethylarmnonium 1,2-di-
O-hexadecy l-rac-glycero-3-H-phosphonate (Manoharan et 
26 
In a preferred embodiment, an expression vector com-
prises a nucleic acid molecule with a sequence encoding 
polypeptides described herein. The vector can be capable of 
directing expression of a SipD, SipB, SseB or SseC poly-
5 peptide in, for example, a cell that has been transduced with 
the vector. These vectors can be viral vectors, such as 
retroviral, adenoviral, or adenoviral-associated vectors, as 
well as plasmids or cosmids. Prokaryotic or eukaryotic cells 
that contain and express DNA encoding any of the mol-
10 ecules comprising SipD, SipB, SseB or SseC; mutant SipD, 
SipB, SseB or SseC; SipD, SipB, SseB or SseC antigenic 
epitopes, fusion peptides ( e.g. SEQ ID NOS: 14 and 16) etc, 
are also features of the invention. The method of transduc-
al. Tetrahedron Lett. 1995, 36, 3651; Shea et al. Nucl. Acids 
15 
Res. 1990, 18, 3777), a polyamine or a polyethylene glycol 
chain (Manoharan et al. Nucleosides & Nucleotides 1995, 
tion, the choice of expression vector, and the host cell may 
vary. The precise components of the expression system are 
not critical. It matters only that the components are com-
patible with one another, a determination that is well within 
the abilities of skilled artisans. Furthermore, for guidance in 
selecting an expression system, skilled artisans may consult 
Ausubel et al., Current Protocols in Molecular Biology 
(1993, John Wiley and Sons, New York, N.Y.) and Pouwels 
14, 969), or adamantane acetic acid (Manoharan et al. 
Tetrahedron Lett. 1995, 36, 3651 ). Polynucleotides compris-
ing lipophilic moieties and methods for preparing such 20 
polynucleotides are known in the art, for example, U.S. Pat. 
Nos. 5,138,045, 5,218,105 and 5,459,255. et al., Cloning Vectors: A Laboratory Manual (1987). The 
vector can also have a sequence that encodes a detectable 
marker, such as ~-galactosidase, a-glucuronidase (GUS), 
luciferase, horseradish peroxidase (HRP), alkaline phos-
phatase, acetylcholinesterase, or chloramphenicol acetyl 
It is not necessary for all positions in a given polynucle-
otide to be uniformly modified, and in fact more than one of 
the aforementioned modifications may be incorporated in a 25 
single polynucleotide or even at within a single nucleoside 
within a polynucleotide. The present invention also includes 
polynucleotides which are chimeric polynucleotides as here-
inbefore defined. 
transferase. Fluorescent reporter genes include, but are not 
limited to, green fluorescent protein (GFP), red fluorescent 
protein (RFP), cyan fluorescent protein (CFP), and blue 
Vectors Expressing SPI-1 and/or SPI-2 Molecules 
Also encompassed are vectors which contain such nucleic 
acid sequences ( e.g. plasmids, cosmids, various expression 
vectors, etc.), and host cells such as bacteria, insect cells, 
etc., which comprise the nucleic acid sequences and/or the 
vectors. Such vectors typically include one or more express-
ible gene sequences encoding one or more or the proteins/ 
polypeptides/peptides of interest, operably linked to at least 
one transcription element (e.g. a promoter) that drives 
expression of the gene. The vectors may be used for pro-
duction of the proteins/fragments thereof, or may be used as 
a vaccinating agent, i.e. the invention also encompasses 
nucleic acid vaccines. Those of skill in the art are aware of 
the many protocols for preparing and administering nucleic 
acid vaccines, such as those described in issued U.S. Pat. 
Nos. 7,927,870 and 7,094,410, the complete contents of 
which are hereby incorporated by referenced in entirety. 
Sequence identity may be determined in various ways that 
are within the skill in the art, e.g., using publicly available 
computer software such as BLAST, BLAST-2, ALIGN or 
Megalign (DNASTAR) software, which are used to perform 
sequence alignments and then calculate sequence identity. 
Exemplary software programs available from the National 
Center for Biotechnology Information (NCBI) on the web-
site ncbi.nlm.nih.gov include blastp, blastn, blastx, tblastn 
and tblastx. Those skilled in the art can determine appro-
priate parameters for measuring alignment, including any 
algorithms needed to achieve maximal alignment over the 
full length of the sequences being compared. The search 
parameters for histogram, descriptions, alignments, expect 
(i.e., the statistical significance threshold for reporting 
matches against database sequences), cutoff, matrix and 
filter are used at the default settings. The default scoring 
matrix used by blastp, blastx, tblastn, and tblastx is the 
BLOSUM62 matrix (Henikoff et al, (1992) Proc. Natl. 
Acad. Sci. USA 89: 10915-10919). In one approach, the 
percent identity can be determined using the default param-
eters of blastp, version 2.2.26 available from the NCBI. 
30 fluorescent protein (BFP). The detectable marker can also be 
an epitope tag, such as a myc, FLAG, or HA tag. 
In an embodiment, a vector comprises one or more 
polynucleotides comprising SEQ ID NOS: 1-8 and 13-16, 
variants, mutants, derivatives or fragments thereof. The 
35 vector can be administered to a patient wherein expression 
of SEQ ID NOS: 1-8 and 13-16, variants, mutants, deriva-
tives or fragments thereof, induce response. A number of 
vectors are known to be capable of mediating transfer of 
gene products to mammalian cells, as is known in the art and 
40 described herein. A "vector" (sometimes referred to as gene 
delivery or gene transfer "vehicle") refers to a macromol-
ecule or complex of molecules comprising a polynucleotide 
to be delivered to a host cell, either in vitro or in vivo. The 
polynucleotide to be delivered may comprise a coding 
45 sequence of interest in gene therapy. Vectors include, for 
example, viral vectors (such as adenoviruses ("Ad"), adeno-
associated viruses (AAV), and retroviruses), liposomes and 
other lipid-containing complexes, and other macromolecular 
complexes capable of mediating delivery of a polynucle-
50 otide to a host cell. Vectors can also comprise other com-
ponents or functionalities that further modulate gene deliv-
ery and/or gene expression, or that otherwise provide 
beneficial properties to the targeted cells. As described and 
illustrated in more detail below, such other components 
55 include, for example, components that influence binding or 
targeting to cells (including components that mediate cell-
type or tissue-specific binding); components that influence 
uptake of the vector nucleic acid by the cell; components 
that influence localization of the polynucleotide within the 
60 cell after uptake (such as agents mediating nuclear localiza-
tion); and components that influence expression of the 
polynucleotide. Such components also might include mark-
ers, such as detectable and/or selectable markers that can be 
used to detect or select for cells that have taken up and are 
65 expressing the nucleic acid delivered by the vector. Such 
components can be provided as a natural feature of the 
vector (such as the use of certain viral vectors which have 
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components or functionalities mediating binding and 
uptake), or vectors can be modified to provide such func-
tionalities. Other vectors include those described by Chen et 
28 
Sambrook, et al., Molecular Cloning: A Laboratory Manual, 
Cold Spring Harbor Laboratory press, (1989). The plasmid 
vector may also include a selectable marker such as the 
13-lactamase gene for ampicillin resistance, provided that al; BioTechniques, 34: 167-171 (2003). Large varieties of 
such vectors are known in the art and are generally available. 
A "recombinant viral vector" refers to a viral vector 
comprising one or more heterologous gene products or 
sequences. Since many viral vectors exhibit size-constraints 
associated with packaging, the heterologous gene products 
5 the marker polypeptide does not adversely affect the 
metabolism of the organism being treated. The cassette can 
also be bound to a nucleic acid binding moiety in a synthetic 
delivery system, such as the system disclosed in WO 
95/22618. 
or sequences are typically introduced by replacing one or 10 
more portions of the viral genome. Such viruses may 
become replication-defective, requmng the deleted 
function(s) to be provided in trans during viral replication 
and encapsidation (by using, e.g., a helper virus or a pack-
aging cell line carrying gene products necessary for repli- 15 
cation and/or encapsidation). Modified viral vectors in 
which a polynucleotide to be delivered is carried on the 
outside of the viral particle have also been described (see, 
e.g., Curiel, D T, et al. PNAS 88: 8850-8854, 1991). 
Suitable nucleic acid delivery systems include viral vec- 20 
tor, typically sequence from at least one of an adenovirus, 
adenovirus-associated virus (AAV), helper-dependent 
adenovirus, retrovirus, or hemagglutinating virus of Japan-
liposome (HVJ) complex. Preferably, the viral vector com-
prises a strong eukaryotic promoter operably linked to the 25 
polynucleotide e.g., a cytomegalovirus (CMV) promoter. 
Additionally preferred vectors include viral vectors, 
fusion proteins and chemical conjugates. Retroviral vectors 
include Moloney murine leukemia viruses and HIV-based 
viruses. One HIV-based viral vector comprises at least two 30 
vectors wherein the gag and pol genes are from an HIV 
genome and the env gene is from another virus. DNA viral 
vectors are preferred. These vectors include pox vectors 
such as orthopox or avipox vectors, herpesvirus vectors such 
as a herpes simplex I virus (HSY) vector [Geller, A. I. et al., 35 
J. Neurochem, 64: 487 (1995); Lim, F., et al., in DNA 
Cloning: Mammalian Systems, D. Glover, Ed. (Oxford 
Univ. Press, Oxford England) (1995); Geller, A. I. et al., 
Proc Natl. Acad. Sci.: U.S.A.:90 7603 (1993); Geller, A. I., 
et al., Proc Natl. Acad. Sci USA: 87:1149 (1990)], Adena- 40 
virus Vectors [LeGal LaSalle et al., Science, 259:988 (1993); 
Davidson, et al., Nat. Genet. 3: 219 (1993); Yang, et al., J. 
Viral. 69: 2004 (1995)] and Adena-associated Virus Vectors 
[Kaplitt, M. G., et al., Nat. Genet. 8:148 (1994)]. 
Pox viral vectors introduce the gene into the cells cyto- 45 
plasm. Avipox virus vectors result in only a short term 
expression of the nucleic acid. Adenovirus vectors, adeno-
associated virus vectors and herpes simplex virus (HSY) 
vectors may be an indication for some invention embodi-
ments. The adenovirus vector results in a shorter term 50 
expression (e.g., less than about a month) than adeno-
associated virus, in some embodiments, may exhibit much 
longer expression. The particular vector chosen will depend 
upon the target cell and the condition being treated. The 
selection of appropriate promoters can readily be accom- 55 
plished. Preferably, one would use a high expression pro-
moter. An example of a suitable promoter is the 763-base-
pair cytomegalovirus (CMV) promoter. The Rous sarcoma 
virus (RSV) (Davis, et al., Hum Gene Ther 4:151 (1993)) 
and MMT promoters may also be used. Certain proteins can 60 
expressed using their native promoter. Other elements that 
can enhance expression can also be included such as an 
enhancer or a system that results in high levels of expression 
such as a tat gene and tar element. This cassette can then be 
inserted into a vector, e.g., a plasmid vector such as, pUC19, 65 
pUC118, pBR322, or other known plasmid vectors, that 
includes, for example, an E. coli origin of replication. See, 
If desired, the polynucleotides of the invention may also 
be used with a microdelivery vehicle such as cationic 
liposomes and adenoviral vectors. For a review of the 
procedures for liposome preparation, targeting and delivery 
of contents, see Mannino and Gould-Fogerite, BioTech-
niques, 6:682 (1988). See also, Feigner and Holm, Bethesda 
Res. Lab. Focus, 11(2):21 (1989) and Maurer, R. A., 
Bethesda Res. Lab. Focus, 11(2):25 (1989). 
Replication-defective recombinant adenoviral vectors, 
can be produced in accordance with known techniques. See, 
Quantin, et al., Proc. Natl. Acad. Sci. USA, 89:2581-2584 
(1992); Stratford-Perricadet, et al., J. Clin. Invest., 90:626-
630 (1992); and Rosenfeld, et al., Cell, 68:143-155 (1992). 
Another delivery method is to use single stranded DNA 
producing vectors which can produce the SPI-1 and/or SPI-2 
molecules intracellularly. See for example, Chen et al, 
BioTechniques, 34: 167-171 (2003), which is incorporated 
herein, by reference, in its entirety. 
Expression of SPI-1 and/or SPI-2 molecules may be 
controlled by any promoter/enhancer element known in the 
art, but these regulatory elements must be functional in the 
host selected for expression. Promoters which may be used 
to control gene expression include, but are not limited to, 
cytomegalovirus (CMV) promoter (U.S. Pat. Nos. 5,385,839 
and 5,168,062), the SV40 early promoter region (Benoist 
and Chambon, 1981, Nature 290:304-310), the promoter 
contained in the 3' long terminal repeat of Rous sarcoma 
virus (Yamamoto, et al., Cell 22:787-797, 1980), the herpes 
thymidine kinase promoter (Wagner et al., Proc. Natl. Acad. 
Sci. U.S.A. 78:1441-1445, 1981), the regulatory sequences 
of the metallothionein gene (Brinster et al., Nature 296:39-
42, 1982); prokaryotic expression vectors such as the 
~-lactamase promoter (Villa-Kamaroff, et al., Proc. Natl. 
Acad. Sci. U.S.A. 75:3727-3731, 1978), or the tac promoter 
(DeBoer, et al., Proc. Natl. Acad. Sci. U.S.A. 80:21-25, 
1983); promoter elements from yeast or other fungi such as 
the Gal 4 promoter, the ADC (alcohol dehydrogenase) 
promoter, PGK (phosphoglycerol kinase) promoter, alkaline 
phosphatase promoter; and the animal transcriptional con-
trol regions, which exhibit tissue specificity and have been 
utilized in transgenic animals: elastase I gene control region 
which is active in pancreatic acinar cells (Swift et al., Cell 
38:639-646, 1984; Omitz et al., Cold Spring Harbor Symp. 
Quant. Biol. 50:399-409, 1986; MacDonald, Hepatology 
7:425-515, 1987); insulin gene control region which is 
active in pancreatic beta cells (Hanahan, Nature 315:115-
122, 1985), immunoglobulin gene control region which is 
active in lymphoid cells (Grosschedl et al., Cell 38:647-658, 
1984; Adames et al., Nature 318:533-538, 1985; Alexander 
et al., Mal. Cell. Biol. 7: 1436-1444, 1987), mouse mammary 
tumor virus control region which is active in testicular, 
breast, lymphoid and mast cells (Leder et al., Cell 45:485-
495, 1986), albumin gene control region which is active in 
liver (Pinkert et al., Genes and Devel. 1:268-276, 1987), 
alpha-fetoprotein gene control region which is active in liver 
(Krumlauf et al., Mal. Cell. Biol. 5:1639-1648, 1985; Ham-
mer et al., Science 235:53-58, 1987), alpha 1-antitrypsin 
gene control region which is active in the liver (Kelsey et al., 
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Genes and Devel. 1: 161-171, 1987), beta-globin gene 
control region which is active in myeloid cells (Mogram et 
al., Nature 315:338-340, 1985; Kollias et al., Cell 46:89-94, 
1986), myelin basic protein gene control region which is 
active in oligodendrocyte cells in the brain (Readhead et al., 
Cell 48:703-712, 1987), myosin light chain-2 gene control 
region which is active in skeletal muscle (Sani, Nature 
314:283-286, 1985), and gonadotropic releasing hormone 
gene control region which is active in the hypothalamus 
(Mason et al., Science 234:1372-1378, 1986). 
A wide variety of host/expression vector combinations 
may be employed in expressing the nucleic acid sequences 
of this invention. Useful expression vectors, for example, 
may consist of segments of chromosomal, non-chromo-
somal and synthetic DNA sequences. Suitable vectors 
include derivatives of SV 40 and known bacterial plasmids, 
e.g., E.coli plasmids col El, pCRl, pBR322, pMal-C2, pET, 
pGEX, pMB9 and their derivatives, plasmids such as RP4; 
phage DNAs, e.g., the numerous derivatives of phage 1, e.g., 
NM989, and other phage DNA, e.g., M13 and filamentous 
single stranded phage DNA; yeast plasmids such as the 2 
µplasmid or derivatives thereof, vectors useful in eukaryotic 
cells, such as vectors useful in insect or mammalian cells; 
vectors derived from combinations of plasmids and phage 
DNAs, such as plasmids that have been modified to employ 
phage DNA or other expression control sequences; and the 
like. 
Yeast expression systems can also be used according to 
the invention to express SPI-1 and/or SPI-2 molecules. For 
example, the non-fusion pYES2 vector (XbaI, SphI, ShoI, 
Natl, GstXI, EcoRI, BstXI, BamHl, Sad, Kpnl, and Hin-
dIII cloning sites; Invitrogen) or the fusion p YESHisA, B, C 
(XbaI, SphI, ShoI, Natl, BstXI, EcoRI, BamHl, Sad, Kpnl, 
and HindIII cloning sites, N-terminal peptide purified with 
ProBond resin and cleaved with enterokinase; Invitrogen), 
to mention just two, can be employed according to the 
invention. A yeast two-hybrid expression system can be 
prepared in accordance with the invention. 
In certain embodiments, a single DNA construct express-
ing SPI-1 and/or SPI-2 molecules as two separate genes can 
be introduced into a cell or subject. In certain embodiments, 
a single DNA construct expressing SipD, SipB, SseB, or 
SseC as four separate genes can be introduced into a cell or 
subject. Exemplary expression constructs can be formulated 
as a pharmaceutical composition, e.g., for administration to 
30 
of a DNA vector may be facilitated by combining the DNA 
vector with, for example, a cationic lipid, and forming a 
DNA complex. Typically, viral vectors are double stranded 
circular DNA molecules that are derived from a virus. Viral 
5 vectors typically are larger in size than naked DNA and 
DNA vector constructs and have a greater capacity for the 
introduction of foreign (i.e., not virally encoded) genes. Like 
naked DNA and DNA vectors, viral vectors can be used to 
deliver and express one or more therapeutic nucleic acids in 
10 target cells. Unlike naked DNA and DNA vectors, certain 
viral vectors stably incorporate themselves into chromo-
somal DNA. Typically, viral vectors include at least one 
promoter sequence that allows for replication of one or more 
vector encoded nucleic acids, e.g., a therapeutic nucleic acid, 
15 in a host cell. Viral vectors may optionally include one or 
more non-therapeutic components described herein. Advan-
tageously, uptake of a viral vector into a target cell does not 
require additional components, e.g., cationic lipids. Rather, 
viral vectors transfect or infect cells directly upon contact 
20 with a target cell. 
The approaches described herein include the use of ret-
roviral vectors, adenovirus-derived vectors, and/or adeno-
associated viral vectors as recombinant gene delivery sys-
tems for the transfer of exogenous genes in vivo, particularly 
25 into humans. Protocols for producing recombinant retrovi-
ruses and for infecting cells in vitro or in vivo with such 
viruses can be found in Current Protocols in Molecular 
Biology, Ausubel, F. M. et al. (eds.) Greene Publishing 
Associates, (1989), Sections 9.10-9.14, and other standard 
30 laboratory manuals. 
Viruses that are used as transduction agents of DNA 
vectors and viral vectors such as adenoviruses, retroviruses, 
and lentiviruses may be used in practicing the present 
invention. Illustrative retroviruses include, but are not lim-
35 ited to: Moloney murine leukemia virus (M-MuLV), Molo-
ney murine sarcoma virus (MoMSV), Harvey murine sar-
coma virus (HaMuSV), murine mammary tumor virus 
(MuMTV), gibbon ape leukemia virus (GaLV), feline leu-
kemia virus (FLY), Spumavirus, Friend murine leukemia 
40 virus, Murine Stem Cell Virus (MSCV) and Rous Sarcoma 
Virus (RSV)) and lentivirus. As used herein, the term "len-
tivirus" refers to a group ( or genus) of complex retroviruses. 
Illustrative lentiviruses include, but are not limited to: HIV 
(human immunodeficiency virus; including HIV type 1, and 
45 HIV type 2); visna-maedi virus (VMV) virus; caprine arthri-
tis-encephalitis virus (CAEV); equine infectious anemia 
virus (EIAV); feline immunodeficiency virus (FIV); bovine 
immune deficiency virus (BIV); and simian immunodefi-
a subject. DNA constructs and the therapeutic use of such 
constructs are well known to those of skill in the art (see, e.g. 
Chiarella et al. (2008) Recent Patents Anti-Infect. Drug 
Disc. 3:93-101; Gray et al. (2008) Expert Opin. Biol. Ther. 
8:911-922; Melman et al. (2008) Hum. Gene Ther. 17:1165- 50 
1176). Naked DNA constructs typically include one or more 
therapeutic nucleic acids and a promoter sequence. A naked 
DNA construct can be a DNA vector, commonly referred to 
ciency virus (SIV). 
In certain embodiments, an adenovirus can be used in 
accordance with the methods described herein. The genome 
of an adenovirus can be manipulated such that it encodes and 
expresses a gene product of interest but is inactivated in 
terms of its ability to replicate in a normal lytic viral life as pDNA. Naked DNA typically does not integrate into 
chromosomal DNA. Generally, naked DNA constructs do 
not require, or are not used in conjunction with, the presence 
of lipids, polymers, or viral proteins. Such constructs may 
also include one or more of the non-therapeutic components. 
DNA vectors are known in the art and typically are 
circular double stranded DNA molecules. DNA vectors 
usually range in size from three to five kilo-base pairs ( e.g., 
including inserted therapeutic nucleic acids). Like naked 
DNA, DNA vectors can be used to deliver and express one 
or more therapeutic proteins in target cells. DNA vectors do 
not integrate into chromosomal DNA. 
Generally, DNA vectors include at least one promoter 
sequence that allows for replication in a target cell. Uptake 
55 cycle. Suitable adenoviral vectors derived from the adeno-
virus strain Ad type 5 d1324 or other strains of adenovirus 
(e.g., Ad2, Ad3, Ad7 etc.) are known to those skilled in the 
art. Recombinant adenoviruses can be advantageous in cer-
tain circumstances in that they are not capable of infecting 
60 nondividing cells and can be used to infect a wide variety of 
cell types, including epithelial cells. Furthermore, the virus 
particle is relatively stable and amenable to purification and 
concentration, and as above, can be modified so as to affect 
the spectrum of infectivity. Additionally, introduced adeno-
65 viral DNA (and foreign DNA contained therein) is not 
integrated into the genome of a host cell but remains 
episomal, thereby avoiding potential problems that can 
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occur as a result of insertional mutagenesis in situ where 
introduced DNA becomes integrated into the host genome 
(e.g., retroviral DNA). Moreover, the carrying capacity of 
the adenoviral genome for foreign DNA is large (up to 8 
kilobases) relative to other gene delivery vectors. 
Adena-associated virus is a naturally occurring defective 
virus that requires another virus, such as an adenovirus or a 
herpes virus, as a helper virus for efficient replication and a 
productive life cycle. It is also one of the few viruses that 
may integrate its DNA into non-dividing cells, and exhibits 
a high frequency of stable integration. 
In various embodiments, one or more viral vectors that 
expresses the SPI-1 and/or SPI-2 molecules encoding a 
polypeptide or polypeptides of the invention is administered 
by direct injection to a cell, tissue (e.g. i.m.), or organ of a 
subject, in vivo. 
In some embodiments of the invention, it may be desir-
able to use a cell, cell type, cell lineage or tissue specific 
expression control sequence to achieve cell type specific, 
lineage specific, or tissue specific expression of the SPI-1 
and/or SPI-2 polynucleotide sequences, for example SEQ ID 
NOS: 14, 16, to express a particular nucleic acid encoding 
a polypeptide in only a subset of cell types, cell lineages, or 
tissues, or during specific stages of development. 
Certain embodiments of the invention provide conditional 
expression of the SPI-1 and/or SPI-2 polynucleotides of 
interest. For example, expression is controlled by subjecting 
a cell, tissue, organism, etc., to a treatment or condition that 
causes the polynucleotide to be expressed or that causes an 
increase or decrease in expression of the polynucleotide 
encoded by the polynucleotide of interest. Illustrative 
examples of inducible promoters/systems include, but are 
not limited to, steroid-inducible promoters such as promot-
ers for genes encoding glucocorticoid or estrogen receptors 
(inducible by treatment with the corresponding hormone), 
metallothionine promoter (inducible by treatment with vari-
ous heavy metals), MX-1 promoter (inducible by inter-
feron), the "GeneSwitch" mifepristone-regulatable system 
(Sirin et al, 2003, Gene, 323:67), the cumate inducible gene 
switch (WO 2002/088346), tetracycline-dependent regula-
tory systems, etc. 
In certain embodiments, vectors comprise a selection 
gene, also termed a selectable marker. Typical selection 
genes encode proteins that (a) confer resistance to antibiotics 
32 
including constitutive, tissue-specific or regulated promot-
ers, in particular from the group consisting of the CMV 
promoter, ElFa promoter and metallothionein promoter. 
Further regulatory elements that may be contained within 
5 the vectors of this invention include, without limitation, a 
Bcl-2 gene, UTR sequences and MAR sequences. 
The above nucleic acids and vectors may be used for 
instance to produce recombinant SipD, SipB, SseB or SseC 
polypeptides in various competent host or host cells, as well 
10 as for gene therapy purposes. 
The vector may be a plasmid, virus, phage, cosmid, 
episome, etc. Preferred vectors are viral vectors ( e.g., recom-
binant adenoviruses) and plasmids, which can be produced 
based on commercially available backbones, such as pBR, 
15 pcDNA, pUC, pET, pVITRO, etc. The vector typically 
comprises regulatory elements or sequences to control or 
mediate expression of a polypeptide. The regulatory 
sequences may be chosen from promoters, enhancers, 
silencers, tissue-specific signals, peptide signals, intrans, 
20 terminators, polyA sequences, GC regions, etc., or a com-
bination thereof. Such regulatory elements or sequences 
may be derived from mammalian, fungal, plant, bacterial, 
yeast, bacteriophage or viral genes, or from artificial 
sources. Useful promoters for prokaryote expression (such 
25 as E. coli) include T7 RNA polymerase promoter (pT7), 
TAC promoter (pTAC), Trp promoter, Lac promoter, Tre 
promoter, PhoA promoter for example. Suitable promoters 
for expression in mammalian cells include viral promoters 
(e.g., CMV, LTR, RSV, SV40, TK, pCAG, etc.), domestic 
30 gene promoters (e.g., Elfa, chicken Pactine, Ubiquitine, 
INSMl, etc.), hybrid promoters (e.g., actine/globin, etc.), 
etc. A vector may comprise more than one promoter. The 
promoters may be inducible or regulated. For instance, the 
use of inducible or regulated promoters allows a better 
35 control of production by dissociating the culture from pro-
duction phases. Inducible or regulated promoters may be 
found in the literature, such as the Tetracycline system, the 
Geneswitch system, the Ecdysone system, the Oestradiol 
system, the RU486 system, the Cumate system, the metal-
40 lothionein promoter etc. Other systems are based on electric 
currents or microwaves, such as focalized ultrasound sys-
tem, AIR induced expression system and the like. These 
systems can be used to control expression of a polypeptide 
according to the invention. 
The polypeptides may be co-expressed with other factors. 
The cDNAs coding for each may be both placed down-
stream of the same promoter, but separated by an IRES 
sequence, or each of them downstream of its own promoter. 
The vector may further comprise an origin of replication 
or other toxins, e.g., ampicillin, neomycin, hygromycin, 45 
methotrexate, Zeocin, Blastocidin, or tetracycline, (b) 
complement auxotrophic deficiencies, or ( c) supply critical 
nutrients not available from complex media, e.g., the gene 
encoding D-alanine racemase for Bacilli. Any number of 
selection systems may be used to recover transformed cell 
lines. These include, but are not limited to, the herpes 
simplex virus thymidine kinase (Wigler et al, (1977) Cell, 
11:223-232) and adenine phosphoribosyltransferase (Lowy 
50 and/or a marker gene, which may be selected from conven-
tional sequences. An amplification selection marker such as 
the DHFR gene can be inserted in the backbone of the 
vector. The vector may further comprise various combina-
tions of these different elements which may be organized in et al, (1990) Cell, 22:817-823) genes which can be 
employed in tk- or aprt-cells, respectively. 
The vector may comprise any regulatory sequence allow-
ing proper expression of the coding nucleic acid in a selected 
host cell, e.g., a promoter, terminator, polyA, origin of 
replication, integration region (e.g., homologous region), 
intron, UTR sequences, marker gene, etc. 
In another preferred embodiment, an expression vector 
comprising a nucleic acid molecule as defined above is 
provided, including a signal peptide, operably linked to 
regulatory elements allowing expression of said nucleic acid 
in a mammalian host or host cell. Preferred regulatory 
elements include a promoter, which may be selected, with-
out limitation, from viral, cellular and synthetic promoters, 
55 different ways. 
In certain embodiments, DNA delivery may occur by use 
of liposomes, nanocapsules, microparticles, microspheres, 
lipid particles, vesicles, optionally mixing with cell penetrat-
ing polypeptides, and the like, for the introduction of the 
60 compositions of the present invention into suitable host 
cells. In particular, the compositions of the present invention 
may be formulated for delivery either encapsulated in a lipid 
particle, a liposome, a vesicle, a nanosphere, a nanoparticle 
or the like. The formulation and use of such delivery 
65 vehicles can be carried out 
Cells: The present invention also provides for cells com-
prising a nucleic acid or a vector as described above. 
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In a preferred embodiment, a cell comprises any of the 
polypeptides described herein, any of the nucleic acid mol-
ecules described herein, or any of the expression vectors 
described herein (for example, a stem cell, cell-line, anAPC, 
a T cell or a B cell, in culture or in vivo). 
34 
cells, and attack certain virus infected cells), and the inflam-
matory response (mobilizes leukocytes such as macrophages 
and dendritic cells to phagocytose invaders). 
Some cells of the innate immune system, including mac-
5 rophages and dendritic cells (DC), function as part of the 
adaptive immune system as well by taking up foreign 
antigens through pattern recognition receptors, combining 
peptide fragments of these antigens with major histocom-
In another embodiment, a cell expressing a chimeric 
molecule wherein the chimeric molecule comprises at least 
one Salmonella pathogenicity island 1 (SPI-1) and at least 
one Salmonella pathogenicity island 2 (SPI-2) protein, pep-
tides, derivatives, variants or combinations thereof. In 10 
embodiments, the cell comprises: an animal cell, a mam-
malian cell, a bacterial cell, a yeast cell, a tumor cell, a 
transformed cell, a cell-line or any combinations thereof. 
The cells expressing the SPI-1 and SPI-2 molecules can be 
transfected or transformed and administered to the subject. 15 
The cells can secrete the encoded SPI-1 and SPI-2 molecules 
patibility complex (MHC) class I and class II molecules, and 
stimulating naive CD8+and CD4+T cells respectively 
(Banchereau and Steinman, supra; Holmskov et al., Immu-
nol. Today. 1994, 15:67; Ulevitch and Tobias Annu. Rev. 
Immunol. 1995, 13:437). Professional antigen-presenting 
cells (APCs) communicate with these T cells, leading to the 
differentiation of naive CD4 +T cells into T-helper 1 (Thi) or 
T-helper 2 (Th2) lymphocytes that mediate cellular and 
into blood and lymphatic system. Alternatively, the cells can 
express the SPI-1 and/or SPI-2 molecules on the cell surface 
such that they are presented to immune cell to stimulate an 
immune response. Accordingly, the cells encoding for: SPI-
1, SPI-2, SPI-1 chimeric molecules, SPI-2 chimeric mol-
ecules, or any peptides thereof, can be presented to the 
immune system for priming the immune system to eliciting 
an antigen specific response against any Salmonella sero-
vars. The administration of the cells can be accompanied 
with an adjuvant. 
The host cell may be selected from any eukaryotic and 
prokaryotic cells, typically from a mammalian cell (in 
particular a human, rodent, canine cell), a bacterial cell (in 
particular E. coli, Bacillus brevis, Bacillus subtilis ), a yeast 
cell, a plant cell and an insect cell. These host cells may be 
adapted to serum-free media. Production may also be 
accomplished in a transgenic animal or plant. 
In some embodiments, recombinant host cells are selected 
from mammalian cells, in particular human cells as well as 
derivatives or mutants thereof, including bone marrow cells, 
stem cells, cells of the immune system and the like. Other 
examples of suitable host cells include Chinese Hamster 
Ovary (CHO) cells, Baby Hamster Kidney (BHK) cells, 
Human Embryonic Kidney (HEK-293) cells, human epider-
mal keratinocytes (HEK), human stromal or epithelial cells, 
PERC6, etc. In such manimalian cells, polypeptides may be 
produced as a secreted protein using functional signal pep-
tide sequences. 
Vaccination and Immunogenicity 
humoral immunity, respectively (Trinchieri Annu. Rev. 
Immunol. 1995, 13:251; Howard and O'Garra, Immunol. 
Today. 1992, 13:198; Abbas et al., Nature. 1996, 383:787; 
20 Okamura et al., Adv. Immunol. 1998, 70:281; Mosmann and 
Sad, Immunol. Today. 1996, 17: 138; O'Garra Immunity. 
1998, 8:275). 
In adaptive immunity, adaptive T and B cell immune 
responses work together with innate immune responses. The 
25 basis of the adaptive immune response is that of clonal 
recognition and response. An antigen selects the clones of 
cell which recognize it, and the first element of a specific 
immune response must be rapid proliferation of the specific 
lymphocytes. This is followed by further differentiation of 
30 the responding cells as the effector phase of the immune 
response develops. These effector T lymphocytes, in the 
context of the embodiments, are the tumor specific T lym-
phocytes. 
Delivery of an immunogen to appropriate cells can be 
35 effected ex vivo, in situ, or in vivo by use of any suitable 
approach known in the art. For example, for in vivo therapy, 
a nucleic acid encoding the SPI-1 and/or SPI-2 chimeric 
molecules, either alone or in conjunction with a vector, 
liposome, or precipitate may be injected directly into the 
40 subject, and in some embodiments, may be injected at the 
site where the expression of the molecules is desired. In 
other embodiments, cells comprising the nucleic acids 
encoding the SPI-1 and/or SPI-2 chimeric molecules are 
administered to a subject in need thereof, wherein the cells 
45 producing the immunogenic SPI-1 and/or SPI-2 peptides 
elicit an immune response to the immunogens. For ex vivo 
treatment, the subject's cells are removed, the nucleic acid 
is introduced into these cells, and the modified cells are 
returned to the subject either directly or, for example, 
Immune systems are classified into two general systems, 
the "innate" or "primary" immune system and the "acquired/ 
adaptive" or "secondary" immune system. It is thought that 
the innate immune system initially keeps the infection under 
control, allowing time for the adaptive immune system to 
develop an appropriate response. The various components of 
the innate immune system trigger and augment the compo-
nents of the adaptive immune system, including antigen-
specific B and T lymphocytes (Kos, Immunol. Res. 1998, 
17:303; Romagnani, Immunol. Today. 1992, 13: 379; 
Banchereau and Steinman, Nature. 1988, 392:245). A "pri-
mary immune response" refers to an innate immune 
response that is not affected by prior contact with the 
antigen. The main protective mechanisms of primary immu-
nity are the skin (protects against attachment of potential 60 
environmental invaders), mucous (traps bacteria and other 
foreign material), gastric acid (destroys swallowed invad-
ers), antimicrobial substances such as interferon (IFN) (in-
hibits viral replication) and complement proteins (promotes 
bacterial destruction), fever (intensifies action of interferons, 65 
inhibits microbial growth, and enhances tissue repair), natu-
50 encapsulated within porous membranes which are implanted 
into the patient. See, e.g. U.S. Pat. Nos. 4,892,538 and 
5,283,187. 
There are a variety of techniques available for introducing 
nucleic acids into viable cells. The techniques vary depend-
55 ing upon whether the nucleic acid is transferred into cultured 
cells in vitro or in vivo in the cells of the intended host. 
Techniques suitable for the transfer of nucleic acid into 
mammalian cells in vitro include the use of liposomes, 
electroporation, microinjection, cell fusion, chemical treat-
ments, DEAE-dextran, and calcium phosphate precipitation. 
Other in vivo nucleic acid transfer techniques include trans-
fection with viral vectors (such as adenovirus, Herpes sim-
plex I virus, adeno-associated virus or retrovirus) and lipid-
based systems. The nucleic acid and transfection agent are 
optionally associated with a microparticle. Exemplary trans-
fection agents include calcium phosphate or calcium chlo-
ride co-precipitation, DEAE-dextran-mediated transfection, ral killer (NK) cells (destroy microbes and certain tumor 
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quaternary ammonium amphiphile DOTMA ((dioleoyloxy-
propyl)trimethylammonium bromide, commercialized as 
LIPOFECTIN by GIBCO-BRL)) (Feigner et al, (1987) 
Proc. Natl. Acad. Sci. USA 84, 7413-7417; Malone et al. 
(1989) Proc. Natl. A cad. Sci. USA 86 6077-6081 ); lipophilic 5 
glutamate diesters with pendent trimethylammonium heads 
(Ito et al. (1990) Biochem. Biophys. Acta 1023, 124-132); 
the metabolizable parent lipids such as the cationic lipid 
dioctadecylamido glycylspermine (DOGS, Transfectam, 
Promega) and dipalmitoylphosphatidyl ethanolamylsper- 10 
mine (DPPES) (J. P. Behr (1986) Tetrahedron Lett. 27, 
5861-5864; J. P. Behr et al. (1989) Proc. Natl. Acad. Sci. 
USA 86, 6982-6986); metabolizable quaternary ammonium 
salts (DOTB, N-(1-[2,3-dioleoyloxy]propyl)-N,N,N-trim-
15 
ethylammonium methylsulfate (DOTAP) (Boehringer Man-
nheim), polyethyleneimine (PEI), dioleoyl esters, ChoTB, 
ChoSC, DOSC) (Leventis et al. (1990) Biochim. Inter. 22, 
235-241); 3~[N-(N',N'-dimethylaminoethane)-carbamoyl] 
cholesterol (DC-Chol), dioleoylphosphatidyl ethanolamine 20 
(DOPE)/3~[N-(N',N'-dimethylaminoethane)-carbamoyl] 
cholestero!DC-Chol in one to one mixtures (Gao et al., 
(1991) Biochim. Biophys. Acta 1065, 8-14), spermine, sper-
midine, lipopolyamines (Behr et al., Bioconjugate Chem, 
1994, 5: 382-389), lipophilic polylysines (LPLL) (Zhou et 25 
al., (1991) Biochim. Biophys. Acta 939, 8-18), [[(1,1,3,3-
tetramethy lbuty l)cre-soxy ]ethoxy] ethyl] dimethylbenzylam-
monium hydroxide (DEB DA hydroxide) with excess phos-
phatidylcholine/cholesterol (Ballas et al., (1988) Biochim. 
Biophys. Acta 939, 8-18), cetyltrimethylammonium bromide 30 
(CTAB)/DOPE mixtures (Pinnaduwage et al, (1989) Bio-
chim. Biophys. Acta 985, 33-37), lipophilic diester of glu-
tamic acid (TMAG) with DOPE, CTAB, DEBDA, dido-
decylammonium bromide (DDAB), and stearylamine in 
admixture with phosphatidylethanolamine (Rose et al., 35 
(1991) Biotechniques 10, 520-525), DDAB/DOPE (Trans-
fectACE, GIBCO BRL), and oligogalactose bearing lipids. 
Exemplary transfection enhancer agents that increase the 
efficiency of transfer include, for example, DEAE-dextran, 
polybrene, lysosome-disruptive peptide (Ohmori N I et al, 40 
Biochem Biophys Res Commun Jun. 27, 1997; 23 5(3):726-
9), chondroitan-based proteoglycans, sulfated proteogly-
cans, polyethylenimine, polylysine (Pollard H et al. J Biol 
Chem, 1998 273 (13):7507-11), integrin-binding peptide 
CYGGRGDTP (SEQ ID NO: 25), linear dextran nonasac- 45 
charide, glycerol, cholesteryl groups tethered at the 3'-ter-
minal internucleoside link of an oligonucleotide (Letsinger, 
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In an embodiment, a method of enhancing the immune 
response in a mammal comprises the steps of contacting one 
or more lymphocytes with the antigenic compositions, 
wherein the antigen is presented by an immune cell, such as 
an APC. The enhanced immune response may be an active 
or a passive immune response. The response may be part of 
an adoptive immunotherapy approach in which APCs, such 
as dendritic cells, B cells or monocytes/macrophages, are 
obtained from a subject (e.g., a patient), then pulsed with a 
composition comprising the antigenic composition, and then 
administering the APC to a subject in need thereof. In certain 
embodiments, the method of the invention comprises ex 
vivo immunization and/or in vivo therapy in a subject. In 
one embodiment, the subject is a mammal. Preferably, the 
mammal is a human. Ex vivo procedures are well known in 
the art. Briefly, cells are isolated from a subject (preferably 
a human) and contacted with the antigenic compositions to 
produce an antigen-loaded APC. The antigen-loaded APC 
can be administered to a recipient to provide a therapeutic 
benefit. The recipient may be a human and the antigen-
loaded APC can be autologous with respect to the recipient. 
Alternatively, the APC can be allogeneic, syngeneic or 
xenogeneic with respect to the recipient. 
In addition to using a cell-based vaccine in terms of ex 
vivo immunization, the present invention also provides 
compositions and methods for in vivo immunization to elicit 
an immune response directed against an antigen in a patient. 
The preparation of compositions for use as vaccines is 
known to those of skill in the art. Typically, such composi-
tions are prepared either as liquid solutions or suspensions, 
however solid forms such as tablets, pills, powders and the 
like are also contemplated. Solid forms suitable for solution 
in, or suspension in, liquids prior to administration may also 
be prepared (e.g. lyophilized, freeze-dried forms, etc.). The 
preparation may also be emulsified. The active ingredients 
may be mixed with excipients which are pharmaceutically 
acceptable and compatible with the active ingredients. Suit-
able excipients are, for example, water, saline, dextrose, 
glycerol, ethanol and the like, or combinations thereof. In 
addition, the composition may contain minor amounts of 
auxiliary substances such as wetting or emulsifying agents, 
pH buffering agents, and the like. If it is desired to admin-
ister an oral form of the composition, various thickeners, 
flavorings, diluents, emulsifiers, dispersing aids or binders 
and the like may be added. The composition of the present 
invention may contain any such additional ingredients so as 
to provide the composition in a form suitable for adminis-
tration. The final amount of protein, polypeptide or peptide 
(or encoding nucleic acids) in the formulations may vary. 
R. L. 1989 Proc Natl Acad Sci USA 86: (17):6553-6), 
lysophosphatide, lysophosphatidylcholine, lysophosphati-
dylethanolamine, and 1-oleoyl lysophosphatidylcholine. 
Embodiments of the invention include methods of induc-
ing an immune response in a subject comprising delivering 
50 However, in general, the amount of vaccinating/immunizing 
agent in the formulations will be from about 1 to about 99%. 
an antigen to a subject in need thereof. In certain embodi-
ments, the method comprises providing an antigen present-
ing cell (APC) and contacting (stimulating) them in vitro, ex 
vivo or in vivo with an SPI-1 and/or SPI-2 antigen either by 
incubation with the SPI-1 and/or SPI-2 peptides or with the 
cells expressing or secreting the SPI-1 and/or SPI-2 anti-
gens. In certain embodiments, the antigen is delivered to the 
APC in the body of the subject. In certain embodiments, 
administration of a cell expressing one or more SPI-1 and/or 
SPI-2 molecules to the subject results in delivery of the 
antigen into an APC and T cell activation in the subject. 
In another embodiment, an APC of the subject is isolated 
from the subject, the antigen is delivered to the APC outside 
of the body of the subject, and the APC comprising the 
delivered antigen is later administered to the subject. 
In some embodiments, the immunogenic compositions 
embodied herein are administered with an immune modu-
lating effector molecules or adjuvants. In one embodiment, 
55 an immune modulating effector molecule is administered in 
conjunction with or at alternative times the antigenic com-
positions or cells comprising the antigenic compositions. An 
immune-modulating effector molecule positively and/or 
negatively influences the humoral and/or cellular immune 
60 system, particularly its cellular and/or non-cellular compo-
nents, its functions, and/or its interactions with other physi-
ological systems. The immune-modulating effector mol-
ecule comprises cytokines, chemokines, macrophage 
migration inhibitory factor (MIF; as described, inter alia, in 
65 Bernhagen (1998), Mal Med 76(3-4); 151-61 or Metz 
(1997), Adv Immunol 66, 197-223), T-cell receptors and 
soluble MHC molecules. Such immune-modulating effector 
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molecules are well known in the art and are described, inter 
alia, in Paul, "Fundamental immunology", Raven Press, 
New York (1989). In particular, known cytokines and 
chemokines are described in Meager, "The Molecular Biol-
ogy ofCytokines" (1998), John Wiley & Sons, Ltd., Chich-
ester, West Sussex, England; (Bacon (1998). Cytokine 
Growth Factor Rev 9(2):167-73; Oppenheim (1997). Clin 
Cancer Res 12, 2682-6; Taub, (1994) Ther. Immunol. 1(4), 
229-46 or Michie!, (1992). Semin Cancer Biol 3(1), 3-15). 
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not mutated. Preferably, the adjuvant is a detoxified LT 
mutant such as LT-K63, LT-R72, and LT-G192. The use of 
ADP-ribosylating toxins and detoxified derivatives thereof, 
particularly LT-K63 and LT-R72, is known. Such adjuvants 
5 are described, for example, in issued U.S. Pat. No. 8,039,007 
(the complete contents of which is hereby incorporated by 
reference in entirety). Various interleukins may also be used 
as adjuvants to increase the immune response in a subject. 
In preferred embodiments, the adjuvant is a mucosa! adju-
10 vant such as, for example, the double mutant heat-labile 
toxin ( dmLT) from enterotoxigenic E. coli. 
Immune cell activity that may be measured include, but is 
not limited to, (1) cell proliferation by measuring the DNA 
replication; (2) enhanced cytokine production, including 
specific measurements for cytokines, such as IFN-y, GM-
CSF, or TNF-a; (3) cell mediated target killing or lysis; (4) 
cell differentiation; (5) immunoglobulin production; (6) phe- 15 
notypic changes; (7) production of chemotactic factors or 
chemotaxis, meaning the ability to respond to a chemotactin 
with chemotaxis; (8) immunosuppression, by inhibition of 
the activity of some other immune cell type; and, (9) 
apoptosis, which refers to fragmentation of activated 20 
immune cells under certain circumstances, as an indication 
Administration and Formulations 
The vaccine compositions (preparations) and immuno-
genic compositions ( e.g. peptides, polypeptides, oligonucle-
otides, polynucleotides, etc.) of the present invention may be 
administered by any of the many suitable means which are 
well known to those of skill in the art, including but not 
limited to by injection, inhalation, orally, intranasally, topi-
cally, inclusion in a food product, etc. In some embodiments, 
the mode of administration is intradermal or intramuscular. 
In addition, the compositions may be administered in con-
of abnormal activation. 
In addition, the composition may contain adjuvants, many 
of which are known in the art. For example, adjuvants 
suitable for use in the invention include but are not limited 25 
junction with or in a composition which contains other 
antigens of interest. In other words, they may be adminis-
tered as a component of a multivalent vaccine which also 
contains antigens against other related or non-related infec-
tious diseases, e.g. childhood diseases, such as polio, to: bacterial or microbial derivatives such as non-toxic 
derivatives of enterobacterial lipopolysaccharide (LPS), 
Lipid A derivatives, immunostimulatory oligonucleotides 
and ADP-ribosylating toxins and detoxified derivatives 
thereof. Non-toxic derivatives of LPS include monophos-
phoryl lipid A (MPL) and 3-O-deacylated MPL (3dMPL). 
3dMPL is a mixture of 3 de-O-acylated monophosphoryl 
lipid A with 4, 5 or 6 acylated chains. A preferred "small 
particle" form of 3 De-O-acylated monophosphoryl lipid A. 
Other non-toxic LPS derivatives include monophosphoryl 
lipid A mimics, such as aminoalkyl glucosaminide phos-
phate derivatives e.g. RC-529. Lipid A derivatives include 
derivatives of lipid A from Escherichia coli such as 
OM-174. Immunostimulatory oligonucleotides suitable for 
use as adjuvants in the invention include nucleotide 
sequences containing a CpG motif (a dinucleotide sequence 
containing an unmethylated cytosine linked by a phosphate 
bond to a guano sine). Double-stranded RN As and oligo-
nucleotides containing palindromic or poly(dG) sequences 
have also been shown to be immunostimulatory. The CpG's 
can include nucleotide modifications/analogs such as phos-
phorothioate modifications and can be double-stranded or 
single-stranded. e.g. replacement of guanosine with 2'-de-
oxy-7-deazaguanosine. The CpG sequence may include, for 
example, the motif GTCGTT or TTCGTT. The CpG 
sequence may be specific for inducing a Thi immune 
response, such as a CpG-A ODN, or it may be more specific 
for inducing a B cell response, such a CpG-B ODN. CpG-A 
and CpG-B ODNs. Preferably, the CpG is a CpG-A ODN. 
Preferably, the CpG oligonucleotide is constructed so that 
the 5' end is accessible for receptor recognition. Optionally, 
two CpG oligonucleotide sequences may be attached at their 
3' ends to form "immunomers". 
whooping cough, tetanus, diphtheria, etc. 
Recipients of the vaccine of the invention are generally 
mammals, frequently humans, but this is not always the 
30 case. While in some aspects, the vaccine is used to prevent 
illness in humans, in other aspects, the vaccine is used to 
prevent illness and/or to block the carrier states in agricul-
turally important animals, i.e. veterinary applications are 
also contemplated. Animals which could benefit from 
35 receiving the vaccine/immune eliciting compositions of the 
invention include but are not limited to: cattle, poultry, 
swine, horses, sheep and goats. The vaccine is generally 
delivered intranasally or subcutaneously or intramuscularly, 
and may be delivered in combination with other agents such 
40 as other vaccinogens. 
For humans, the vaccines may be administered alone or 
together with so-called "child hood" vaccines. Thus, the 
recipients are preferably human children who may be infants 
( e.g. up to about 1 year of age), toddlers ( e.g. up to about 2 
45 years of age), or older, and administration may be carried out 
as a series of initial inoculations followed by booster doses 
at suitable intervals, e.g. monthly, or every 6-months, or 
yearly, etc. as necessary to provide protection. Thereafter, or 
in the case of adults who have not previously been vacci-
50 nated, the vaccines may be administered as necessary to 
result in a protective immune response, and subjects may be 
re-boosted e.g. about every 10 years throughout adult life. 
Of special interest is vaccination of individuals with com-
promised immune systems, e.g. the elderly, those receiving 
55 cancer or other immune weakening therapy, those afflicted 
with HIV, etc. 
Vaccine recipients may have never been exposed to 
Salmonella, or may have been exposed or suspected of 
having been exposed but be asymptomatic, or may have 
60 actual symptoms of disease, and still benefit from adminis-
tration of the vaccine. Vaccine administration may prevent 
disease symptoms entirely, or may lessen or decrease disease 
symptoms, the latter outcome being less than ideal but still 
Bacterial ADP-ribosylating toxins and detoxified deriva-
tives thereof may be used as adjuvants in the invention. 
Preferably, the protein is derived from E. coli (e.g. E. coli 
heat labile enterotoxin "LT"), cholera ("CT"), or pertussis 
("PT"). The use of detoxified ADP-ribosylating toxins as 
mucosa! adjuvants and as parenteral adjuvants is known. 
The toxin or toxoid is preferably in the form of a holotoxin, 65 
comprising both A and B subunits. Preferably, the A subunit 
contains a detoxifying mutation; preferably the B subunit is 
better than experiencing full-blown disease symptoms. 
In a preferred embodiment, the amount of protein that is 
administered per dose of vaccine is in the range of from 
about 0.0001 to about 1000 µg/kg. In one embodiment, the 
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amount is in the range of from about 0.001 to about 1000 
µg/kg of body weight of the recipient. In one embodiment, 
the amount is in the range of from about 0.01 to about 1000 
µg/kg of body weight of the recipient. In one embodiment, 
the amount is in the range of from about 0.01 to about 100 5 
µg/kg of body weight of the recipient. Those of skill in the 
art will recognize that the precise dosage may vary from 
situation to situation and from patient to patient, depending 
on e.g. age, gender, overall health, various genetic factors, 
and other variables known to those of skill in the art. 10 
Dosages are typically determined e.g. in the course of 
animal and/or human clinical trials as conducted by skilled 
medical personnel, e.g. physicians. 
40 
In some embodiments, the compos1t10ns embodied 
herein, may be administered as a regimen in conjunction 
with other therapeutics, such, antibiotics, anti-inflammatory 
agents, 
The invention has been described in detail with reference 
to preferred embodiments thereof. However, it will be 
appreciated that those skilled in the art, upon consideration 
of this disclosure, may make modifications and improve-
ments within the spirit and scope of the invention. 
All documents mentioned herein are incorporated herein 
by reference. All publications and patent documents cited in 
this application are incorporated by reference for all pur-
poses to the same extent as if each individual publication or 
patent document were so individually denoted. By their 
15 citation of various references in this document, Applicants 
do not admit any particular reference is "prior art" to their 
The vaccines and immunogenic compositions of the 
invention are broad-based vaccines and may be used to 
provide immune protection against a variety of Salmonella 
species, including both typhoidal and non-typhoidal species, 
and all S. enterica subspecies. Examples of these two 
categories of Salmonella include but are not limited to: for 20 
typhoidal Salmonella: Paratyphi A&B; and for non-ty-
phoidal Salmonella: Typhimurium, Enteriditis, Newport, 
Dublin. Administration of the compositions of the invention 
results in the production of an immune response, which may 
invention. 
EXAMPLES 
be a protective immune response, in subjects who receive 25 
the compositions, e.g. by elicitation of antibody production 
against the administered antigens. Such antibodies are also 
encompassed by the invention, for example, those generated 
using laboratory techniques in experimental animals, or 
using cell culture, or by chemical syntheses, etc. Such 30 
antibodies may be polyclonal or monoclonal, and may be 
specific for the antigens (reacting with no other antigens) or 
selective for the antigens (reacting more strongly or prefer-
ably with the antigens, compared to other antigens). The 
35 
antibodies may be multivalent. The antibodies may be used 
for research and/or diagnostic purposes, or alternatively, for 
treatment, especially of individuals who are infected with 
Salmonella. 
The following non-limiting Examples serve to illustrate 
selected embodiments of the invention. It will be appreci-
ated that variations in proportions and alternatives in ele-
ments of the components shown will be apparent to those 
skilled in the art and are within the scope of embodiments of 
the present invention. 
In the case of Salmonella, an effective vaccine could be 
used to prevent illness in humans and to block the carrier 
activity in agriculturally important animals. Although some 
progress has been made in recent years, available vaccines 
against Salmonella spp. are not broadly protective and are 
almost entirely directed at the typhoid causing serovars, 
even though the non-typhoid serovars are a major public 
health problem. 
Because the SPI-1 and SPI-2 proteins are surface local-
ized prior to the invasion of host cells, they serve as prime 
targets for subunit vaccines. These four tip proteins are the 
initial tip protein SipD and the first 'translocator' protein 
SipB from SPI-1, and SseB and SseC from SPI-2, which are 
The invention provides methods of vaccinating, or, alter-
natively, of eliciting an immune response, in a subject in 
need thereof. The method generally involves identifying a 
suitable subject, and administering the composition as 
described herein. The method may also encompass follow-
up of administration, e.g. by assessing the production of 
protective antibodies by the subject, or the presence ( or lack 
thereof) of disease symptoms, etc. The immune response 
that is elicited may be of any type, i.e. any type of antibody 
may be produced in response to administration, and cell-
mediated immunity may also be elicited. 
In addition, the invention provides methods of treating or 
preventing Salmonella infection by one or both of a typhoid 
Salmonella serovar and a non-typhoid Salmonella serovar in 
a subject, methods of lessening the severity of symptoms of 
Salmonella infection in a subject, and methods of decreasing 
fecal shedding of Salmonella from a subject who is or is 
likely to be infected with Salmonella. Each of these methods 
involves administering to the subject an amount of a com-
position comprising at least one Salmonella pathogenicity 
island 1 (SPI-1) and/or Salmonella pathogenicity island 2 
(SPI-2) extracellular protein; and a physiologically accept-
able carrier. The amount of the composition is administered 
is sufficient to elicit an immune response to the at least one 
Salmonella serovar in said subject, thereby of treating or 
preventing Salmonella infection, lessening the severity of 
symptoms of Salmonella infection, and/or decreasing fecal 
shedding of Salmonella. 
40 expressed and are surface exposed after entry of the bacte-
rium into the cell. We previously demonstrated that the SipD 
and SipB homologs in Shigella, IpaD and IpaB, respectively, 
are protective antigens against challenge with serotypically 
distinct S. jlexneri and S. sonnei strains using the mouse 
45 pulmonary model (see US patent application 20130149329, 
the complete contents of which is hereby incorporated by 
reference in entirety). A similar Salmonella serotype-inde-
pendent subunit vaccine would be of tremendous public 
health value. Thus, we have determined the protective 
50 efficacy of SipD, SipB and SseB administered with adju-
vants against challenge by Salmonella spp. 
For Examples 1-3 below, recombinant SipD and SseB 
were prepared by expression in E. coli using His-tag tech-
nology and pET vectors ( commercially available from 
55 Novagen), and purification was carried out via column 
chromatography. Within the cytoplasm of Salmonella, SipB 
forms a complex with its cognant chaperone SicA, and 
recombinant SipB was prepared with its chaperone by 
co-expression of His-tagged recombinants in E. coli and 
60 co-purification via column chromatography in a method 
similar to that ofBirket et al. (Biochemistry [2007] 46:8128-
8137). SipB was also produced alone by inducing its release 
from the chaperone using different detergents. 
SipB, SipD, and SseB were then examined as protective 
65 antigens by immunizing mice (Examples 1 and 2) and calves 
(Example 3) intranasally or subcutaneous, followed by 
challenge, as described below. The results showed that SseB, 
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SipB and SipD are effective in reducing the severity and 
length of disease caused by Salmonella. These findings 
impart a significant advancement over the live-attenuated 
and lipopolysaccharide-based vaccines that are currently 
being tested, because they provide serotype-independent 5 
protection and they can be given to children. 
Holstein-Jersey) were immunized subcutaneously at days 0, 
14. 28 and 42 as follows: Group A, 2 mg SseB+50 µg of 
dmLT; Group B, Aro strain (Typhimurium); and Group C, 
PBS (control). Serum IgG (FIG. lOA) and saliva IgA (FIG. 
lOB) was measured. Calves were challenged with S. 
enterica Newport (9xl05 CPUs) or Typhimurium (1.lxl08 
Example 1 
CPUs) on day 56. The amount of bacterial shedding in the 
two groups of challenged animals is shown in FIGS. llA 
and B. As can be seen, the total bacterial shedding over the 
10 course of ten days for the group vaccinated with SseB+ 
dmLT was not only lower, but the variation over the course 
of ten days was less than one log unit which is consistent 
with no effective increase in shedding over time. This is in 
contrast to the group vaccinated with PBS which had a 
FIG. 1 provides a Schematic illustration of a first mouse 
testing protocol for Example 1. Briefly, Balb-c mice (N=5 
per group) were immunized intranasally 2 times with Aro 
strain or 3 times (days 0, 14 and 28) with 10 µg each of 
SipB/SipD/SseB protein with or without dmLT. Serum IgG 
and stool IgA were monitored throughout. Serum IgG anti-
body titers at day 28 are shown in FIG. 2. Mice were 
orogastrically challenged with 108 colony forming units 
(CPUs) of Salmonella enterica serovar Typhimurium 
SL1344 after streptomycin treatment on day 56 and survival 
after challenge was monitored for 14 days after challenge. 20 
The results are shown in FIG. 3. 
15 higher average shedding and an average over the course of 
the study that spanned over 2.5 log units. Thus, the SseB+ 
dmLT vaccine reduced disease severity relative to the con-
trol group and reduces shedding from the initial time point. 
Example 4 
As can be seen, the proteins provide protection against a 
S. typhimurium challenge at a level approaching the live 
attenuated vaccine (Aro strain). 
Example 2 
FIG. 4 provides a Schematic illustration of a mouse 
testing protocol for Example 2. Briefly, Balb-c mice, n=30) 
were immunized on Days 0, 14 and 28 as follows: Group A: 
10 µg SseB+2.5 µg of dmLT (double mutant E. coli heat 
labile toxin) as adjuvant; Group B: 10 µg SipB+l0 µg 
SipD+2.5 µg dmLT; Group C: 10 µg SseB+20 µg MPL 
(monophosphooryl Lipid A); Group D: 10 µg SipB+l0 µg 
SipD+20 µg MPL; Group E: Aro (Aro attenuated S. enterica 
var. Typhimurium vaccine strain, "Typhimurium!Ty2l a 
strain"); Group F: phosphate buffered saline (PBS, i.e. 
vehicle). At day 42 post immunization, some mice were 
euthanized and their spleens were analyzed for antibody 
secreting cells (ASCs). On day 56, additional mice were 
euthanized and analyzed for ASCs, IFNy secretion, and 
cytokine production and the remaining mice were chal-
lenged with S. enterica typhi or typhimurium (typhoid mod-
els). 
Immunogenicity as shown by spleenASC results is shown 
in FIG. SA-F. FIG. 6A-C shows IgG titers in immunized 
mice at day 56, FIG. 7 shows stool IgA titers in immunized 
mice at day 56, and FIG. SA and FIG. SB show protection 
efficacy in immunized mice after challenge (at day 56) with 
S. enterica typhi (FIG. SA) or S. enterica typhimurium (FIG. 
SB). 
As can be seen, the results indicated that SipB, SipD and 
SseB are immunogenic in mice in that both serum and stool 
antibodies were detected after immunization, as were spleen 
ASCs specific for SipB and SipD. Interestingly, the chal-
lenge experiments showed different outcomes, with the 
combination of SipB/SipD being protective in Typhi intra-
peritoneal (IP) mucin challenge model and SseB being 
protective in the Typhimurium orogastric (OG) challenge 
model. 
Example 3 
First Calf Testing 
A schematic representation of the experimental protocol is 
provided in FIG. 9. Calves (21 day old male Holstein or 
Preparation of a Chimeric (Fusion) Protein 
A SipD-SipB chimeric protein has been developed that 
25 allows the protective potential of SipD and SipB to be 
encompassed in single recombinant protein. This reduces 
the vaccine composition components to two proteins, the 
chimeric SipD-SipB and the SipA protein. 
The sipD and sipB genes have been genetically fused in 
30 a single plasmid and co-transformed into E. coli TUNER 
(DE3) cells with a plasmid encoding sicA, using the fol-
lowing protocol: combine 1 µg of each plasmid with 30 µl 
chemically competent cells, heat shock, add one ml LB 
media, incubate at 3 7° C. for 1 hr and then plated on LB agar 
35 containing 100 µg/ml ampicillin and 30 µg Chlorampheni-
col. sipD was copied by PCR using primers with NdeI at 5' 
end and Sall at 3' end. sipB was copied by PCR using 
primers with Sall at 5' end and XhoI at 3' end. The PCR 
fragments were digested with the restriction enzymes and 
40 ligated together and then into NdeI/XhoI digested pET15b 
from Novagen. The ligation product was used to transform 
NovaB!ue E. coli. Transformants were screened for the 
proper insert and subjected to double stranded sequencing. 
The gene encoding SicA was copied by PCR from S. 
45 Typhimurium SL1344 (accession number 104117). The PCR 
fragment was digested with the restriction enzymes NdeI 
and XhoI and ligated into NdeI/XhoI digested pACYC-
Duet-1 from Novagen. The ligation product was used to 
transform NovaB!ue E. coli. Transformants were screened 
50 for the proper insert and subjected to double stranded 
sequencing. A plasmid containing the correct sequence for 
the fusion and a plasmid containing the correct sequence for 
SicA were transformed into TUNER (DE3) E. coli (Nova-
gen). This strain was used to inoculate LB media containing 
55 ampicillin and chloramphenicol. The bacteria were grown to 
an absorbance at 600 of about 0.6 at which time they were 
induced to over express IpaB/IpgC with Isopropyl-~-D-thio-
galactoside (IPTG). The bacteria were grown an additional 
three hours to allow protein expression to occur. Altema-
60 tively, a starter culture of 100 ml was used to inoculate a 5-
or IO-liter fermentor vessel containing TB media. After 
growing overnight (16 hours), the bacteria were induced and 
allowed to express protein for three hours. The bacteria were 
collected by centrifugation, resuspended in binding buffer 
65 (see below for recipe), and lysed by microfluidization. This 
suspension was clarified by centrifugation and was loaded 
onto a nickel charged immobilized metal affinity column 
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(IMAC). The column (5 ml) was washed with 10 bed 
volumes each of binding and wash buffers and then sub-
jected to a gradient of 0% to 40% elution buffer. Peak 
fractions were collected, the buffer exchanged into IM 
ammonium sulfate in 50 mM sodium phosphate pH 7 .0 and 5 
loaded onto a Butyl Sepharose High Performance column (5 
ml) with a linear gradient from IM ammonium sulfate in 50 
mM sodium phosphate pH 7 .0 to 50 mM sodium phosphate. 
For preparation of His-tag fusion, the !MAC-bound protein 
complex was incubated overnight in the presence of 1 % 10 
OPOE. The chaperone was removed in the flow through and 
subsequent wash steps. His-tag fusion was eluted in the 
presence of OPOE to maintain the protein in a soluble form. 
All proteins were concentrated by ultrafiltration and dia- 15 
lyzed into PBS pH 7.2. Protein concentrations were deter-
mined via absorbance at 280 nm using extinction coeffi-
cients based on the amino acid composition of each protein. 
duce these proteins with one fermentor run, significantly 
reducing the protein purification costs. 
The chimeric protein is administered to a subject as 
described herein and, as a result, a protective immune 
response is elicited in the subject. 
Example 5 
In Vivo Vaccine Evaluation. 
Food safety is a health issue that affects not only the 
United States, but the rest of the world. Today, the global-
ization of the food chain means tainted beef in the United 
States could cause illness or death halfway across the globe. 
In fact, Salmonella tainted beef may be the most significant 
challenge facing ranchers and the beef industry today. From 
the dinner plate to the pet food bowl, Salmonella contami-
nation is a top story demanding solutions. A broad and wide 
immunization policy with an effective vaccine that works Buffers that were utilized are listed below: 
TABLE 1 
4 X Charge Buffer ( 5 00 ml) 
200 mM NiSO4 52.56 g 
TABLE 2 
8X Binding Buffer (1 Liter) 
40 mM Imidazole 
4M NaCl 




Mix together and pH to 7.9 with HCI. 
TABLE 3 
8X Wash Buffer (500 mL) 
480 mM Imidazole 
4M NaCl 




lX = 50 mM 
lX = 5 mM 
500 mM 
20mM 
lX = 60 mM 
500 mM 
20mM 
Mix together and pH to 7 .9 with HCI. If using urea drop 
the imidazole to 20 mM. 8x=160. 
TABLE 4 
4X Elution Buffer (500 mL) 
4M Imidazole 
2M NaCl 
















lX = 100 mM 
500 mM 
20 mM 
Mix together. Add NaOH pellets to get pH to 8.0 so that 
EDTA will dissolve. Then adjust pH to 7.9. 
A chimeric protein containing both SipD and SipB pro-
teins was produced (FIG. 13; SEQ ID NO: 7), together with 
SipA protein. This method allows a cGMP facility to pro-
20 regardless of serovar across multiple species would allow 
the elimination of Salmonella as an endemic disease on 
farms across the States. 
The currently available Salmonella vaccines protect 
against a limited number of serovars and thus lack the 
25 impact and economic strength to change farm behavior, so 
subclinical infections continue to have a negative effect on 
both producer and consumer. By having a single vaccine that 
is cross-protective against virtually all Salmonella, would 
eliminate disease, morbidity and mortality for both animals 
30 and people. 
The specific objective was to demonstrate homologous 
protection of the vaccine against S. enterica serovar Typh-
imurium in a calf model. The proof of concept experiments 
were conducted in mice and the data with one component of 
35 the vaccine demonstrated that this vaccine can reduce bac-
terial shedding of a heterologous serotype, S. Newport, to the 
serotype from which the subunit vaccine was derived. 
Materials and methods 
Protein Purification. The recombinant proteins, S 1 F and 
40 S2F, were constructed as per the standard protocol (Chen, 
X., et al. Infect Immun. 2015;83(1):292-299; Choudhari, S. 
P., et al. Protein Sci. 2013;22(5):666-670; Choudhari, S. P., 
et al. J Pharm Sci. 2014. doi: 10.1002/jps.24047). Briefly, 
for SlF, the sipD-sipB gene fusion was cloned into pET9d 
45 which is kanamycin resistant and the gene for the cognate 
SipB chaperone SicA, was cloned into pACYC which is 
chloramphenicol resistant. The plasmids were co-trans-
formed into E. coli Tuner (DE3) for expression. The bacteria 
are grown at 37° C. to an A600 of 0.8 at which point IPTG 
50 was added to induce protein expression. After three hours, 
the bacteria were collected by centrifugation, lysed, and the 
inclusion bodies collected again in the pellet. The pellet was 
resuspended in IMAC binding buffer containing 6M urea. 
The solution was clarified by centrifugation and loaded onto 
55 a nickel charged IMAC column. The column was washed 
and the protein eluted. The eluted protein was passed over a 
Q column with the eluted protein slowly refolded by step 
dialysis into IMAC binding buffer with 0.05% (v/v) N,N-
dimethyldodecylamine N-oxide (LDAO). The solution was 
60 passed again over an IMAC column to remove the chaper-
one which was released from the complex by the detergent. 
Fractions were collected and the final dialysis step 
exchanges the proteins into phosphate buffered saline (PBS) 
containing LDAO which is required to maintain solubility of 
65 the proteins and has a GRAS (Generally Regarded As Safe) 
Profile. Furthermore, this detergent confers a significant 
degree of thermal stability to this class of proteins as well 
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(Chen, X. et al., 2015). The proteins were concentrated to 5 
mg/ml and stored at -80° C. For S2F, the sseB-sseC gene 
fusion has been cloned into pET9d which is kanamycin 
resistant and the gene for the cognate SseC chaperone SscA, 
was cloned into pACYC which is chloramphenicol resistant. 5 
The plasmids were co-transformed into E. coli Tuner (DE3) 
for expression. The remainder of the purification is the same 
as SlF. 
46 
in the bottom. Kinetics of serum IgG and fecal IgA titers are 
determined. The Immunological Core of the KVI performs 
the ELISAs to determine the antigen-specific IgG and IgA 
levels. (Martinez-Becerra, F. J. et al. Infect Immun. 2013a; 
81(12):4470-4477; Martinez-Becerra, F. J., et al. Vaccine. 
2013b; 31(24):2667-2672). The preliminary data provided 
for the protective efficacy of SseB in calves included deter-
mination of the kinetics of serum IgG and fecal IgA pro-
duction by the calves. Peripheral blood mononuclear cells Vaccine Preparation. The adjuvant for preparing purified 
subunit vaccine is monophosphoryl lipid A (MPL; Sigma 
Chemical Co.) combined with dipalmitoylphosphatidyl cho-
line (DPPC) in a 4: 1 molar ratio. Two milligrams of each 
protein were combined with -2 mg of Alhydrogel (AH) and 
allowed to bind for one hour with gentle shaking at room 
temperature. Currently, binding isotherms are being per-
formed to determine the actual optimal Alhydrogel ratio per 
unit protein. MPL (100 µg) was added to the formulation 
with a final vaccine formulation containing 1 ml. A live 
attenuated li.SPI-1/2 S. Typhimurium strain was used for the 
positive control and grown overnight at 37° C. with shaking, 
collected by centrifugation, washed and finally resuspended 
in PBS at lxl07 cfu/ml. The negative control was PBS only. 
10 (PBMCs) separated from blood samples are incubated in 
plates with SipD, SipB, SseB, and SseC to assess the 
frequency of antibody secreting cells. Similarly, after stimu-
lation with the antigens, the cells and supernatant are 
assessed for IFNy and IL-17 levels via flow cytometry and 
15 ELISA respectively. Statistical analysis is performed using 
Graphpad prism and FlowJo software. Differences among 
treatments are analyzed using ANOVAs and t-tests. A P 
value <0.05 is considered significant for all analysis. 
Go/No Go to Challenge. Based on previous immunologi-
Large Animal Efficacy Study. The calf experiments are 
performed at the Veterinary and Biomedical Research Cen-
ter (VBRC), Manhattan, Kans. by Kelly Lechtenberg, DVM, 
PhD. All animals used are approved by the VBRC Institu-
tional Animal Care and Use Committee. Holstein steers, 200 
pounds, are obtained from one of the commercial Holstein 
calf vendors that can assure study candidates are Salmo-
nella-free and have not been given any commercial vaccine 
against Salmonella by pre-screening fecal samples and by 
control of vaccination and management protocols. Fecal 
samples are obtained prior to the experiment to ensure no 
Salmonella is detectable. Calves are housed individually in 
indoor pens. Calves are initially fed twice daily (bottle or 
pail) with a commercial milk replacer appropriate for the age 
of the calves. As calves start to consume non-medicated dry 
feed, milk feeding is reduced to once daily to enhance dry 
feed consumption. Calves will have access to fresh water ad 
libitum. 
20 cal results, the titers for the anti-SipD, SipB, SseB, SseC-
specific IgG were at least 103 -104 ELISA units/ml with IgA 
units being 103 ELISA units/ml. Background was less than 
25 EU/ml. Similarly, there should be 100 IgG and 50 IgA 
antibody secreting cells (ASC) specifically directed against 
25 each antigen per 106 peripheral blood mononuclear cells 
(PBMCs). In a previous calf experiment (see challenge 
results below), an increase in IFNy and IL-17 levels were 
observed. If these conditions are not met, another vaccina-
tion is performed. Three vaccinations stimulate a complete 
30 immune response since maximal IgG and IgA titers were 
detected at the sampling associated with day 48 vaccination. 
S. Typhimurium Challenge. Calves are challenged orally 
with 1.2xl07 S. typhimurium SL1344 (Sm') which is the 
inoculum required to result in Salmonella-positive periph-
35 era! lymph nodes (Brown, T. R., et al. Journal of Food 
Protection. 2015; 78(3):573-578). The bacteria are grown at 
VBRC at 37° C. overnight with shaking, collected by 
centrifugation, washed and finally resuspended in PBS at 
1.2xl07 cfu/ml. A sample of the final inoculum is subjected 
40 to dilution plating to determine the actual final inoculum 
(prior to challenge, growth, manipulation and dilution is 
performed until the dilution plating is within 1 % error on 3 
consecutive trials). Upon challenge, weight loss is moni-
Vaccination. Two groups (n=l0/group) of calves are vac-
cinated subcutaneously three times on days 0, 14, and 28, 
with either PBS or the S 1 F +S2F (2 mg each) adsorbed to AH 
then admixed with 100 µg MPL (see above vaccine formu-
lation). The li.SPI-1/2 strain (2 ml) is fed to another group of 45 
10 calves on days 0 and 28 by mixing with milk. Groups of 
ten were chosen as this is the minimum number that is 
required to obtain significant results in both the challenge 
experiment and the immunology determinations. In addi-
tion, performance of a power analysis evidences that a 50 
number of 10 animals per group are enough to discern a 
difference of -20% in protective capacity. 
Sample collection. Blood is drawn at 0, 14, 28, and 42 to 
obtain serum (from clotted blood) and peripheral blood 
mononuclear cells (PBMCs, from Heparinized blood) via 55 
standard procedures. Fecal samples and saliva are collected 
at these times as well. One mg of fecal contents is suspended 
in 1 ml of PBS containing sodium azide and the suspension 
shaken vigorously by vortexer for 15 min. The suspension is 
clarified and the supernatant is frozen at -80° C. until 60 
analyzed by ELISA. Although total IgA can be detected, it 
is possible that rectal secretions need to be obtained to detect 
antigen-specific IgA in fecal samples. As an alternative, six 
cotton-tipped applicators are used to collect saliva from 
under the tongue and around the cheek. The saliva is 65 
transferred via centrifugation into a 50 ml conical tube from 
the applicators that are in a 15 ml conical tube with a hole 
tored over a seven day period (Day 0 and Day 7). Tempera-
ture is monitored in the morning (daily). Health scores are 
determined (Snider, T. A., et al. Vet Microbial. 2014; 170 
(1-2):65-72) in the morning (daily). Fecal shedding is moni-
tored over a seven day period by resuspending 1 mg of fecal 
matter in 10 ml of PBS by vortexing, and serial dilutions 
plated onto TSB+streptomycin (50 µg/ml). At the end of the 
study, the calves are euthanized, necropsies performed, and 
the Salmonella burden assessed in the matter of the gastro-
intestinal tract (rumen, cecum, colon, and rectum) and in the 
major lymph nodes (mesenteric, subiliac, popliteal, and 
superficial cervical) as per standard published methods 
(Brown, T. R. et al. 2015). 
Go/No Go to heterologous challenge and Phase II. The 
Salmonella carriage in the lymph nodes of the vaccinated 
calves should be reduced by 90-100% from unvaccinated 
animals. The shedding should be eliminated in the vacci-
nated calves earlier relative to the unvaccinated as well as 
the level of shedding should be reduced at least four logs. 
Results 
SipD and SipB alone or together did not provide complete 
protective efficacy. SseB, in contrast, does provide some 
protection (see calf data, FIG. 17). Salmonella fusion pro-
teins SlF and S2F were made recombinantly in E. coli. Five 
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total groups (n= 15) of female BALB/c mice were used with 
the experimental plan depicted in FIG. 14. Four groups were 
vaccinated intramuscularly three times with 100 µl of vac-
cine formulation containing the following: 1) 20 µg S1F+50 
µg monophosphoryl lipid A (MPL)+50 µg Alhydrogel (AH); 
2) 20 µg S2F+50 µg MPL+50 µg AH; 3)20 µg S1F+20 µg 
S2F+50 µg MPL+50 µg AH; 4) buffer only (phosphate-
buffered saline; PBS). Finally, one group was vaccinated on 
day 28 with a live-attenuated strain of either S. Typhimurium 
or S. Enteritidis. Blood samples (processed to obtain serum) 
from all the mice were collected at day 0, 14, 18, 42 and 56 
during the course of vaccination. Anti-SipB, -SipD, -SseB, 
and-SseC IgG serum titers were determined along with the 
IgA titers from fecal samples. No IgA response against any 
of the antigens was detected in fecal samples. This result was 
observed with parenteral immunization using the Shigella 
IpaD-IpaB Fusion. Mice that were vaccinated with SlF 
elicited a robust anti-SipB and -SipD IgG response (FIGS. 
15A-15D). Interestingly, a modest amount of cross-reactiv-
ity was detected with the S2F group. Likewise, mice vac-
cinated with S2F elicited a robust anti-SseB and -SseC IgG 
responses. Samples from mice vaccinated with live-attenu-
ated strain were not tested since, in the past, this strain has 
elicited a response to LPS and not to these antigens. 
At day 56 post-immunization, five mice from each immu-
nized group were euthanized to collect spleen and bone 
marrow. Single cell suspensions obtained from spleens and 
bone marrows were stimulated with the four antigens and 
the frequency of IgG antigen-secreting cells (ASC) in the 
spleen and bone marrow was determined by ELISpot assay 
(FIGS. 16A, 16B). Mice groups immunized with SlF dem-
onstrated high frequencies of anti-SipB IgG ASC, but more 
modest frequencies of anti-SipD IgG ASC in bone marrow. 
The groups immunized with S2F had high frequencies of 
anti-SseB IgG ASC and moderate frequencies of anti-SseC 
IgG ASC in bone marrow. No profound IgG ASC against the 
four antigens was detected in the spleens from mice vacci-
nated with the live-attenuated strain or PBS. 
On day 56, the remaining mice were challenged with 
2xl08 cfu (10 LD50) of S. Typhimurium SL1344 (wild-type) 
48 
time, there was an increase in shedding from the sham-
vaccinated calves and the majority of these calves continued 
shedding up to 105 CPU/gram for most of the study. The 
sham-vaccinated animals were only able to achieve baseline 
5 levels on day 10. In contrast, the calves vaccinated with 
SseB+dmLT did not exhibit increased fecal shedding of S. 
Newport. Instead, day 2 and 3 shedding was maintained near 
104 with a drop to baseline levels at day 4. The lack of 
shedding on day 4 coincided with the return of normal rectal 
10 temperatures on this day. Although a slight increase was 
seen on day 5 for 2 animals, the remaining days saw baseline 
shedding levels. When the ten day total shedding was 
calculated, the vaccine efficacy in reducing S. Newport 
shedding was significant. The total ten day bacterial shed-
15 ding for the group vaccinated with SseB+dmLT was not only 
lower than the sham-vaccinated group, but the variation over 
the ten day period was less than one log unit which is 
consistent with no effective increase in shedding over time 
(FIG. 17, bottom). Thus, the SseB+dmLT vaccine reduced 
20 disease severity relative to the control group and reduced 
shedding from the initial time point. 
Conclusion 
Vaccine prevention of Salmonella infections in livestock 
reduces time and money spent treating infections and 
25 reduces development of antibiotic resistance. There will be, 
in tum, less need for segregation and/or culling of sick 
animals that would be reservoirs for pathogen spread. The 
technology described herein for the production of this vac-
cine is one that is of use globally. Subunit vaccines are 
30 among the safest and there is no stigma like that encountered 
with genetically modified agricultural products. Thus, not 
only can this vaccine be used within the US, but it can be 
marketed for sale abroad. 
Slfusion ((Nde-SipD-Sal-SipB-Xho) in pET28; SEQ ID 




or 8xl07 cfu (10 LD50) of S. Enteritidis (wild-type). In this 
model, mice do not exhibit symptoms of gastroenteritis but 
they do develop a systemic typhoid-like illness with death as 
the endpoint. Mice that were immunized with the live-
attenuated strain showed 80% and 70% survival in case of 45 
S. Typhimurium and S. Enteritidis challenges, respectively 
(FIGS. 16A, 16B). This was an expected observation since 
the protection afforded to the mice by this strain is serotype 
specific. Although the SlF and S2F vaccine formulations 
conferred no protection, the combination of S1F+S2F 50 
showed an encouraging survival pattern with 60% protection 
against lethal challenges regardless of serovar used for 
challenge. The fact that the current vaccine formulation 
confers significant protection before even optimizing the 













Previously, SseB was tested in a calf study to assess 
protective efficacy. Calves were vaccinated subcutaneously 
(n=6) with 2 mg SseB (a component of S2F) admixed with 
50 µg dmLT (double mutant labile toxin from enterotoxi-
genic E. coli) or PBS (n=6). These twelve calves were 
challenged with S. Newport. Each set of calves exhibited a 
significant increase in body temperature by day 2 indicating 
a successful S. Newport infection (FIG. 17, top). Except for 
days 2 and 3, the trend of the temperatures exhibited by the 
SseB+dmLT group was lower than those of the PBS group. 
Fecal shedding was also monitored. On day 1 both groups 
















































































S2fusion ((Nde-SseB-Sac-SseC-Bam) in pET15; SEQ ID 










































































Salmonella enterica subsp. enterica serovar Typhimurium 


















































Salmonella enterica subsp. enterica serovar Typhimurium 
SL1344 (SEQ ID NO: 18): 
M L N I Q N Y S A S P H P G I V A E R P Q T P S 
A S E H V E T A V V P S T T E H R G T D I I S L 
S Q A A T K I H Q A Q Q T L Q S T P P I S E E N 
N D E R T L A R Q Q L T S S L N A L A K S G V S 
L S A E Q N E N L R S A F S A P T S A L F S A S 
P M A Q P R T T I S D A E I W D M V S Q N I S A 
I G D S Y L G V Y E N V V A V Y T D F Y Q A F S 
D I L S K M G G W L L P G K D G N T V K L D V T 
S L K N D L N S L V N K Y N Q I N S N T V L F P 
A Q S G S G V K V A T E A E A R Q W L S E L N L 
P N S C L K S Y G S G Y V V T V D L T P L Q K M 
V Q D I D G L G A P G K D S K L E M D N A K Y Q 
A W Q S G F K A Q E E N M K T T L Q T L T Q K Y 









































Salmonella enterica subsp. enterica serovar Typhimurium 55 atgacgcaagtagcattagccgtagcggatatacccaaaatccgcgc 









































K E A T E A K E A L D K A T D A T V K A G T D A 
K A K A E K A D N I L T K F Q G T A N A A S Q N 
Q V S Q G E Q D N L S N V A R L T M L M A M F I 
E I V G K N T E E S L Q N D L A L F N A L Q E G 
R Q A E M E K K S A E F Q E E T R K A E E T N R 
I M G C I G K V L G A L L T I V S V V A A V F T 
GGASLALAAVGLAVMVADEIVKAA 
T G V S F I Q Q A L N P I M E H V L K P L M E L 
I G K A I T K A L E G L G V D K K T A E M A G S 
IVGAIVAAIAMVAVIVVVAVVGKG 
A A A K L G N A L S K M M G E T I K K L V P N V 
20 LKQ LA Q NG SK L FT Q GM QR ITS G LG 
N V G S K M G L Q T N A L S K E L V G N T L N K 
V A L G M E V T N T A A Q S A G G V A E G V F I 
25 KN ASE AL AD FM LA RF AM D QI Q Q W L 
K Q S V E I F G E N Q K V T A E L Q K A M S S A 
V Q Q N A D A S R F I L R Q S R A 
30 Salmonella typhimurium pathogenicity island 2 (SPI-2), 















Salmonella enterica subsp. enterica serovar Typhimurium 
SL1344 (SEQ ID NO: 20): 
M V N D A S S I S R S G Y T Q N P R L A E A A F 
E G V R K N T D F L K A A D K A F K D V V A T K 
A G D L K A G T K S G E S A I N T V G L K P P T 
D A A R E K L S S E G Q L T L L L G K L M T L L 
G D V S L S Q L E S R L A V W Q A M I E S Q K E 
M G I Q V S K E F Q T A L G E A Q E A T D L Y E 
A S I K K T D T A K S V Y D A A T K K L T Q A Q 




























Salmonella typhimurium pathogenicity island 2 (SPI-2), 
partial sequence (SEQ ID NO: 22): 
M s s G N I L w G s Q N p I V F K N s F G V s N 
A D T G s Q D D L s Q Q N p F A E G y G V L L I 
L L M V I Q A I A N N K F I E V Q K N A E R A R 
N T Q E K s N E M D E V I A K A A K G D A K T K 
E E V p E D V I K y M R D N G I L I D G M T I D 
D y M A K y G D H G K L D K G G L Q A I K A A L 
D N D A N R N T D L M s Q G Q I T I Q K M s Q E 
L N A V L T Q L T G L I s K w G E I s s M I A Q 






















cgttatgccaacagcttgagcgggcaactgaggtgcaaaatgcatta Salmonella typhimurium pathogenicity island 2, partial 
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-continued Salmonella typhimurium pathogenicity island 2, partial 
sequence (SEQ ID NO: 24): F G E E V S E S F S K Q F E P L E R E M A M A N 
M N R I H S N S D S A A G V T A L T H H H L S N 
V S C V S S G S L G K R Q H R V N S T F G D G N 
A A C L L S G K I S L Q E A S N A L K Q L L D A 
V P G N H K R P S L P D F L Q T N P A V L S M M 
M T S L I L N V F G N N A Q S L C Q Q L E R A T 
E V Q N A L R N K Q V K E Y Q E Q I Q K A I E Q 
E D K A R K A G I F G A I F D W I T G I F E T V 
I G A L K V V E G F L S G N P A E M A S G V A Y 
M A A G C A G M V K A G A E T A M M C G A D H D 
T C Q A I I D V T S K I Q F G C E A V A L A L D 
V F Q I G R A F M A T R G L S G A A A K V L D S 
G F G E E V V E R M V G A G E A E I E E L A E K 
<160> NUMBER OF SEQ ID NOS, 25 
<210> SEQ ID NO 1 
<211> LENGTH, 593 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM: Salmonella enterica 
<400> SEQUENCE, 1 
E M A E E A A E F S R N V E N N M T R S A G K S 
5 F T K E G V K A M A K E A A K E A L E K C V Q E 
G G K F L L K K F R N K V L F N M F K K I L Y A 
L L R D C S F K G L Q A I R C A T E G A S Q M N 
10 T GM V NT EK AK IE K KIE Q LIT Q QR F 
L D F I M Q Q T E N Q K K I E Q K R L E E L Y K 
G S G A A L R D V L D T I D H Y S S V Q A R I A 
15 G Y R A -
Thus, the present invention is well adapted to carry out the 
objectives and attain the ends and advantages mentioned 
above as well as those inherent therein. While presently 
20 preferred embodiments have been described for purposes of 
this disclosure, numerous changes and modifications will be 
apparent to those of ordinary skill in the art. Such changes 
and modifications are encompassed within the spirit of this 
invention as defined by the claims. 
Met Val Asn Asp Ala Ser Ser Ile Ser Arg Ser Gly Tyr Thr Gln Asn 
1 5 10 15 
Pro Arg Leu Ala Glu Ala Ala Phe Glu Gly Val Arg Lys Asn Thr Asp 
20 25 30 
Phe Leu Lys Ala Ala Asp Lys Ala Phe Lys Asp Val Val Ala Thr Lys 
35 40 45 
Ala Gly Asp Leu Lys Ala Gly Thr Lys Ser Gly Glu Ser Ala Ile Asn 
50 55 60 
Thr Val Gly Leu Lys Pro Pro Thr Asp Ala Ala Arg Glu Lys Leu Ser 
65 70 75 80 
Ser Glu Gly Gln Leu Thr Leu Leu Leu Gly Lys Leu Met Thr Leu Leu 
85 90 95 
Gly Asp Val Ser Leu Ser Gln Leu Glu Ser Arg Leu Ala Val Trp Gln 
100 105 110 
Ala Met Ile Glu Ser Gln Lys Glu Met Gly Ile Gln Val Ser Lys Glu 
115 120 125 
Phe Gln Thr Ala Leu Gly Glu Ala Gln Glu Ala Thr Asp Leu Tyr Glu 
130 135 140 
Ala Ser Ile Lys Lys Thr Asp Thr Ala Lys Ser Val Tyr Asp Ala Ala 
145 150 155 160 
Thr Lys Lys Leu Thr Gln Ala Gln Asn Lys Leu Gln Ser Leu Asp Pro 
165 170 175 
Ala Asp Pro Gly Tyr Ala Gln Ala Glu Ala Ala Val Glu Gln Ala Gly 
180 185 190 
Lys Glu Ala Thr Glu Ala Lys Glu Ala Leu Asp Lys Ala Thr Asp Ala 
195 200 205 
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-continued 
Thr Val Lys Ala Gly Thr Asp Ala Lys Ala Lys Ala Glu Lys Ala Asp 
210 215 220 
Asn Ile Leu Thr Lys Phe Gln Gly Thr Ala Asn Ala Ala Ser Gln Asn 
225 230 235 240 
Gln Val Ser Gln Gly Glu Gln Asp Asn Leu Ser Asn Val Ala Arg Leu 
245 250 255 
Thr Met Leu Met Ala Met Phe Ile Glu Ile Val Gly Lys Asn Thr Glu 
260 265 270 
Glu Ser Leu Gln Asn Asp Leu Ala Leu Phe Asn Ala Leu Gln Glu Gly 
275 280 285 
Arg Gln Ala Glu Met Glu Lys Lys Ser Ala Glu Phe Gln Glu Glu Thr 
290 295 300 
Arg Lys Ala Glu Glu Thr Asn Arg Ile Met Gly Cys Ile Gly Lys Val 
305 310 315 320 
Leu Gly Ala Leu Leu Thr Ile Val Ser Val Val Ala Ala Val Phe Thr 
325 330 335 
Gly Gly Ala Ser Leu Ala Leu Ala Ala Val Gly Leu Ala Val Met Val 
340 345 350 
Ala Asp Glu Ile Val Lys Ala Ala Thr Gly Val Ser Phe Ile Gln Gln 
355 360 365 
Ala Leu Asn Pro Ile Met Glu His Val Leu Lys Pro Leu Met Glu Leu 
370 375 380 
Ile Gly Lys Ala Ile Thr Lys Ala Leu Glu Gly Leu Gly Val Asp Lys 
385 390 395 400 
Lys Thr Ala Glu Met Ala Gly Ser Ile Val Gly Ala Ile Val Ala Ala 
405 410 415 
Ile Ala Met Val Ala Val Ile Val Val Val Ala Val Val Gly Lys Gly 
420 425 430 
Ala Ala Ala Lys Leu Gly Asn Ala Leu Ser Lys Met Met Gly Glu Thr 
435 440 445 
Ile Lys Lys Leu Val Pro Asn Val Leu Lys Gln Leu Ala Gln Asn Gly 
450 455 460 
Ser Lys Leu Phe Thr Gln Gly Met Gln Arg Ile Thr Ser Gly Leu Gly 
465 470 475 480 
Asn Val Gly Ser Lys Met Gly Leu Gln Thr Asn Ala Leu Ser Lys Glu 
485 490 495 
Leu Val Gly Asn Thr Leu Asn Lys Val Ala Leu Gly Met Glu Val Thr 
500 505 510 
Asn Thr Ala Ala Gln Ser Ala Gly Gly Val Ala Glu Gly Val Phe Ile 
515 520 525 
Lys Asn Ala Ser Glu Ala Leu Ala Asp Phe Met Leu Ala Arg Phe Ala 
530 535 540 
Met Asp Gln Ile Gln Gln Trp Leu Lys Gln Ser Val Glu Ile Phe Gly 
545 550 555 560 
Glu Asn Gln Lys Val Thr Ala Glu Leu Gln Lys Ala Met Ser Ser Ala 
565 570 575 
Val Gln Gln Asn Ala Asp Ala Ser Arg Phe Ile Leu Arg Gln Ser Arg 
580 585 590 
Ala 
<210> SEQ ID NO 2 
<211> LENGTH: 1782 
<212> TYPE: DNA 
62 
US 9,950,053 B2 
63 
-continued 
<213> ORGANISM: Salmonella enterica 
<400> SEQUENCE, 2 
ttatgcgcga ctctggcgca gaataaaacg cgaagcatcc gcattttgct gtaccgcaga 
agacatggct ttttgcagtt ccgccgttac cttctggttt tcaccaaata tttctacgga 
ttgtttaagc cactgctgaa tctgatccat ggcaaaacgg gcgagcataa aatcagcaag 
cgcctcgctg gcatttttaa taaatacgcc ctcggcaaca ccaccggctg actgggctgc 
ggtattcgtg acttccatgc ccaacgccac tttatttagg gtattaccta ccagctcttt 
acttaaggca ttcgtttgca ggcccatctt gctacccaca ttacccagac cgctagtaat 
acgttgcatc ccctgggtaa agagtttgct gccgttttgc gccaactgtt tcagcacgtt 
aggcaccaac ttcttaatcg tttcgcccat cattttgctc agcgcgttac ccagtttcgc 
cgccgcgcct ttcccgacaa ctgcgaccac cacaatgacc gccaccatgg caatagcggc 
gacaatcgca ccaacaatgc tgccggccat ctctgccgtt ttcttatcga cgcctaatcc 
ttccagcgct ttggtaatcg ccttgccaat cagctccatt aacggcttca gcacatgctc 
cataatcggg tttagcgcct gctgaataaa cgacactccc gtcgccgcct tcacaatttc 
atcggccacc attaccgcaa gtcccaccgc agccagcgcc agactcgccc caccggtaaa 
aacagcggcc acaacgctga caatggttag cagcgcgccg aggactttcc cgatacatcc 
cataatgcgg ttcgtttcct cggctttgcg cgtctcttcc tggaattcag ccgatttctt 
ttccatctcc gcctgacgcc cttcctgcaa ggcgttgaaa agcgcaagat cgttttgcag 
gctttcttcc gtatttttgc ccacaatctc aataaacatg gccatgagca tagtgaggcg 
ggcgacattt gacagattat cctgctcacc ctgggaaacc tgattctgag aggcggcatt 
agccgttccc tggaatttgg tcagaatgtt atccgctttc tcggctttcg ctttggcgtc 
tgtgcctgct ttaaccgtcg catccgtggc cttatctaag gcctctttcg cctctgtcgc 
ttcttttccg gcctgttcta ccgcggcttc agcttgtgca tagccggggt cagccgggtc 
cagcgattgc aatttatttt gcgcctgcgt cagttttttg gtcgcagcgt cataaacact 
cttggcggta tccgtctttt tgatactggc ttcatagaga tccgtcgcct cctgagcctc 
tcccagagcc gtctggaatt ctttcgatac ctgaatcccc atctcttttt gtgactcaat 
catcgcctgc cataccgcca gacgagactc cagttgagac agcgaaacat cgcccagtag 
ggtcattaac ttgccaagca gtaatgtcaa ttgcccttcg ctggagagtt tttcccgggc 
ggcgtccgta ggcggcttta gacccaccgt attaatagcg ctctcgccgg actttgttcc 
ggctttaagg tcgcccgctt tcgttgccac cacatcttta aaagctttat ccgccgcttt 
taaaaagtcc gtgttcttac gaacgccttc aaaagccgcc tcagcgaggc gcggattttg 
ggtatatccg ctacggctaa tgctacttgc gtcatttacc at 
<210> SEQ ID NO 3 
<211> LENGTH, 339 
<212> TYPE, PRT 
<213> ORGANISM, Salmonella enterica 
<400> SEQUENCE, 3 
Met Leu Asn Ile Gln Asn Tyr Ser Ala Ser Pro His Pro Gly Ile Val 
1 5 10 15 
Ala Glu Arg Pro Gln Thr Pro Ser Ala Ser Glu His Ala Glu Ile Ala 
20 25 30 
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35 40 45 
Ser Gln Ala Ala Thr Lys Ile Gln Gln Ala Gln Gln Thr Leu Gln Ser 
50 55 60 
Thr Pro Pro Ile Ser Glu Glu Asn Asn Asp Glu Arg Thr Leu Ala Arg 
65 70 75 80 
Gln Gln Leu Thr Ser Ser Leu Asn Ala Leu Ala Lys Ser Gly Val Ser 
85 90 95 
Leu Ser Ala Glu Gln Asn Glu Asn Leu Arg Ser Thr Phe Ser Ala Arg 
100 105 110 
Arg Arg Pro Tyr Leu Ala Leu Arg Leu Trp Pro Ala Arg Thr Thr Ile 
115 120 125 
Ser Asp Ala Glu Ile Trp Asp Met Val Ser Gln Asn Ile Ser Ala Ile 
130 135 140 
Gly Asp Ser Tyr Leu Gly Val Tyr Glu Asn Val Val Ala Val Tyr Thr 
145 150 155 160 
Asp Phe Tyr Gln Ala Phe Ser Asp Ile Leu Ser Lys Met Gly Gly Trp 
165 170 175 
Leu Ser Pro Gly Lys Asp Gly Asn Thr Ile Lys Leu Asn Val Asp Ser 
180 185 190 
Leu Lys Ser Glu Ile Ser Ser Leu Ile Asn Lys Tyr Thr Gln Ile Asn 
195 200 205 
Lys Asn Thr Ile Leu Phe Pro Ser Gln Thr Gly Ser Gly Met Thr Thr 
210 215 220 
Ala Thr Lys Ala Glu Ala Glu Gln Trp Ile Lys Glu Leu Asn Leu Pro 
225 230 235 240 
Asp Ser Cys Leu Lys Ala Ser Gly Ser Gly Tyr Val Val Leu Val Asp 
245 250 255 
Thr Gly Pro Leu Ser Lys Met Val Ser Asp Leu Asn Gly Ile Gly Ser 
260 265 270 
Gly Ser Ala Leu Glu Leu Asp Asn Ala Lys Tyr Gln Ala Trp Gln Ser 
275 280 285 
Gly Phe Lys Ala Gln Glu Glu Asn Leu Lys Thr Thr Leu Gln Thr Leu 
290 295 300 
Thr Gln Lys Tyr Ser Asn Ala Asn Ser Leu Tyr Asp Asn Leu Val Lys 
305 310 315 320 
Val Leu Ser Ser Thr Ile Ser Ser Ser Leu Glu Thr Ala Lys Ser Phe 
325 330 335 
Leu Gln Gly 
<210> SEQ ID NO 4 
<211> LENGTH, 1020 
<212> TYPE, DNA 
<213> ORGANISM, Salmonella enterica 
<400> SEQUENCE, 4 
atgcttaata ttcaaaatta ttccgcttct cctcatccgg ggatcgttgc cgaacggccg 
cagactcctt cggcgagcga gcacgccgag attgccgtgg taccgtctac cacagaacat 
cgcggcacag atatcatttc attatcgcag gcggctacta aaatccagca ggcacagcag 
acgctgcagt caacgccacc gatttctgaa gagaataatg acgagcgcac gctggcgcgc 
caacagttga ccagcagcct gaatgcgctg gcgaagtccg gcgtgtcatt atccgcagaa 
caaaatgaga acctgcggag cacgttttct gcgcgacgtc ggccttattt agcgcttcgc 



















<210> SEQ ID NO 5 
<211> LENGTH, 196 












<213> ORGANISM: Salmonella enterica 
<400> SEQUENCE, 5 












Met Ser Ser Gly Asn Ile Leu Trp Gly Ser Gln Asn Pro Ile Val Phe 
1 5 10 15 
Lys Asn Ser Phe Gly Val Ser Asn Ala Asp Thr Gly Ser Gln Asp Asp 
20 25 30 
Leu Ser Gln Gln Asn Pro Phe Ala Glu Gly Tyr Gly Val Leu Leu Ile 
35 40 45 
Leu Leu Met Val Ile Gln Ala Ile Ala Asn Asn Lys Phe Ile Glu Val 
50 55 60 
Gln Lys Asn Ala Glu Arg Ala Arg Asn Thr Gln Glu Lys Ser Asn Glu 
65 70 75 80 
Met Asp Glu Val Ile Ala Lys Ala Ala Lys Gly Asp Ala Lys Thr Lys 
85 90 95 
Glu Glu Val Pro Glu Asp Val Ile Lys Tyr Met Arg Asp Asn Gly Ile 
100 105 110 
Leu Ile Asp Gly Met Thr Ile Asp Asp Tyr Met Ala Lys Tyr Gly Asp 
115 120 125 
His Gly Lys Leu Asp Lys Gly Gly Leu Gln Ala Ile Lys Ala Ala Leu 
130 135 140 
Asp Asn Asp Ala Asn Arg Asn Thr Asp Leu Met Ser Gln Gly Gln Ile 
145 150 155 160 
Thr Ile Gln Lys Met Ser Gln Glu Leu Asn Ala Val Leu Thr Gln Leu 
165 170 175 
Thr Gly Leu Ile Ser Lys Trp Gly Glu Ile Ser Ser Met Ile Ala Gln 
180 185 190 
Lys Thr Tyr Ser 
195 
<210> SEQ ID NO 6 
<211> LENGTH, 591 
<212> TYPE, DNA 
<213> ORGANISM, Salmonella enterica 











atgtcttcag gaaacatctt atggggaagt caaaacccta ttgtgtttaa aaatagcttc 60 










<210> SEQ ID NO 7 
<211> LENGTH, 934 










<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 9,950,053 B2 
-continued 
aggctatcgc aaataataaa 180 
cccaggaaaa gtcaaatgag 240 
aaaccaaaga ggaggtgcct 300 
tcgatggtat gaccattgat 360 
aaggtggcct acaggcgatc 420 
ttatgagtca ggggcagata 480 
cccaactgac agggcttatc 540 
cgtactcatg a 591 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
SipB-SipD chimera 
<400> SEQUENCE, 7 
Met Leu Asn Ile Gln Asn Tyr Ser Ala Ser Pro His Pro Gly Ile Val 
1 5 10 15 
Ala Glu Arg Pro Gln Thr Pro Ser Ala Ser Glu His Ala Glu Ile Ala 
20 25 30 
Val Val Pro Ser Thr Thr Glu His Arg Gly Thr Asp Ile Ile Ser Leu 
35 40 45 
Ser Gln Ala Ala Thr Lys Ile Gln Gln Ala Gln Gln Thr Leu Gln Ser 
50 55 60 
Thr Pro Pro Ile Ser Glu Glu Asn Asn Asp Glu Arg Thr Leu Ala Arg 
65 70 75 80 
Gln Gln Leu Thr Ser Ser Leu Asn Ala Leu Ala Lys Ser Gly Val Ser 
85 90 95 
Leu Ser Ala Glu Gln Asn Glu Asn Leu Arg Ser Thr Phe Ser Ala Arg 
100 105 110 
Arg Arg Pro Tyr Leu Ala Leu Arg Leu Trp Pro Ala Arg Thr Thr Ile 
115 120 125 
Ser Asp Ala Glu Ile Trp Asp Met Val Ser Gln Asn Ile Ser Ala Ile 
130 135 140 
Gly Asp Ser Tyr Leu Gly Val Tyr Glu Asn Val Val Ala Val Tyr Thr 
145 150 155 160 
Asp Phe Tyr Gln Ala Phe Ser Asp Ile Leu Ser Lys Met Gly Gly Trp 
165 170 175 
Leu Ser Pro Gly Lys Asp Gly Asn Thr Ile Lys Leu Asn Val Asp Ser 
180 185 190 
Leu Lys Ser Glu Ile Ser Ser Leu Ile Asn Lys Tyr Thr Gln Ile Asn 
195 200 205 
Lys Asn Thr Ile Leu Phe Pro Ser Gln Thr Gly Ser Gly Met Thr Thr 
210 215 220 
Ala Thr Lys Ala Glu Ala Glu Gln Trp Ile Lys Glu Leu Asn Leu Pro 
225 230 235 240 
Asp Ser Cys Leu Lys Ala Ser Gly Ser Gly Tyr Val Val Leu Val Asp 
245 250 255 
Thr Gly Pro Leu Ser Lys Met Val Ser Asp Leu Asn Gly Ile Gly Ser 
260 265 270 
70 
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Gly Ser Ala Leu Glu Leu Asp Asn Ala Lys Tyr Gln Ala Trp Gln Ser 
275 280 285 
Gly Phe Lys Ala Gln Glu Glu Asn Leu Lys Thr Thr Leu Gln Thr Leu 
290 295 300 
Thr Gln Lys Tyr Ser Asn Ala Asn Ser Leu Tyr Asp Asn Leu Val Lys 
305 310 315 320 
Val Leu Ser Ser Thr Ile Ser Ser Ser Leu Glu Thr Ala Lys Ser Phe 
325 330 335 
Leu Gln Gly Val Asp Met Val Asn Asp Ala Ser Ser Ile Ser Arg Ser 
340 345 350 
Gly Tyr Thr Gln Asn Pro Arg Leu Ala Glu Ala Ala Phe Glu Gly Val 
355 360 365 
Arg Lys Asn Thr Asp Phe Leu Lys Ala Ala Asp Lys Ala Phe Lys Asp 
370 375 380 
Val Val Ala Thr Lys Ala Gly Asp Leu Lys Ala Gly Thr Lys Ser Gly 
385 390 395 400 
Glu Ser Ala Ile Asn Thr Val Gly Leu Lys Pro Pro Thr Asp Ala Ala 
405 410 415 
Arg Glu Lys Leu Ser Ser Glu Gly Gln Leu Thr Leu Leu Leu Gly Lys 
420 425 430 
Leu Met Thr Leu Leu Gly Asp Val Ser Leu Ser Gln Leu Glu Ser Arg 
435 440 445 
Leu Ala Val Trp Gln Ala Met Ile Glu Ser Gln Lys Glu Met Gly Ile 
450 455 460 
Gln Val Ser Lys Glu Phe Gln Thr Ala Leu Gly Glu Ala Gln Glu Ala 
465 470 475 480 
Thr Asp Leu Tyr Glu Ala Ser Ile Lys Lys Thr Asp Thr Ala Lys Ser 
485 490 495 
Val Tyr Asp Ala Ala Thr Lys Lys Leu Thr Gln Ala Gln Asn Lys Leu 
500 505 510 
Gln Ser Leu Asp Pro Ala Asp Pro Gly Tyr Ala Gln Ala Glu Ala Ala 
515 520 525 
Val Glu Gln Ala Gly Lys Glu Ala Thr Glu Ala Lys Glu Ala Leu Asp 
530 535 540 
Lys Ala Thr Asp Ala Thr Val Lys Ala Gly Thr Asp Ala Lys Ala Lys 
545 550 555 560 
Ala Glu Lys Ala Asp Asn Ile Leu Thr Lys Phe Gln Gly Thr Ala Asn 
565 570 575 
Ala Ala Ser Gln Asn Gln Val Ser Gln Gly Glu Gln Asp Asn Leu Ser 
580 585 590 
Asn Val Ala Arg Leu Thr Met Leu Met Ala Met Phe Ile Glu Ile Val 
595 600 605 
Gly Lys Asn Thr Glu Glu Ser Leu Gln Asn Asp Leu Ala Leu Phe Asn 
610 615 620 
Ala Leu Gln Glu Gly Arg Gln Ala Glu Met Glu Lys Lys Ser Ala Glu 
625 630 635 640 
Phe Gln Glu Glu Thr Arg Lys Ala Glu Glu Thr Asn Arg Ile Met Gly 
645 650 655 
Cys Ile Gly Lys Val Leu Gly Ala Leu Leu Thr Ile Val Ser Val Val 
660 665 670 
Ala Ala Val Phe Thr Gly Gly Ala Ser Leu Ala Leu Ala Ala Val Gly 
675 680 685 
Leu Ala Val Met Val Ala Asp Glu Ile Val Lys Ala Ala Thr Gly Val 
72 
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690 695 700 
Ser Phe Ile Gln Gln Ala Leu Asn Pro Ile Met Glu His Val Leu Lys 
705 710 715 720 
Pro Leu Met Glu Leu Ile Gly Lys Ala Ile Thr Lys Ala Leu Glu Gly 
725 730 735 
Leu Gly Val Asp Lys Lys Thr Ala Glu Met Ala Gly Ser Ile Val Gly 
740 745 750 
Ala Ile Val Ala Ala Ile Ala Met Val Ala Val Ile Val Val Val Ala 
755 760 765 
Val Val Gly Lys Gly Ala Ala Ala Lys Leu Gly Asn Ala Leu Ser Lys 
770 775 780 
Met Met Gly Glu Thr Ile Lys Lys Leu Val Pro Asn Val Leu Lys Gln 
785 790 795 800 
Leu Ala Gln Asn Gly Ser Lys Leu Phe Thr Gln Gly Met Gln Arg Ile 
805 810 815 
Thr Ser Gly Leu Gly Asn Val Gly Ser Lys Met Gly Leu Gln Thr Asn 
820 825 830 
Ala Leu Ser Lys Glu Leu Val Gly Asn Thr Leu Asn Lys Val Ala Leu 
835 840 845 
Gly Met Glu Val Thr Asn Thr Ala Ala Gln Ser Ala Gly Gly Val Ala 
850 855 860 
Glu Gly Val Phe Ile Lys Asn Ala Ser Glu Ala Leu Ala Asp Phe Met 
865 870 875 880 
Leu Ala Arg Phe Ala Met Asp Gln Ile Gln Gln Trp Leu Lys Gln Ser 
885 890 895 
Val Glu Ile Phe Gly Glu Asn Gln Lys Val Thr Ala Glu Leu Gln Lys 
900 905 910 
Ala Met Ser Ser Ala Val Gln Gln Asn Ala Asp Ala Ser Arg Phe Ile 
915 920 925 
Leu Arg Gln Ser Arg Ala 
930 
<210> SEQ ID NO 8 
<211> LENGTH, 2805 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
nucleic acid sequence encoding SipB-SipD chimera 
<400> SEQUENCE, 8 
atgcttaata ttcaaaatta ttccgcttct cctcatccgg ggatcgttgc cgaacggccg 60 
cagactcctt cggcgagcga gcacgccgag attgccgtgg taccgtctac cacagaacat 120 
cgcggcacag atatcatttc attatcgcag gcggctacta aaatccagca ggcacagcag 180 
acgctgcagt caacgccacc gatttctgaa gagaataatg acgagcgcac gctggcgcgc 240 
caacagttga ccagcagcct gaatgcgctg gcgaagtccg gcgtgtcatt atccgcagaa 300 
caaaatgaga acctgcggag cacgttttct gcgcgacgtc ggccttattt agcgcttcgc 360 
ctatggccag cgagaacaac catttctgat gctgagattt gggatatggt ttcccaaaat 420 
atatcggcga taggtgacag ctacctgggc gtttatgaaa acgttgtcgc agtctatacc 480 
gatttttatc aggccttcag tgatattctt tccaaaatgg gaggctggtt atcgcctggt 540 
aaggatggaa ataccattaa gctaaatgtt gactcactta aaagtgaaat aagtagttta 600 
attaataaat acactcaaat aaataaaaat acgattttat ttccctcgca aactggcagc 660 
74 
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ggaatgacaa cagcaacgaa agcggaagct gagcagtgga ttaaagaatt gaatttaccg 720 
gacagctgtc taaaggcgtc tggttctggt tatgtcgtac tggtggatac ggggccactg 780 
agcaaaatgg ttagcgatct taatggaata ggatcgggtt cagcccttga actggataac 840 
gccaaatatc aagcctggca gtcgggtttt aaagcacagg aagaaaatct gaaaaccaca 900 
ttacagacgc tgacgcaaaa atatagcaat gccaattcat tgtacgacaa cctggtaaaa 960 
gtgctgagca gtacgataag tagcagcctg gaaaccgcca aaagcttcct gcaaggagtc 1020 
gacttatgcg cgactctggc gcagaataaa acgcgaagca tccgcatttt gctgtaccgc 1080 
agaagacatg gctttttgca gttccgccgt taccttctgg ttttcaccaa atatttctac 1140 
ggattgttta agccactgct gaatctgatc catggcaaaa cgggcgagca taaaatcagc 1200 
aagcgcctcg ctggcatttt taataaatac gccctcggca acaccaccgg ctgactgggc 1260 
tgcggtattc gtgacttcca tgcccaacgc cactttattt agggtattac ctaccagctc 1320 
tttacttaag gcattcgttt gcaggcccat cttgctaccc acattaccca gaccgctagt 1380 
aatacgttgc atcccctggg taaagagttt gctgccgttt tgcgccaact gtttcagcac 1440 
gttaggcacc aacttcttaa tcgtttcgcc catcattttg ctcagcgcgt tacccagttt 1500 
cgccgccgcg cctttcccga caactgcgac caccacaatg accgccacca tggcaatagc 1560 
ggcgacaatc gcaccaacaa tgctgccggc catctctgcc gttttcttat cgacgcctaa 1620 
tccttccagc gctttggtaa tcgccttgcc aatcagctcc attaacggct tcagcacatg 1680 
ctccataatc gggtttagcg cctgctgaat aaacgacact cccgtcgccg ccttcacaat 1740 
ttcatcggcc accattaccg caagtcccac cgcagccagc gccagactcg ccccaccggt 1800 
aaaaacagcg gccacaacgc tgacaatggt tagcagcgcg ccgaggactt tcccgataca 1860 
tcccataatg cggttcgttt cctcggcttt gcgcgtctct tcctggaatt cagccgattt 1920 
cttttccatc tccgcctgac gcccttcctg caaggcgttg aaaagcgcaa gatcgttttg 1980 
caggctttct tccgtatttt tgcccacaat ctcaataaac atggccatga gcatagtgag 2040 
gcgggcgaca tttgacagat tatcctgctc accctgggaa acctgattct gagaggcggc 2100 
attagccgtt ccctggaatt tggtcagaat gttatccgct ttctcggctt tcgctttggc 2160 
gtctgtgcct gctttaaccg tcgcatccgt ggccttatct aaggcctctt tcgcctctgt 2220 
cgcttctttt ccggcctgtt ctaccgcggc ttcagcttgt gcatagccgg ggtcagccgg 2280 
gtccagcgat tgcaatttat tttgcgcctg cgtcagtttt ttggtcgcag cgtcataaac 2340 
actcttggcg gtatccgtct ttttgatact ggcttcatag agatccgtcg cctcctgagc 2400 
ctctcccaga gccgtctgga attctttcga tacctgaatc cccatctctt tttgtgactc 2460 
aatcatcgcc tgccataccg ccagacgaga ctccagttga gacagcgaaa catcgcccag 2520 
tagggtcatt aacttgccaa gcagtaatgt caattgccct tcgctggaga gtttttcccg 2580 
ggcggcgtcc gtaggcggct ttagacccac cgtattaata gcgctctcgc cggactttgt 2640 
tccggcttta aggtcgcccg ctttcgttgc caccacatct ttaaaagctt tatccgccgc 2700 
ttttaaaaag tccgtgttct tacgaacgcc ttcaaaagcc gcctcagcga ggcgcggatt 2760 
ttgggtatat ccgctacggc taatgctact tgcgtcattt accat 2805 
<210> SEQ ID NO 9 
<400> SEQUENCE: 9 
000 
US 9,950,053 B2 
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-continued 
<210> SEQ ID NO 10 
<400> SEQUENCE, 10 
000 
<210> SEQ ID NO 11 
<400> SEQUENCE, 11 
000 
<210> SEQ ID NO 12 
<400> SEQUENCE, 12 
000 
<210> SEQ ID NO 13 
<211> LENGTH, 2877 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
polynucleotide 
<400> SEQUENCE, 13 
atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 60 
atgcttaata ttcaaaatta ttccgcttct cctcatccgg ggatcgttgc cgaacggccg 120 
cagactccct cggcgagcga gcacgtcgag actgccgtgg taccgtctac cacagaacat 180 
cgcggtacag atatcatttc attatcgcag gcggctacta aaatccacca ggcacagcag 240 
acgctgcagt caacgccacc gatctctgaa gagaataatg acgagcgcac gctggcgcgc 300 
cagcagttga ccagcagcct gaatgcgctg gcgaagtccg gcgtgtcatt atccgcagaa 360 
caaaatgaga acctgcggag cgcgttttct gcgccgacgt cggccttatt tagcgcttcg 420 
cctatggcgc agccgagaac aaccatttct gatgctgaga tttgggatat ggtttcccaa 480 
aatatatcgg cgataggtga cagctatctg ggcgtttatg aaaacgttgt cgcagtctat 540 
accgattttt atcaggcctt cagtgatatt ctttccaaaa tgggaggctg gttattacca 600 
ggtaaggacg gtaataccgt taagctagat gttacctcac tcaaaaatga tttaaacagt 660 
ttagtcaata aatataatca aataaacagt aataccgttt tatttccagc gcagtcaggc 720 
agcggcgtta aagtagccac tgaagcggaa gcgagacagt ggctcagtga attgaattta 780 
ccgaatagct gcctgaaatc ttatggatcc ggttatgtcg tcaccgttga tctgacgcca 840 
ttacaaaaaa tggttcagga tattgatggt ttaggcgcgc cgggaaaaga ctcaaaactc 900 
gaaatggata acgccaaata tcaagcctgg cagtcgggtt ttaaagcgca ggaagaaaat 960 
atgaaaacca cattacagac gctgacgcaa aaatatagca atgccaattc attgtacgac 1020 
aacctggtaa aagtgctgag cagtacgata agtagcagcc tggaaaccgc caaaagcttc 1080 
ctgcaaggag tcgacatggt aaatgacgca agtagcatta gccgtagcgg atatacccaa 1140 
aatccgcgcc tcgctgaggc ggcttttgaa ggcgttcgta agaacacgga ctttttaaaa 1200 
gcggcggata aagcttttaa agatgtggtg gcaacgaaag cgggcgacct taaagccgga 1260 
acaaagtccg gcgagagcgc tattaatacg gtgggtctaa agccgcctac ggacgccgcc 1320 
cgggaaaaac tctccagcga agggcaattg acattactgc ttggcaagtt aatgacccta 1380 
US 9,950,053 B2 
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ctgggcgatg tttcgctgtc tcaactggag tctcgtctgg cggtatggca ggcgatgatt 
gagtcacaaa aagagatggg gattcaggta tcgaaagaat tccagacggc tctgggagag 
gctcaggagg cgacggatct ctatgaagcc agtatcaaaa agacggatac cgccaagagt 
gtttatgacg ctgcgaccaa aaaactgacg caggcgcaaa ataaattgca atcgctggac 
ccggctgacc ccggctatgc acaagctgaa gccgcggtag aacaggccgg aaaagaagcg 
acagaggcga aagaggcctt agataaggcc acggatgcga cggttaaagc aggcacagac 
gccaaagcga aagccgagaa agcggataac attctgacca aattccaggg aacggctaat 
gccgcctctc agaatcaggt ttcccagggt gagcaggata atctgtcaaa tgtcgcccgc 
ctcactatgc tcatggccat gtttattgag attgtgggca aaaatacgga agaaagcctg 
caaaacgatc ttgcgctttt caacgccttg caggaagggc gtcaggcgga gatggaaaag 
aaatcggctg aattccagga agagacgcgc aaagccgagg aaacgaaccg cattatggga 
tgtatcggga aagtcctcgg cgcgctgcta accattgtca gcgttgtggc cgctgttttt 
accggtgggg cgagtctggc gctggctgcg gtgggacttg cggtaatggt ggccgatgaa 
attgtgaagg cggcgacggg agtgtcgttt attcagcagg cgctaaaccc gattatggag 
catgtgctga agccgttaat ggagctgatt ggcaaggcga ttaccaaagc gctggaagga 
ttaggcgtcg ataagaaaac ggcagagatg gccggcagca ttgttggtgc gattgtcgcc 
gctattgcca tggtggcggt cattgtggtg gtcgcagttg tcgggaaagg cgcggcggcg 
aaactgggta acgcgctgag caaaatgatg ggcgaaacga ttaagaagtt ggtgcctaac 
gtgctgaaac agttggcgca aaacggcagc aaactcttta cccaggggat gcaacgtatt 
actagcggtc tgggtaatgt gggtagcaag atgggcctgc aaacgaatgc cttaagtaaa 
gagctggtag gtaataccct aaataaagtg gcgttgggca tggaagtcac gaataccgca 
gcccagtcag ccggtggtgt tgccgagggc gtatttatta aaaatgccag cgaggcgctt 
gctgatttta tgctcgcccg ttttgccatg gatcagattc agcagtggct taaacaatcc 
gtagaaatat ttggtgaaaa ccagaaggta acggcggaac tgcaaaaagc catgtcttct 
gcggtacagc aaaatgcgga tgcttcgcgt tttattctgc gccagagtcg cgcataa 
<210> SEQ ID NO 14 
<211> LENGTH, 958 
<212> TYPE, PRT 



























<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polypeptide 
<400> SEQUENCE, 14 
Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 
1 5 10 15 
Arg Gly Ser His Met Leu Asn Ile Gln Asn Tyr Ser Ala Ser Pro His 
20 25 30 
Pro Gly Ile Val Ala Glu Arg Pro Gln Thr Pro Ser Ala Ser Glu His 
35 40 45 
Val Glu Thr Ala Val Val Pro Ser Thr Thr Glu His Arg Gly Thr Asp 
50 55 60 
Ile Ile Ser Leu Ser Gln Ala Ala Thr Lys Ile His Gln Ala Gln Gln 
65 70 75 80 
Thr Leu Gln Ser Thr Pro Pro Ile Ser Glu Glu Asn Asn Asp Glu Arg 
85 90 95 
80 
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Thr Leu Ala Arg Gln Gln Leu Thr Ser Ser Leu Asn Ala Leu Ala Lys 
100 105 110 
Ser Gly Val Ser Leu Ser Ala Glu Gln Asn Glu Asn Leu Arg Ser Ala 
115 120 125 
Phe Ser Ala Pro Thr Ser Ala Leu Phe Ser Ala Ser Pro Met Ala Gln 
130 135 140 
Pro Arg Thr Thr Ile Ser Asp Ala Glu Ile Trp Asp Met Val Ser Gln 
145 150 155 160 
Asn Ile Ser Ala Ile Gly Asp Ser Tyr Leu Gly Val Tyr Glu Asn Val 
165 170 175 
Val Ala Val Tyr Thr Asp Phe Tyr Gln Ala Phe Ser Asp Ile Leu Ser 
180 185 190 
Lys Met Gly Gly Trp Leu Leu Pro Gly Lys Asp Gly Asn Thr Val Lys 
195 200 205 
Leu Asp Val Thr Ser Leu Lys Asn Asp Leu Asn Ser Leu Val Asn Lys 
210 215 220 
Tyr Asn Gln Ile Asn Ser Asn Thr Val Leu Phe Pro Ala Gln Ser Gly 
225 230 235 240 
Ser Gly Val Lys Val Ala Thr Glu Ala Glu Ala Arg Gln Trp Leu Ser 
245 250 255 
Glu Leu Asn Leu Pro Asn Ser Cys Leu Lys Ser Tyr Gly Ser Gly Tyr 
260 265 270 
Val Val Thr Val Asp Leu Thr Pro Leu Gln Lys Met Val Gln Asp Ile 
275 280 285 
Asp Gly Leu Gly Ala Pro Gly Lys Asp Ser Lys Leu Glu Met Asp Asn 
290 295 300 
Ala Lys Tyr Gln Ala Trp Gln Ser Gly Phe Lys Ala Gln Glu Glu Asn 
305 310 315 320 
Met Lys Thr Thr Leu Gln Thr Leu Thr Gln Lys Tyr Ser Asn Ala Asn 
325 330 335 
Ser Leu Tyr Asp Asn Leu Val Lys Val Leu Ser Ser Thr Ile Ser Ser 
340 345 350 
Ser Leu Glu Thr Ala Lys Ser Phe Leu Gln Gly Val Asp Met Val Asn 
355 360 365 
Asp Ala Ser Ser Ile Ser Arg Ser Gly Tyr Thr Gln Asn Pro Arg Leu 
370 375 380 
Ala Glu Ala Ala Phe Glu Gly Val Arg Lys Asn Thr Asp Phe Leu Lys 
385 390 395 400 
Ala Ala Asp Lys Ala Phe Lys Asp Val Val Ala Thr Lys Ala Gly Asp 
405 410 415 
Leu Lys Ala Gly Thr Lys Ser Gly Glu Ser Ala Ile Asn Thr Val Gly 
420 425 430 
Leu Lys Pro Pro Thr Asp Ala Ala Arg Glu Lys Leu Ser Ser Glu Gly 
435 440 445 
Gln Leu Thr Leu Leu Leu Gly Lys Leu Met Thr Leu Leu Gly Asp Val 
450 455 460 
Ser Leu Ser Gln Leu Glu Ser Arg Leu Ala Val Trp Gln Ala Met Ile 
465 470 475 480 
Glu Ser Gln Lys Glu Met Gly Ile Gln Val Ser Lys Glu Phe Gln Thr 
485 490 495 
Ala Leu Gly Glu Ala Gln Glu Ala Thr Asp Leu Tyr Glu Ala Ser Ile 
500 505 510 
Lys Lys Thr Asp Thr Ala Lys Ser Val Tyr Asp Ala Ala Thr Lys Lys 
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515 520 525 
Leu Thr Gln Ala Gln Asn Lys Leu Gln Ser Leu Asp Pro Ala Asp Pro 
530 535 540 
Gly Tyr Ala Gln Ala Glu Ala Ala Val Glu Gln Ala Gly Lys Glu Ala 
545 550 555 560 
Thr Glu Ala Lys Glu Ala Leu Asp Lys Ala Thr Asp Ala Thr Val Lys 
565 570 575 
Ala Gly Thr Asp Ala Lys Ala Lys Ala Glu Lys Ala Asp Asn Ile Leu 
580 585 590 
Thr Lys Phe Gln Gly Thr Ala Asn Ala Ala Ser Gln Asn Gln Val Ser 
595 600 605 
Gln Gly Glu Gln Asp Asn Leu Ser Asn Val Ala Arg Leu Thr Met Leu 
610 615 620 
Met Ala Met Phe Ile Glu Ile Val Gly Lys Asn Thr Glu Glu Ser Leu 
625 630 635 640 
Gln Asn Asp Leu Ala Leu Phe Asn Ala Leu Gln Glu Gly Arg Gln Ala 
645 650 655 
Glu Met Glu Lys Lys Ser Ala Glu Phe Gln Glu Glu Thr Arg Lys Ala 
660 665 670 
Glu Glu Thr Asn Arg Ile Met Gly Cys Ile Gly Lys Val Leu Gly Ala 
675 680 685 
Leu Leu Thr Ile Val Ser Val Val Ala Ala Val Phe Thr Gly Gly Ala 
690 695 700 
Ser Leu Ala Leu Ala Ala Val Gly Leu Ala Val Met Val Ala Asp Glu 
705 710 715 720 
Ile Val Lys Ala Ala Thr Gly Val Ser Phe Ile Gln Gln Ala Leu Asn 
725 730 735 
Pro Ile Met Glu His Val Leu Lys Pro Leu Met Glu Leu Ile Gly Lys 
740 745 750 
Ala Ile Thr Lys Ala Leu Glu Gly Leu Gly Val Asp Lys Lys Thr Ala 
755 760 765 
Glu Met Ala Gly Ser Ile Val Gly Ala Ile Val Ala Ala Ile Ala Met 
770 775 780 
Val Ala Val Ile Val Val Val Ala Val Val Gly Lys Gly Ala Ala Ala 
785 790 795 800 
Lys Leu Gly Asn Ala Leu Ser Lys Met Met Gly Glu Thr Ile Lys Lys 
805 810 815 
Leu Val Pro Asn Val Leu Lys Gln Leu Ala Gln Asn Gly Ser Lys Leu 
820 825 830 
Phe Thr Gln Gly Met Gln Arg Ile Thr Ser Gly Leu Gly Asn Val Gly 
835 840 845 
Ser Lys Met Gly Leu Gln Thr Asn Ala Leu Ser Lys Glu Leu Val Gly 
850 855 860 
Asn Thr Leu Asn Lys Val Ala Leu Gly Met Glu Val Thr Asn Thr Ala 
865 870 875 880 
Ala Gln Ser Ala Gly Gly Val Ala Glu Gly Val Phe Ile Lys Asn Ala 
885 890 895 
Ser Glu Ala Leu Ala Asp Phe Met Leu Ala Arg Phe Ala Met Asp Gln 
900 905 910 
Ile Gln Gln Trp Leu Lys Gln Ser Val Glu Ile Phe Gly Glu Asn Gln 
915 920 925 
Lys Val Thr Ala Glu Leu Gln Lys Ala Met Ser Ser Ala Val Gln Gln 
930 935 940 
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Asn Ala Asp Ala Ser Arg Phe Ile Leu Arg Gln Ser Arg Ala 
945 950 955 
<210> SEQ ID NO 15 
<211> LENGTH, 2109 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polynucleotide 
<400> SEQUENCE, 15 
atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 
atgtcttcag gaaacatctt atggggaagt caaaacccta ttgtgtttaa aaatagcttc 
ggcgtcagca acgctgatac cgggagccag gatgacttat cccagcaaaa tccgtttgcc 
gaagggtatg gtgttttgct tattctcctt atggttattc aggctatcgc aaataataaa 
tttattgaag tccagaagaa cgctgaacgt gccagaaata cccaggaaaa gtcaaatgag 
atggatgagg tgattgctaa agcagccaaa ggggatgcta aaaccaaaga ggaggtgcct 
gaggatgtaa ttaaatacat gcgtgataat ggtattctca tcgatggtat gaccattgat 
gattatatgg ctaaatatgg cgatcatggg aagctggata aaggtggcct acaggcgatc 
aaagcggctt tggataatga cgccaaccgg aataccgatc ttatgagtca ggggcagata 
acaattcaaa aaatgtctca ggagcttaac gctgtcctta cccaactgac agggcttatc 
agtaagtggg gggaaatttc cagtatgata gcgcagaaaa cgtactcacc gcggatgaat 
cgaattcaca gtaatagcga cagcgccgca ggagtaaccg ccttaacaca tcatcactta 
agcaatgtca gttgcgtttc ctcgggttcg ctgggaaagc gccagcatcg tgtgaattct 
acttttggcg atggcaacgc cgcgtgtctg ctatccggga aaattagtct tcaggaggca 
agcaatgcgt tgaagcaact gcttgatgcc gtacccggaa atcataagcg tccatcattg 
cctgactttt tgcagaccaa tcccgcggtt ttatcaatga tgatgacgtc attaatactc 
aacgtctttg gtaataacgc tcaatcgtta tgccaacagc ttgagcgggc aactgaggtg 
caaaatgcat tacgtaataa gcaggtaaag gagtatcagg agcagatcca gaaagcgata 
gagcaggagg ataaagcgcg taaagcgggt atttttggcg ctatttttga ctggattacc 
ggcatatttg aaaccgtgat tggcgcctta aaagttgtgg aaggttttct gtccggaaat 
cccgcagaaa tggctagcgg cgtagcttat atggccgcag gttgtgcagg aatggttaaa 
gccggagccg aaacggcaat gatgtgcggt gctgaccacg atacctgtca ggcaattatt 
gacgtgacaa gtaagattca atttggttgt gaagccgtcg cgctggcact ggatgttttc 
cagattggcc gtgcttttat ggcgacgaga ggtttatctg gcgcagctgc aaaagtgctt 
gactccggtt ttggcgagga agtggttgag cgtatggtag gtgcagggga agcagaaata 
gaggagttgg ctgaaaagtt tggcgaagaa gtgagcgaaa gtttttccaa acaatttgag 
ccgcttgaac gtgaaatggc tatggcgaat gagatggcag aggaggctgc cgagttttct 
cgtaacgtag aaaataatat gacgcgaagc gcgggaaaaa gctttacgaa agagggggtg 
aaagccatgg caaaagaagc ggcaaaagaa gccctggaaa aatgtgtgca agaaggtgga 
aagttcctgt taaaaaaatt ccgtaataaa gttctcttca atatgttcaa aaaaatcctg 
tatgccttac tgagggattg ttcatttaaa ggcttacagg ctatcagatg tgcaaccgag 
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atagagcaat taataactca gcaacggttt ctggatttca taatgcaaca aacagaaaac 
cagaaaaaga tagaacaaaa acgcttagag gagctttata aggggagcgg tgccgcgctt 
agagatgtat tagataccat tgatcactat agtagcgttc aggcgagaat agctggctat 
cgcgcttaa 
<210> SEQ ID NO 16 
<211> LENGTH, 702 
<212> TYPE, PRT 






<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polypeptide 
<400> SEQUENCE, 16 
Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 
1 5 10 15 
Arg Gly Ser His Met Ser Ser Gly Asn Ile Leu Trp Gly Ser Gln Asn 
20 25 30 
Pro Ile Val Phe Lys Asn Ser Phe Gly Val Ser Asn Ala Asp Thr Gly 
35 40 45 
Ser Gln Asp Asp Leu Ser Gln Gln Asn Pro Phe Ala Glu Gly Tyr Gly 
50 55 60 
Val Leu Leu Ile Leu Leu Met Val Ile Gln Ala Ile Ala Asn Asn Lys 
65 70 75 80 
Phe Ile Glu Val Gln Lys Asn Ala Glu Arg Ala Arg Asn Thr Gln Glu 
85 90 95 
Lys Ser Asn Glu Met Asp Glu Val Ile Ala Lys Ala Ala Lys Gly Asp 
100 105 110 
Ala Lys Thr Lys Glu Glu Val Pro Glu Asp Val Ile Lys Tyr Met Arg 
115 120 125 
Asp Asn Gly Ile Leu Ile Asp Gly Met Thr Ile Asp Asp Tyr Met Ala 
130 135 140 
Lys Tyr Gly Asp His Gly Lys Leu Asp Lys Gly Gly Leu Gln Ala Ile 
145 150 155 160 
Lys Ala Ala Leu Asp Asn Asp Ala Asn Arg Asn Thr Asp Leu Met Ser 
165 170 175 
Gln Gly Gln Ile Thr Ile Gln Lys Met Ser Gln Glu Leu Asn Ala Val 
180 185 190 
Leu Thr Gln Leu Thr Gly Leu Ile Ser Lys Trp Gly Glu Ile Ser Ser 
195 200 205 
Met Ile Ala Gln Lys Thr Tyr Ser Pro Arg Met Asn Arg Ile His Ser 
210 215 220 
Asn Ser Asp Ser Ala Ala Gly Val Thr Ala Leu Thr His His His Leu 
225 230 235 240 
Ser Asn Val Ser Cys Val Ser Ser Gly Ser Leu Gly Lys Arg Gln His 
245 250 255 
Arg Val Asn Ser Thr Phe Gly Asp Gly Asn Ala Ala Cys Leu Leu Ser 
260 265 270 
Gly Lys Ile Ser Leu Gln Glu Ala Ser Asn Ala Leu Lys Gln Leu Leu 
275 280 285 
Asp Ala Val Pro Gly Asn His Lys Arg Pro Ser Leu Pro Asp Phe Leu 
290 295 300 
Gln Thr Asn Pro Ala Val Leu Ser Met Met Met Thr Ser Leu Ile Leu 
305 310 315 320 
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Asn Val Phe Gly Asn Asn Ala Gln Ser Leu Cys Gln Gln Leu Glu Arg 
325 330 335 
Ala Thr Glu Val Gln Asn Ala Leu Arg Asn Lys Gln Val Lys Glu Tyr 
340 345 350 
Gln Glu Gln Ile Gln Lys Ala Ile Glu Gln Glu Asp Lys Ala Arg Lys 
355 360 365 
Ala Gly Ile Phe Gly Ala Ile Phe Asp Trp Ile Thr Gly Ile Phe Glu 
370 375 380 
Thr Val Ile Gly Ala Leu Lys Val Val Glu Gly Phe Leu Ser Gly Asn 
385 390 395 400 
Pro Ala Glu Met Ala Ser Gly Val Ala Tyr Met Ala Ala Gly Cys Ala 
405 410 415 
Gly Met Val Lys Ala Gly Ala Glu Thr Ala Met Met Cys Gly Ala Asp 
420 425 430 
His Asp Thr Cys Gln Ala Ile Ile Asp Val Thr Ser Lys Ile Gln Phe 
435 440 445 
Gly Cys Glu Ala Val Ala Leu Ala Leu Asp Val Phe Gln Ile Gly Arg 
450 455 460 
Ala Phe Met Ala Thr Arg Gly Leu Ser Gly Ala Ala Ala Lys Val Leu 
465 470 475 480 
Asp Ser Gly Phe Gly Glu Glu Val Val Glu Arg Met Val Gly Ala Gly 
485 490 495 
Glu Ala Glu Ile Glu Glu Leu Ala Glu Lys Phe Gly Glu Glu Val Ser 
500 505 510 
Glu Ser Phe Ser Lys Gln Phe Glu Pro Leu Glu Arg Glu Met Ala Met 
515 520 525 
Ala Asn Glu Met Ala Glu Glu Ala Ala Glu Phe Ser Arg Asn Val Glu 
530 535 540 
Asn Asn Met Thr Arg Ser Ala Gly Lys Ser Phe Thr Lys Glu Gly Val 
545 550 555 560 
Lys Ala Met Ala Lys Glu Ala Ala Lys Glu Ala Leu Glu Lys Cys Val 
565 570 575 
Gln Glu Gly Gly Lys Phe Leu Leu Lys Lys Phe Arg Asn Lys Val Leu 
580 585 590 
Phe Asn Met Phe Lys Lys Ile Leu Tyr Ala Leu Leu Arg Asp Cys Ser 
595 600 605 
Phe Lys Gly Leu Gln Ala Ile Arg Cys Ala Thr Glu Gly Ala Ser Gln 
610 615 620 
Met Asn Thr Gly Met Val Asn Thr Glu Lys Ala Lys Ile Glu Lys Lys 
625 630 635 640 
Ile Glu Gln Leu Ile Thr Gln Gln Arg Phe Leu Asp Phe Ile Met Gln 
645 650 655 
Gln Thr Glu Asn Gln Lys Lys Ile Glu Gln Lys Arg Leu Glu Glu Leu 
660 665 670 
Tyr Lys Gly Ser Gly Ala Ala Leu Arg Asp Val Leu Asp Thr Ile Asp 
675 680 685 
His Tyr Ser Ser Val Gln Ala Arg Ile Ala Gly Tyr Arg Ala 
690 695 700 
<210> SEQ ID NO 17 
<211> LENGTH: 2064 
<212> TYPE: DNA 
<213> ORGANISM: Salmonella enterica 
<400> SEQUENCE: 17 
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ttatccttgc aggaagcttt tggcggtttc caggctgcta cttatcgtac tgctcagcac 60 
ttttaccagg ttgtcgtaca atgaattggc attgctatat ttttgcgtca gcgtctgtaa 120 
tgtggttttc atattttctt cctgcgcttt aaaacccgac tgccaggctt gatatttggc 180 
gttatccatt tcgagttttg agtcttttcc cggcgcgcct aaaccatcaa tatcctgaac 240 
cattttttgt aatggcgtca gatcaacggt gacgacataa ccggatccat aagatttcag 300 
gcagctattc ggtaaattca attcactgag ccactgtctc gcttccgctt cagtggctac 360 
tttaacgccg ctgcctgact gcgctggaaa taaaacggta ttactgttta tttgattata 420 
tttattgact aaactgttta aatcattttt gagtgaggta acatctagct taacggtatt 480 
accgtcctta cctggtaata accagcctcc cattttggaa agaatatcac tgaaggcctg 540 
ataaaaatcg gtatagactg cgacaacgtt ttcataaacg cccagatagc tgtcacctat 600 
cgccgatata ttttgggaaa ccatatccca aatctcagca tcagaaatgg ttgttctcgg 660 
ctgcgccata ggcgaagcgc taaataaggc cgacgtcggc gcagaaaacg cgctccgcag 720 
gttctcattt tgttctgcgg ataatgacac gccggacttc gccagcgcat tcaggctgct 780 
ggtcaactgc tggcgcgcca gcgtgcgctc gtcattattc tcttcagaga tcggtggcgt 840 
tgactgcagc gtctgctgtg cctggtggat tttagtagcc gcctgcgata atgaaatgat 900 
atctgtaccg cgatgttctg tggtagacgg taccacggca gtctcgacgt gctcgctcgc 960 
cgagggagtc tgcggccgtt cggcaacgat ccccggatga ggagaagcgg aataattttg 1020 
aatattaagc atatgcttaa tattcaaaat tattccgctt ctcctcatcc ggggatcgtt 1080 
gccgaacggc cgcagactcc ctcggcgagc gagcacgtcg agactgccgt ggtaccgtct 1140 
accacagaac atcgcggtac agatatcatt tcattatcgc aggcggctac taaaatccac 1200 
caggcacagc agacgctgca gtcaacgcca ccgatctctg aagagaataa tgacgagcgc 1260 
acgctggcgc gccagcagtt gaccagcagc ctgaatgcgc tggcgaagtc cggcgtgtca 1320 
ttatccgcag aacaaaatga gaacctgcgg agcgcgtttt ctgcgccgac gtcggcctta 1380 
tttagcgctt cgcctatggc gcagccgaga acaaccattt ctgatgctga gatttgggat 1440 
atggtttccc aaaatatatc ggcgataggt gacagctatc tgggcgttta tgaaaacgtt 1500 
gtcgcagtct ataccgattt ttatcaggcc ttcagtgata ttctttccaa aatgggaggc 1560 
tggttattac caggtaagga cggtaatacc gttaagctag atgttacctc actcaaaaat 1620 
gatttaaaca gtttagtcaa taaatataat caaataaaca gtaataccgt tttatttcca 1680 
gcgcagtcag gcagcggcgt taaagtagcc actgaagcgg aagcgagaca gtggctcagt 1740 
gaattgaatt taccgaatag ctgcctgaaa tcttatggat ccggttatgt cgtcaccgtt 1800 
gatctgacgc cattacaaaa aatggttcag gatattgatg gtttaggcgc gccgggaaaa 1860 
gactcaaaac tcgaaatgga taacgccaaa tatcaagcct ggcagtcggg ttttaaagcg 1920 
caggaagaaa atatgaaaac cacattacag acgctgacgc aaaaatatag caatgccaat 1980 
tcattgtacg acaacctggt aaaagtgctg agcagtacga taagtagcag cctggaaacc 2040 
gccaaaagct tcctgcaagg ataa 2064 
<210> SEQ ID NO 18 
<211> LENGTH: 343 
<212> TYPE: PRT 
<213> ORGANISM: Salmonella enterica 
<400> SEQUENCE: 18 
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Met Leu Asn Ile Gln Asn Tyr Ser Ala Ser Pro His Pro Gly Ile Val 
1 5 10 15 
Ala Glu Arg Pro Gln Thr Pro Ser Ala Ser Glu His Val Glu Thr Ala 
20 25 30 
Val Val Pro Ser Thr Thr Glu His Arg Gly Thr Asp Ile Ile Ser Leu 
35 40 45 
Ser Gln Ala Ala Thr Lys Ile His Gln Ala Gln Gln Thr Leu Gln Ser 
50 55 60 
Thr Pro Pro Ile Ser Glu Glu Asn Asn Asp Glu Arg Thr Leu Ala Arg 
65 70 75 80 
Gln Gln Leu Thr Ser Ser Leu Asn Ala Leu Ala Lys Ser Gly Val Ser 
85 90 95 
Leu Ser Ala Glu Gln Asn Glu Asn Leu Arg Ser Ala Phe Ser Ala Pro 
100 105 110 
Thr Ser Ala Leu Phe Ser Ala Ser Pro Met Ala Gln Pro Arg Thr Thr 
115 120 125 
Ile Ser Asp Ala Glu Ile Trp Asp Met Val Ser Gln Asn Ile Ser Ala 
130 135 140 
Ile Gly Asp Ser Tyr Leu Gly Val Tyr Glu Asn Val Val Ala Val Tyr 
145 150 155 160 
Thr Asp Phe Tyr Gln Ala Phe Ser Asp Ile Leu Ser Lys Met Gly Gly 
165 170 175 
Trp Leu Leu Pro Gly Lys Asp Gly Asn Thr Val Lys Leu Asp Val Thr 
180 185 190 
Ser Leu Lys Asn Asp Leu Asn Ser Leu Val Asn Lys Tyr Asn Gln Ile 
195 200 205 
Asn Ser Asn Thr Val Leu Phe Pro Ala Gln Ser Gly Ser Gly Val Lys 
210 215 220 
Val Ala Thr Glu Ala Glu Ala Arg Gln Trp Leu Ser Glu Leu Asn Leu 
225 230 235 240 
Pro Asn Ser Cys Leu Lys Ser Tyr Gly Ser Gly Tyr Val Val Thr Val 
245 250 255 
Asp Leu Thr Pro Leu Gln Lys Met Val Gln Asp Ile Asp Gly Leu Gly 
260 265 270 
Ala Pro Gly Lys Asp Ser Lys Leu Glu Met Asp Asn Ala Lys Tyr Gln 
275 280 285 
Ala Trp Gln Ser Gly Phe Lys Ala Gln Glu Glu Asn Met Lys Thr Thr 
290 295 300 
Leu Gln Thr Leu Thr Gln Lys Tyr Ser Asn Ala Asn Ser Leu Tyr Asp 
305 310 315 320 
Asn Leu Val Lys Val Leu Ser Ser Thr Ile Ser Ser Ser Leu Glu Thr 
325 330 335 
Ala Lys Ser Phe Leu Gln Gly 
340 
<210> SEQ ID NO 19 
<211> LENGTH: 3558 
<212> TYPE: DNA 
<213> ORGANISM: Salmonella enterica 
<400> SEQUENCE: 19 
tgcgcgactc tggcgcagaa taaaacgcga agcatccgca ttttgctgta ccgcagaaga 60 
catggctttt tgcagttccg ccgttacctt ctggttttca ccaaatattt ctacggattg 120 
tttaagccac tgctgaatct gatccatggc aaaacgggcg agcataaaat cagcaagcgc 180 
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ctcgctggca tttttaataa atacgccctc ggcaacacca ccggctgact gggctgcggt 240 
attcgtgact tccatgccca acgccacttt atttagggta ttacctacca gctctttact 300 
taaggcattc gtttgcaggc ccatcttgct acccacatta cccagaccgc tagtaatacg 360 
ttgcatcccc tgggtaaaga gtttgctgcc gttttgcgcc aactgtttca gcacgttagg 420 
caccaacttc ttaatcgttt cgcccatcat tttgctcagc gcgttaccca gtttcgccgc 480 
cgcgcctttc ccgacaactg cgaccaccac aatgaccgcc accatggcaa tagcggcgac 540 
aatcgcacca acaatgctgc cggccatctc tgccgttttc ttatcgacgc ctaatccttc 600 
cagcgctttg gtaatcgcct tgccaatcag ctccattaac ggcttcagca catgctccat 660 
aatcgggttt agcgcctgct gaataaacga cactcccgtc gccgccttca caatttcatc 720 
ggccaccatt accgcaagtc ccaccgcagc cagcgccaga ctcgccccac cggtaaaaac 780 
agcggccaca acgctgacaa tggttagcag cgcgccgagg actttcccga tacatcccat 840 
aatgcggttc gtttcctcgg ctttgcgcgt ctcttcctgg aattcagccg atttcttttc 900 
catctccgcc tgacgccctt cctgcaaggc gttgaaaagc gcaagatcgt tttgcaggct 960 
ttcttccgta tttttgccca caatctcaat aaacatggcc atgagcatag tgaggcgggc 1020 
gacatttgac agattatcct gctcaccctg ggaaacctga ttctgagagg cggcattagc 1080 
cgttccctgg aatttggtca gaatgttatc cgctttctcg gctttcgctt tggcgtctgt 1140 
gcctgcttta accgtcgcat ccgtggcctt atctaaggcc tctttcgcct ctgtcgcttc 1200 
ttttccggcc tgttctaccg cggcttcagc ttgtgcatag ccggggtcag ccgggtccag 1260 
cgattgcaat ttattttgcg cctgcgtcag ttttttggtc gcagcgtcat aaacactctt 1320 
ggcggtatcc gtctttttga tactggcttc atagagatcc gtcgcctcct gagcctctcc 1380 
cagagccgtc tggaattctt tcgatacctg aatccccatc tctttttgtg actcaatcat 1440 
cgcctgccat accgccagac gagactccag ttgagacagc gaaacatcgc ccagtagggt 1500 
cattaacttg ccaagcagta atgtcaattg cccttcgctg gagagttttt cccgggcggc 1560 
gtccgtaggc ggctttagac ccaccgtatt aatagcgctc tcgccggact ttgttccggc 1620 
tttaaggtcg cccgctttcg ttgccaccac atctttaaaa gctttatccg ccgcttttaa 1680 
aaagtccgtg ttcttacgaa cgccttcaaa agccgcctca gcgaggcgcg gattttgggt 1740 
atatccgcta cggctaatgc tacttgcgtc atttaccata tggtaaatga cgcaagtagc 1800 
attagccgta gcggatatac ccaaaatccg cgcctcgctg aggcggcttt tgaaggcgtt 1860 
cgtaagaaca cggacttttt aaaagcggcg gataaagctt ttaaagatgt ggtggcaacg 1920 
aaagcgggcg accttaaagc cggaacaaag tccggcgaga gcgctattaa tacggtgggt 1980 
ctaaagccgc ctacggacgc cgcccgggaa aaactctcca gcgaagggca attgacatta 2040 
ctgcttggca agttaatgac cctactgggc gatgtttcgc tgtctcaact ggagtctcgt 2100 
ctggcggtat ggcaggcgat gattgagtca caaaaagaga tggggattca ggtatcgaaa 2160 
gaattccaga cggctctggg agaggctcag gaggcgacgg atctctatga agccagtatc 2220 
aaaaagacgg ataccgccaa gagtgtttat gacgctgcga ccaaaaaact gacgcaggcg 2280 
caaaataaat tgcaatcgct ggacccggct gaccccggct atgcacaagc tgaagccgcg 2340 
gtagaacagg ccggaaaaga agcgacagag gcgaaagagg ccttagataa ggccacggat 2400 
gcgacggtta aagcaggcac agacgccaaa gcgaaagccg agaaagcgga taacattctg 2460 
accaaattcc agggaacggc taatgccgcc tctcagaatc aggtttccca gggtgagcag 2520 





















<210> SEQ ID NO 20 
<211> LENGTH, 593 
<212> TYPE, PRT 
ccgcctcact atgctcatgg ccatgtttat 
cctgcaaaac gatcttgcgc ttttcaacgc 
aaagaaatcg gctgaattcc aggaagagac 
gggatgtatc gggaaagtcc tcggcgcgct 
ttttaccggt ggggcgagtc tggcgctggc 
tgaaattgtg aaggcggcga cgggagtgtc 
ggagcatgtg ctgaagccgt taatggagct 
aggattaggc gtcgataaga aaacggcaga 
cgccgctatt gccatggtgg cggtcattgt 
ggcgaaactg ggtaacgcgc tgagcaaaat 
taacgtgctg aaacagttgg cgcaaaacgg 
tattactagc ggtctgggta atgtgggtag 
taaagagctg gtaggtaata ccctaaataa 
cgcagcccag tcagccggtg gtgttgccga 
gcttgctgat tttatgctcg cccgttttgc 
atccgtagaa atatttggtg aaaaccagaa 
ttctgcggta cagcaaaatg cggatgcttc 
<213> ORGANISM: Salmonella enterica 
<400> SEQUENCE, 20 
Met Val Asn Asp Ala Ser Ser Ile Ser Arg Ser Gly Tyr Thr 
1 5 10 
Pro Arg Leu Ala Glu Ala Ala Phe Glu Gly Val Arg Lys Asn 





















Phe Leu Lys Ala Ala Asp Lys Ala Phe Lys Asp Val Val Ala Thr Lys 
35 40 45 
Ala Gly Asp Leu Lys Ala Gly Thr Lys Ser Gly Glu Ser Ala Ile Asn 
50 55 60 
Thr Val Gly Leu Lys Pro Pro Thr Asp Ala Ala Arg Glu Lys Leu Ser 
65 70 75 80 
Ser Glu Gly Gln Leu Thr Leu Leu Leu Gly Lys Leu Met Thr Leu Leu 
85 90 95 
Gly Asp Val Ser Leu Ser Gln Leu Glu Ser Arg Leu Ala Val Trp Gln 
100 105 110 
Ala Met Ile Glu Ser Gln Lys Glu Met Gly Ile Gln Val Ser Lys Glu 
115 120 125 
Phe Gln Thr Ala Leu Gly Glu Ala Gln Glu Ala Thr Asp Leu Tyr Glu 
130 135 140 
Ala Ser Ile Lys Lys Thr Asp Thr Ala Lys Ser Val Tyr Asp Ala Ala 
145 150 155 160 
Thr Lys Lys Leu Thr Gln Ala Gln Asn Lys Leu Gln Ser Leu Asp Pro 
165 170 175 
Ala Asp Pro Gly Tyr Ala Gln Ala Glu Ala Ala Val Glu Gln Ala Gly 
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Lys Glu Ala Thr Glu Ala Lys Glu Ala Leu Asp Lys Ala Thr Asp Ala 
195 200 205 
Thr Val Lys Ala Gly Thr Asp Ala Lys Ala Lys Ala Glu Lys Ala Asp 
210 215 220 
Asn Ile Leu Thr Lys Phe Gln Gly Thr Ala Asn Ala Ala Ser Gln Asn 
225 230 235 240 
Gln Val Ser Gln Gly Glu Gln Asp Asn Leu Ser Asn Val Ala Arg Leu 
245 250 255 
Thr Met Leu Met Ala Met Phe Ile Glu Ile Val Gly Lys Asn Thr Glu 
260 265 270 
Glu Ser Leu Gln Asn Asp Leu Ala Leu Phe Asn Ala Leu Gln Glu Gly 
275 280 285 
Arg Gln Ala Glu Met Glu Lys Lys Ser Ala Glu Phe Gln Glu Glu Thr 
290 295 300 
Arg Lys Ala Glu Glu Thr Asn Arg Ile Met Gly Cys Ile Gly Lys Val 
305 310 315 320 
Leu Gly Ala Leu Leu Thr Ile Val Ser Val Val Ala Ala Val Phe Thr 
325 330 335 
Gly Gly Ala Ser Leu Ala Leu Ala Ala Val Gly Leu Ala Val Met Val 
340 345 350 
Ala Asp Glu Ile Val Lys Ala Ala Thr Gly Val Ser Phe Ile Gln Gln 
355 360 365 
Ala Leu Asn Pro Ile Met Glu His Val Leu Lys Pro Leu Met Glu Leu 
370 375 380 
Ile Gly Lys Ala Ile Thr Lys Ala Leu Glu Gly Leu Gly Val Asp Lys 
385 390 395 400 
Lys Thr Ala Glu Met Ala Gly Ser Ile Val Gly Ala Ile Val Ala Ala 
405 410 415 
Ile Ala Met Val Ala Val Ile Val Val Val Ala Val Val Gly Lys Gly 
420 425 430 
Ala Ala Ala Lys Leu Gly Asn Ala Leu Ser Lys Met Met Gly Glu Thr 
435 440 445 
Ile Lys Lys Leu Val Pro Asn Val Leu Lys Gln Leu Ala Gln Asn Gly 
450 455 460 
Ser Lys Leu Phe Thr Gln Gly Met Gln Arg Ile Thr Ser Gly Leu Gly 
465 470 475 480 
Asn Val Gly Ser Lys Met Gly Leu Gln Thr Asn Ala Leu Ser Lys Glu 
485 490 495 
Leu Val Gly Asn Thr Leu Asn Lys Val Ala Leu Gly Met Glu Val Thr 
500 505 510 
Asn Thr Ala Ala Gln Ser Ala Gly Gly Val Ala Glu Gly Val Phe Ile 
515 520 525 
Lys Asn Ala Ser Glu Ala Leu Ala Asp Phe Met Leu Ala Arg Phe Ala 
530 535 540 
Met Asp Gln Ile Gln Gln Trp Leu Lys Gln Ser Val Glu Ile Phe Gly 
545 550 555 560 
Glu Asn Gln Lys Val Thr Ala Glu Leu Gln Lys Ala Met Ser Ser Ala 
565 570 575 
Val Gln Gln Asn Ala Asp Ala Ser Arg Phe Ile Leu Arg Gln Ser Arg 
580 585 590 
Ala 
100 
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-continued 
<210> SEQ ID NO 21 
<211> LENGTH, 1182 
<212> TYPE, DNA 
<213> ORGANISM, Salmonella t-yphimurium 





















<210> SEQ ID NO 22 
<211> LENGTH, 196 





















<213> ORGANISM, Salmonella typhimurium 





















Met Ser Ser Gly Asn Ile Leu Trp Gly Ser Gln Asn Pro Ile Val Phe 
1 5 10 15 
Lys Asn Ser Phe Gly Val Ser Asn Ala Asp Thr Gly Ser Gln Asp Asp 
20 25 30 
Leu Ser Gln Gln Asn Pro Phe Ala Glu Gly Tyr Gly Val Leu Leu Ile 
35 40 45 
Leu Leu Met Val Ile Gln Ala Ile Ala Asn Asn Lys Phe Ile Glu Val 
50 55 60 
Gln Lys Asn Ala Glu Arg Ala Arg Asn Thr Gln Glu Lys Ser Asn Glu 
65 70 75 80 
Met Asp Glu Val Ile Ala Lys Ala Ala Lys Gly Asp Ala Lys Thr Lys 
85 90 95 
Glu Glu Val Pro Glu Asp Val Ile Lys Tyr Met Arg Asp Asn Gly Ile 
100 105 110 
Leu Ile Asp Gly Met Thr Ile Asp Asp Tyr Met Ala Lys Tyr Gly Asp 
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His Gly Lys Leu Asp Lys Gly Gly Leu Gln Ala Ile Lys Ala Ala Leu 
130 135 140 
Asp Asn Asp Ala Asn Arg Asn Thr Asp Leu Met Ser Gln Gly Gln Ile 
145 150 155 160 
Thr Ile Gln Lys Met Ser Gln Glu Leu Asn Ala Val Leu Thr Gln Leu 
165 170 175 
Thr Gly Leu Ile Ser Lys Trp Gly Glu Ile Ser Ser Met Ile Ala Gln 
180 185 190 
Lys Thr Tyr Ser 
195 
<210> SEQ ID NO 23 
<211> LENGTH, 2910 
<212> TYPE, DNA 
<213> ORGANISM, Salmonella typhimurium 
<400> SEQUENCE, 23 
atgaatcgaa ttcacagtaa tagcgacagc gccgcaggag taaccgcctt aacacatcat 
cacttaagca atgtcagttg cgtttcctcg ggttcgctgg gaaagcgcca gcatcgtgtg 
aattctactt ttggcgatgg caacgccgcg tgtctgctat ccgggaaaat tagtcttcag 
gaggcaagca atgcgttgaa gcaactgctt gatgccgtac ccggaaatca taagcgtcca 
tcattgcctg actttttgca gaccaatccc gcggttttat caatgatgat gacgtcatta 
atactcaacg tctttggtaa taacgctcaa tcgttatgcc aacagcttga gcgggcaact 
gaggtgcaaa atgcattacg taataagcag gtaaaggagt atcaggagca gatccagaaa 
gcgatagagc aggaggataa agcgcgtaaa gcgggtattt ttggcgctat ttttgactgg 
attaccggca tatttgaaac cgtgattggc gccttaaaag ttgtggaagg ttttctgtcc 
ggaaatcccg cagaaatggc tagcggcgta gcttatatgg ccgcaggttg tgcaggaatg 
gttaaagccg gagccgaaac ggcaatgatg tgcggtgctg accacgatac ctgtcaggca 
attattgacg tgacaagtaa gattcaattt ggttgtgaag ccgtcgcgct ggcactggat 
gttttccaga ttggccgtgc ttttatggcg acgagaggtt tatctggcgc agctgcaaaa 
gtgcttgact ccggttttgg cgaggaagtg gttgagcgta tggtaggtgc aggggaagca 
gaaatagagg agttggctga aaagtttggc gaagaagtga gcgaaagttt ttccaaacaa 
tttgagccgc ttgaacgtga aatggctatg gcgaatgaga tggcagagga ggctgccgag 
ttttctcgta acgtagaaaa taatatgacg cgaagcgcgg gaaaaagctt tacgaaagag 
ggggtgaaag ccatggcaaa agaagcggca aaagaagccc tggaaaaatg tgtgcaagaa 
ggtggaaagt tcctgttaaa aaaattccgt aataaagttc tcttcaatat gttcaaaaaa 
atcctgtatg ccttactgag ggattgttca tttaaaggct tacaggctat cagatgtgca 
accgagggcg ccagtcagat gaatactggc atggttaaca cagaaaaagc gaagatcgaa 
aagaaaatag agcaattaat aactcagcaa cggtttctgg atttcataat gcaacaaaca 
gaaaaccaga aaaagataga acaaaaacgc ttagaggagc tttataaggg gagcggtgcc 
gcgcttagag atgtattaga taccattgat cactatagta gcgttcaggc gagaatagct 
ggctatcgcg cttaaatgaa tcgaattcac agtaatagcg acagcgccgc aggagtaacc 
gccttaacac atcatcactt aagcaatgtc agttgcgttt cctcgggttc gctgggaaag 
cgccagcatc gtgtgaattc tacttttggc gatggcaacg ccgcgtgtct gctatccggg 






















































<210> SEQ ID NO 24 
<211> LENGTH, 484 






















<213> ORGANISM, Salmonella typhimurium 





















Met Asn Arg Ile His Ser Asn Ser Asp Ser Ala Ala Gly Val Thr Ala 
1 5 10 15 
Leu Thr His His His Leu Ser Asn Val Ser Cys Val Ser Ser Gly Ser 
20 25 30 
Leu Gly Lys Arg Gln His Arg Val Asn Ser Thr Phe Gly Asp Gly Asn 
35 40 45 
Ala Ala Cys Leu Leu Ser Gly Lys Ile Ser Leu Gln Glu Ala Ser Asn 
50 55 60 
Ala Leu Lys Gln Leu Leu Asp Ala Val Pro Gly Asn His Lys Arg Pro 
65 70 75 80 
Ser Leu Pro Asp Phe Leu Gln Thr Asn Pro Ala Val Leu Ser Met Met 
85 90 95 
Met Thr Ser Leu Ile Leu Asn Val Phe Gly Asn Asn Ala Gln Ser Leu 
100 105 110 
Cys Gln Gln Leu Glu Arg Ala Thr Glu Val Gln Asn Ala Leu Arg Asn 
115 120 125 
Lys Gln Val Lys Glu Tyr Gln Glu Gln Ile Gln Lys Ala Ile Glu Gln 
130 135 140 
Glu Asp Lys Ala Arg Lys Ala Gly Ile Phe Gly Ala Ile Phe Asp Trp 
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Ile Thr Gly Ile Phe Glu Thr Val Ile Gly Ala Leu Lys Val Val Glu 
165 170 175 
Gly Phe Leu Ser Gly Asn Pro Ala Glu Met Ala Ser Gly Val Ala Tyr 
180 185 190 
Met Ala Ala Gly Cys Ala Gly Met Val Lys Ala Gly Ala Glu Thr Ala 
195 200 205 
Met Met Cys Gly Ala Asp His Asp Thr Cys Gln Ala Ile Ile Asp Val 
210 215 220 
Thr Ser Lys Ile Gln Phe Gly Cys Glu Ala Val Ala Leu Ala Leu Asp 
225 230 235 240 
Val Phe Gln Ile Gly Arg Ala Phe Met Ala Thr Arg Gly Leu Ser Gly 
245 250 255 
Ala Ala Ala Lys Val Leu Asp Ser Gly Phe Gly Glu Glu Val Val Glu 
260 265 270 
Arg Met Val Gly Ala Gly Glu Ala Glu Ile Glu Glu Leu Ala Glu Lys 
275 280 285 
Phe Gly Glu Glu Val Ser Glu Ser Phe Ser Lys Gln Phe Glu Pro Leu 
290 295 300 
Glu Arg Glu Met Ala Met Ala Asn Glu Met Ala Glu Glu Ala Ala Glu 
305 310 315 320 
Phe Ser Arg Asn Val Glu Asn Asn Met Thr Arg Ser Ala Gly Lys Ser 
325 330 335 
Phe Thr Lys Glu Gly Val Lys Ala Met Ala Lys Glu Ala Ala Lys Glu 
340 345 350 
Ala Leu Glu Lys Cys Val Gln Glu Gly Gly Lys Phe Leu Leu Lys Lys 
355 360 365 
Phe Arg Asn Lys Val Leu Phe Asn Met Phe Lys Lys Ile Leu Tyr Ala 
370 375 380 
Leu Leu Arg Asp Cys Ser Phe Lys Gly Leu Gln Ala Ile Arg Cys Ala 
385 390 395 400 
Thr Glu Gly Ala Ser Gln Met Asn Thr Gly Met Val Asn Thr Glu Lys 
405 410 415 
Ala Lys Ile Glu Lys Lys Ile Glu Gln Leu Ile Thr Gln Gln Arg Phe 
420 425 430 
Leu Asp Phe Ile Met Gln Gln Thr Glu Asn Gln Lys Lys Ile Glu Gln 
435 440 445 
Lys Arg Leu Glu Glu Leu Tyr Lys Gly Ser Gly Ala Ala Leu Arg Asp 
450 455 460 
Val Leu Asp Thr Ile Asp His Tyr Ser Ser Val Gln Ala Arg Ile Ala 
465 470 475 480 
Gly Tyr Arg Ala 
<210> SEQ ID NO 25 
<211> LENGTH: 9 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
peptide 
<400> SEQUENCE: 25 
Cys Tyr Gly Gly Arg Gly Asp Thr Pro 
1 5 
108 
What is claimed: 
US 9,950,053 B2 
109 
1. A vaccine formulation comprising a therapeutically 
effective amount of a first chimeric molecule and a second 
chimeric molecule in a pharmaceutically acceptable carrier, 
the first chimeric molecule comprising at least one Salmo- 5 
nella pathogenicity island 1 (SPI-1) molecule linked to at 
least one SPI-1 molecule; the second chimeric molecule 
comprising at least one Salmonella pathogenicity island 2 
(SPI-2) linked to at least one SPI-2 molecule, wherein the 
first chimeric molecule and the second chimeric molecule 10 
comprise a sequence having a sequence identity of at least 
about 90% to sequences comprising SEQ ID NOS: 14 and 
16. 
2. The vaccine of claim 1, wherein the first chimeric 
molecule and the second chimeric molecule comprise SEQ 15 
ID NOS: 14 or 16. 
3. The vaccine of claim 1, further comprising SicA, SscA, 
proteins, polypeptides, peptides or combinations thereof. 
4. The vaccine of claim 1, further comprising an adjuvant. 
5. The vaccine formulation of claim 1, further comprising 20 
an adjuvant. 
* * * * * 
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